

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mazindol	3-[5-imidazo[2,1-a]isoxazol-5-yl-5-(4-chlorophenyl)-2,5-dihydro- [CAS]	22232-71-9	US 3763178	Anorectic/Antiobesity	Obesity
Mazipredone					
MC-5723	(2-amino-6-(4-methoxyphenylthio)-6-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)	13085-08-0	US 6043259	Cardiovascular	Unspecified
MCC-478					
MCI-154	3-(H)-Pyridazine, 4,5-dihydro-6-[4-(4-pyridylamino)phenyl]-, monohydrochloride [CAS]	98328-32-0 98328-33-1	EP 145018	Antiviral, other	Infection, hepatitis-B virus
m-Cresyl Acetate		122-46-3		Cardio stimulant	Heart failure
MDAM	Gamma-Methylene-10-deazaaminopterin				
MDI-101			US 4886311	Anticancer, antimetabolite	Cancer, general
MDI-403		433948-94-5	US 4677120	Antiacne	Acne
MDL-100907	1-[2-(piperidin-1-yl)-4-(4-(4-methoxyphenyl)-1-(2-(4-fluorophenyl)-1H-1,3,4-oxadiazol-2-yl)-5-benzoyl)-2-methylimidazole-2-carbonyl]benzoic acid, 3,4-dimethoxy-, 4-[ethy(2-(4-methoxyphenyl)-1-methylethylamino)butyl ester] [CAS]	139290-85-6 31431-39-7		Hypnotic/Sedative	Sleep disorder, general
mebendazole			GB 1307306	Antheimetic	
mebeverine		3625-06-7		Antispasmodic	Irritable bowel syndrome
Mebhydroline		524-81-2			
Mebrofenin		78266-06-5			
Mebutamate		64-85-1			
mecamylamine	Biocod(2,1)heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2		Neurological	Unspecified
Mechlorethamine		51-75-2			
Mechlorethamine Oxide		302-70-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
meclizine	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6Beta,1)-] (CAS)	32887-01-7 32887-03-9	GB 1293590	Penicillin, injectable	Infection, general
Meclizine		569-65-3			
Meclizine		2013-58-3			
meclizine	Benzoic acid, 2-[(2S-dichloro-3-phenyl)amino], monosodium salt (CAS)	6385-02-0 644-62-2			
Meclizine		644-62-2		Antiarthritic, other	Arthritis, osteo
Meclizine		51-68-3			
Meclizine		340-57-8			
Meclizine		18598-63-5			
Meclizine		126/2898			
Meclizine	Ethanamine, N,N-dimethyl-2,2-diphenyl- (CAS)	3289-34-5	FR M5488	Antidepressant	
Meclizine		977-79-7			
Meclizine		1984-15-2			
Meclizine	Plagin-4-ene-3,20-dione, 17-(acetoxy)-methyl-, (6Alpha)	71-58-9 520-85-4			
Meclizine		2668-66-8		Formulation, fixed-dose combinations	Contraceptive, female
Meclizine		61-68-7			
Meclizine		17243-57-1			
Meclizine		1227-61-8			
Meclizine		51773-32-3			
Meclizine	4-Quinolinemethanol, Alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*, S*+)(CAS)	53230-10-7 69191-18-0			
Meclizine		7195-27-9	GB 1594282	Antimalarial	
Meclizine		595-33-5			
Meclizine		22154-43-4			
Meclizine		131-49-7			
Meclizine	2-Hydroxy-2-methyl-1,3-propanedicarboxylic acid	503-49-1	US 3629449	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
melagatran	Glicine, N-[(1R)-2, [(2S)-2, [(4R)-aminomino]methyl]phenyl]methyl]amino]-2-oxoethyl]-[CAS]	159776-70-2	WO 9616671	Antithrombotic	Thromboasis, general
melanocortin-4 agonist	N-[(3R)-1,2,3,4-Tetrahydroquinolinium-3-ylcarbonyl]-(1R)-1,4-bis[2-oxo-1-oxoethyl]-4-(1H-1,2,4-triazol-1-yl)methyl]piperidin-1-yl]-2-oxoethyl]amine(1)				
Melarsoprol		494-79-1			
Melengestrol		5633-18-1			
melivodopa	Alanine, 3-(3,4-dihydroxyphenyl)-methyl ester [CAS]	7101-51-1	EP 252290	Antiparkinsonian	Parkinson's disease
Melinamide		14417-88-0			
Meliracene		5118-29-6			
meloxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-1,1-dioxide- [CAS]	71125-38-7	US 4233299	Antiarthritic, other	Arthritis, rheumatoid
melperone	1-Ethylpiperazine-1-(4-benzophenyl)-4-(4-methyl-1-piperidinyl)-[CAS]	182278-3 3875-86-2	BE 651144	Neuroleptic	
Melphalan		148-82-3			
melixastine	Benzeneethanol, 2-chloro-Alpha-((1,1-dimethylamino)methyl)-4-hydroxy-, (R)-, (R', R'')-2,3-dihydroxybutanediole (1:1) (salt) [CAS]	134865-37-5	EP 420120	Labour inhibitor	Labour, preterm
memantine	Tricyclo[3.3.1.1 ^{3,7}]octan-1-amine, 3,5-dimethyl [CAS]	11100-92-1 19982-08-2	EP 392059	Cognition enhancer	Dementia, AIDS-related
MEM-10700	Acetamide, 2-[[[(5R,6S)-6-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl]methyl]methylamino]-[CAS]	195874-55-6	WO 9406803	Beta-lactam antibiotic	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
AMEN-10755	5,12-Naphthazenedione, 7-[(4-O-(3-aminod-2,3,6-tridecyl-Alpha-L-lyxohexopyranosyl)-2,6-difluoro-Alpha-L-lyxohexopyranosyl)oxy]-7,8,10-tetrahydro-6,9,11-trihydroxy-9-hydroxyacetyl-, hydrochloride, (7S,9S) [CAS]	169317-77-5	WO 9509173	Anticancer, antibiotic	Cancer, breast
Monadol		481-85-6			
Menadione		58-27-5			
Menadoxime		573-01-3			
Menbutone		3562-95-0			
Menogaril		71628-96-1			
MENT	Alpha-Methyl-9-nortestosterone				
menthol	Cyclohexanol, 5-methyl-2-(1-methyl-ethyl)- [CAS]	134904-5 89-78-1		Formulation, transdermal, systemic	Contraceptive, male
Menthyl Valerate		89-47-4			
Meobentine		46464-11-3		Formulation, dermal, topical	Puritus
Meparlynol		77-75-8			
meparitinon	Paritinol, methyl ester [CAS]	1121-32-7	US 3780173	Antifungal	Infection, Candida, general
Mepezine		60-88-9			
Meperizolate Bromide		76-90-4			
Meperidine		57-42-1			
Mephesisin		59-47-2			
Mephenoqualone		70-07-5			
Mephentermine		100-82-5			
Mephentanyl		50-12-4			
Mephobarbital		115-38-8			
Mepindolol		23694-81-7			
Mepitostane		21362-69-6 96-88-8			
mepivacaine	N-(2,6-Dimethylphenyl)-N-methyl-2-piperidinecarboxamide			Formulation, modified-release, >24hr	Pain, post-operative
Mepixanox		17854-59-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Meprednisone		1247-42-3			
Meprobamate		57-53-4			
meprosacilin	Buta-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl- α -L-mannopyranosyloxy)-14-hydroxy-, (3S)- [CAS]	33396-37-1	DE 1910207	Cardio stimulant	Heart failure
mepizolol	Phenol, 3-[3-ethoxyhexahydro-1-methyl-1H-azepin-3-yl]- [CAS]	57370-59-8			
mesazoline	azepin-3-yl]- [CAS]	59263-76-2	GB 1285025	Analgesic, other	Pain, general
mesazoline	10H-Phenothiazine, 10-(1'-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	29216-28-2	GB 1250634	Antiallergic, non-asthma	
Meralluride		4386-35-0			
Merbromin		8089-64-5			
Mercaptopurine		129-16-8			
Mercumallic Acid		21259-76-7			
Mercure Chloride, Ammoniated		86-36-2			
Mercure Chloride, Ammoniated		10124-48-8			
Mercure Oleate		1191-80-8			
Mercure Oxycyanide		1335-31-5			
merimepodis	Carbamic acid, (3-(((3-methoxy-4-(5-oxazolylphenyl)amino)carbonyl)amino)phenyl)methyl-, (3S)-tetrahydro-3-furanyl ester [CAS]	198921-22-6	US 5907876	Antiviral, other	Infection, hepatitis-C virus
meropenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[(5-((dimethylamino)carbonyl)-3-pyrrolidinyl)imino]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-3'(3S',5S'), 4Alpha,5b,6b(1R')]]- [CAS]	96038-03-2	EP 126567	Beta lactam antibiotic	Infection, respiratory tract, lower
Mersalyl		492-18-2			
Mesalamine		89-57-6			
mesalazine	Benzonic acid, 5-amino-2-hydroxy- [CAS]	89-57-6			
Mesna		19787-45-4	WO 5541170	Formulation, oral, other	Colitis, ulcerative
Mesoridazine		5588-33-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mestanolone		521-11-9			
Mesterolone		1424-00-6			
Mestranol		72-33-3			
Mestifen		135-58-0			
Metaciazepam		84031-17-4			
Metampicillin		6489-97-0			
Metapramine		21730-16-5			
Metaproterenol		585-06-1			
Metaraminol		54-48-9			
Metazocine		3734-52-9			
metergoline	Carbamic acid, [(80)-1,6-dimethylergolin-2-yl(methyl)-, phenylmethyl ester] [CAS]	17682-51-2 20183-131-6 2706-42-5			
metformin	1-miscrocarboximidic diamide, N,N-dimethyl- [CAS]	657-24-9	GB 1401935	Antiprolactin	Amenorrhea
Methacholine		62-51-1		Formulation, modified-release, <24hr	Diabetes, Type II
Methacycline		914-00-1			
Methadone		76-59-3			
Methafurylene		531-06-6			
Methamphetamine		537-46-2			
Methandriol		521-10-8			
Methandrostenedione		72-63-9			
Methantheline		53-46-3			
Methapyrilene		91-80-5			
Methaqualone		72-44-6			
Metharbital		50-11-3			
Methazolamide		554-57-4			
Methdilazine		1082-37-2			
Methenamine		100-97-0			
Methenolone		153-00-4			
Methestrol		130-73-4			
Methetoin		5696-06-0			
Methicillin		132-92-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methimazole		60-56-0			
Methiodal		126-31-8			
Methionine Acid		503-40-2			
Methionine		63-68-3			
Methisazone		1910-68-5			
Methital		467-43-6			
Methixene		27214969			
Methocarbamol		532-03-6			
Methohexital		22151-68-4			
Methotrexate	L-Glutamic acid, N-[4-[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl- [CAS]	59-05-2	US 2512572	Anticancer, anti-metabolite	Cancer, general
Methotrimeprazine		60-99-1			
Methoxamine		390-28-3			
Methoxsalen		298-81-7			
Methoxyflurane		76-38-0			
Methoxyphenamine		93-30-1			
Methoxypromazine		61-01-8			
Methscopolamine		165-41-9			
Methsuximide		77-41-8			
Methyclothiazide		135-07-9			
Methyl Blue		28883-56-4			
Methyl Nicotinate		93-80-7			
Methyl Propyl Ether		557-17-6			
Methyl Salicylate		119-36-8			
Methyl tert-Butyl Ether		1634-04-4			
Methylbenzethonium Chloride		25165-18-4			
Methylcobalamin		13422-65-4			
Methylcoba	L-Tyrosine, 3-Hydroxy-Alpha-methyl- [CAS]	555-90-6		Formulation, modified-release, <=24hr	Hypertension, general
Methylene Blue		61-73-4			
Methylergonovine		1113-42-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methylhexanamine	2-Piperidineacetic acid, Alpha-phenyl-methyl ester [CAS]	105-41-9 11345-1 298-59-9			
Methylprednisolone	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-4,10,14,17,17-dimethyl-, (6alpha,11b)- [CAS]	83-43-2 86401-95-8	EP 72547	Formulation, modified-release, multi	Attention deficit disorder
Methylprednisolone ascorbate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[(8-methyl(2-sulfoethyl)amino)-1,6-dioxocyclohexyl]monosodium salt, (6alpha,11b)- [CAS]	90350-40-6 58-04-2	JP 56137500	Antipruritic/Inflamm. allergic	Pruritus
Methylthiouracil		965-93-5		Antiestrogen	Asthma
Methyltrienolone		125-64-4			
Methypyrrolone		361-37-5			
Methysergide		13983-66-2			
Metazinc Acid	Phenol, 4-[2-hydroxy-5-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-1-acetate [CAS]	22664-55-7	GB 1206148	Antihypertensive, adrenergic	
metipranolol	Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- [CAS]	364-82-5 7601-55-0 388-51-2		Formulation, modified-release, <=24hr	Gastro-esophageal reflux
Metocurine Iodide					
Metofenazate	8-Quinazolinethylionamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- [CAS]	17560-51-9 14008-44-7	US 4517779	Antihypertensive, diuretic	
Metopimazine		143-52-2 51384-51-1			
Metopon	2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (H)- [CAS]	56392-17-7 37350-98-6 54188-36-4		Formulation, modified-release, other	Hypertension, general
metoprolol		31112-82-6 1949-45-7			
Metralindole					
Metrizamide					
Metrizoic Acid					
Metron S		13946-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mefenopone		54-36-4			
Mefenopone		572-87-7			
Mefenopone		31868-18-5			
Mefenopone		1641-17-4			
Mefenopone		31828-71-4			
Mefenopone	4-(Thia-1-arabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-III)-3-(methylsulfonyl)-2-oxo-1-imidazolidinylcarbonylamino(phenyl)acetyl amino-7-oxo-1,2,3,4-tetrahydro-2H-pyridine-5-carboxylic acid, 3,4,5-trihydroxy-, ethyl ester, hydrochloride	42057-22-7 51481-65-3 72539-76-5	GB 1301961	Penicillin, injectable	Infection, general
Mefenopone	Diethylzinc (pyrazine)1,2-diazepine, 1,2,3,4,10,14-hexahydro-2-methyl-, [CAS]	95033-76-9	US 4623659	Cardiovascular	Reperfusion injury
Mefenopone	Diethylzinc (pyrazine)1,2-diazepine, 1,2,3,4,10,14-hexahydro-2-methyl-, [CAS]	21535-47-7 24219-97-4	GB 1173783	Antidepressant	Depression, general
Mefenopone		116844-53-2			
Mefenopone		103775-75-3			
Mefenopone		235114-32-6			
Mefenopone	1H-Imidazole, 1-(2,4-dichlorophenyl)-2(4-dichlorophenyl)methoxy]ethyl]	22916-47-8		Formulation, modified-release, other	Infection, Candida, general
Mefenopone	1H-Pyrimidin-2-ylidene, 8-(1'-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-, [CAS]	52093-21-7	US 5378844	Cardiovascular	Unspecified
Mefenopone	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-(59467-70-8) chloro-6-(2-fluorophenyl)-1-methyl-, [CAS]	59467-70-8 59467-94-6	US 4280957	Anesthetic, injectable	Infection, general
Mefenopone	Leuconycin V, 3,4B-dipropionate [CAS]	35457-80-8	US 3781588	Macrolide antibiotic	Infection, general
Mefenopone	Leuconycin V, 3,4B-dipropionate 3,4B-dipropionate [CAS]	55681-07-7	JP 48124087	Macrolide antibiotic	Infection, general
Mefenopone	2-Thiophenecarboxylic acid, 5-(1-methyl-4-oxo-2-thienylthio-2-oxo-3-phenylamino)ethyl ester [CAS]	94149-41-4	EP 120534	COOP treatment	Empyema, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
midodrine	Axetamide, 2-amino-N-(2,5-dimethoxyphenyl)-2-hydroxyethyl- [CAS] Benzamide, N-(2,3,10,11,12,13-hexahydro-10H-benzo[5,6-b]pyrido[4,3-b][1,5]oxazin-11-yl)-N-methyl-, (6Alpha,10b,13bAlpha)- [CAS]	42318-55-0 42794-76-3	EP 164571	Urological	Incontinence
midostaurin	Extra-2,3-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propenyl)-, (11b,17b)- [CAS]	120585-11-2	EP 206110	Anticancer, other	Cancer, leukaemia, acute myelogenous
mifepristone	3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, [2R-, (2Alpha,3b,4Alpha,5b)-] [CAS]	84371-85-3	EP 57115	Abortifacient	Abortion
miglitol	3,4,5-Piperidinetriol, 1-benzyl-2-(hydroxymethyl)-, [2R-, (2Alpha,3b,4Alpha,5b)-] [CAS]	72432-03-2	EP 55431	Antidiabetic	Diabetes, Type I
mingualat	Hydrazinium, 2-[2-carboxyethyl]-1,1,1-trimethyl-, inner salt- [CAS]	72569-27-0	DE 2756025	Metabolic and enzyme disorders	Gaucher's disease
midronate	Cyclopropanecarboxamides, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, de-(4)-[CAS]	76144-81-5	WO 8001068	Cardio stimulant	Heart failure
milnacipran	Hydrazinium, 2-[2-carboxyethyl]-1,1,1-trimethyl-, inner salt- [CAS]	101152-94-7 92623-85-3	US 4478636	Antidepressant	Depression, general
Miloxacin	3,4,2-Bipyridine-5-carbonitrile, 1,2-dihydro-2-methyl-6-oxo- [CAS]	371065-29-5			
milnirone	Elthansaminium, 2-[[[tricyclohexylhydroxyphosphoryl]oxyl-N,N,N-trimethyl, hydroxide, inner salt [CAS]	78415-72-2	US 4313551	Cardio stimulant	Heart failure
miltofosine	4-Morpholinethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)- [CAS]	53949-20-5 59086-55-6 23385-17-5	EP 225608	Anticancer, other	Cancer, skin, general
milatipine		25953-17-7	GB 1345680	Antidepressant	Depression, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
minocycline	2-Naphthalenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S], [(4S)-4a(Alpha,5a.alpha.,12a(Alpha))-][CAS]	10118-90-8		Formulation, optimized, microparticles	Infection, oral
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-yl)ethylidenebis-, [CAS]	180064-38-4	EP 354806	Anticancer, other	Cancer, myeloma
minoxidil	2-Ethyl-2-imidazoline, 8-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	US 4139819	Vasodilator, peripheral	Hypertension, general
Mitomycin		55881-07-7			
mitrazapine	Pyrazino[2,1-a]pyrido[2,3-c]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	86650-52-8 61337-67-5	GB 1543171	Antidepressant	Depression, general
misoprostol	Prost-13-en-1-ol acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, [(11Alpha,13E)-(4S)] [CAS]	59122-46-2 59122-48-4	US 4301146	Prostaglandin	Ulcer, gastric
mitomical	Erythromycin, 8,9-didehydro-N-demethyl-9-deoxo-8,11-dideoxy-8,9-epoxy-12-O-methyl-N(1-methylethyl)-11-oxo-, (2E)-, butenediolate (2:1) [CAS]	154802-96-7	WO 9324509	Gastroprokinetic	Gastro-oesophageal reflux
mitigilide	Calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isobutylidene)butyrate, dihydrate, [CAS]	145525-41-3	EP 507534	Antidiabetic	Diabetes, Type II
Mitobronitol		488-41-5			
Mitoguanzone		459-86-9			
mitolactol	Galactitol, 1,6-dibromo-1,6-dideoxy- [CAS]	10318-26-0	US 3993781	Anticancer, alkylating	Cancer, cervical

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
miltomycin	oxaziridinol (2,3,4-epoxy)-1,2-azabicyclo-4,7-dione, 6-amino-6-deoxy-1-[(1S)-1-methoxy-2-methyl-1-oxo-1,1,2,2,8a,8b-hexahydro-6a-methoxy-5-methyl-11a,8-(1a α)-8,8a,8b,8b α]-[CAS]	59-07-7		Formulation, parenteral, other	Cancer, stomach
Mifotane	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethyl)amino]ethyl- [CAS]	53-19-0			
mifoxatone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethyl)amino]ethyl- [CAS]	65271-80-9 70476-82-3	US 4197249	Anticancer, other	Cancer, breast
mifoxatone MIV-210	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethyl)amino]ethyl- [CAS]	65271-80-9 70476-82-3		Formulation, optimized, liposomes Antiviral, other	Cancer, general infection, hepatitis-B virus
mivacurium	3'-Fluoro-2'-3'-dideoxy guanosine				
Mivazerol	1,8-dihydroxy-3,1-propanediylbis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)methyl-, dichloride, [R,R'-R'-E]]-[CAS]	106861-44-3	EP 181055	Muscle relaxant	Anaesthesia, adjunct
mizolastine	4(1H)-Pyrimidinone, 2-[1-(1,4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinylmethyl- [CAS]	125472-02-8			
Mizoribine	(R)-N-(3-quinolidinyl)-2-oxo-4,7-dihydrothien[3,2-b]pyridine-6-carboxamide hydrochloride	108612-45-9 50924-49-7	EP 217700	Antiallergic, non-asthma	Rhinitis, allergic, general
MKC-733	9-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S)- [CAS]	194093-42-0	JP 09216888	Gastroprokinetic	Gastro-oesophageal reflux
MLN-519	4-Methoxy-benzofuran-2-carboxylic acid (2-(dimethylamino)-1-(R-methyl)-amide	211886-70-5	WO 9915183	Neuroprotective	Ischaemia, cerebral
MLN-578				Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moclobemide	Benzamide, 4-chloro-N-(2-(4-morpholinylethyl)-CAS]	71320-77-9	EP 326023	Anidepressant	Depression, general
modafinil	Acetamidate, 2-[(diphenylmethyl)sulfinyl]-[CAS]	69893-11-8	DE 2908625	Psychostimulant	Narcolepsy
mosepil	3-Isopropylindolecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-5-phenylpropyl]amino]-1-(oxopropyl)-1,2,3,4-tetrahydro-6-7-dimethoxy- (3S-(2(R*(R*),3R*))]-CAS]	103775-10-8 103775-14-0	US 4344949	Antihypertensive, renin system	Hypertension, general
Mofarotene		125533-88-2			
Mofebutazone		2210-63-1			
Mofegiline		119386-96-8			
mofezolac	5-Isoazabenzazolinic acid, 3,4-bis(4-methoxyphenyl)- [CAS]	78667-07-4	EP 26928	Anaesthetic, NSAID	Pain, post-operative
	N-[4-(aminomethyl)benzyl]-8(S)-11-14-12-(4-aminophenyl)-acetic acid/butylpyrrolidine-4-yl]-2-(naphthalen-1-ylmethyl)-1,3-dioxo-2,3,5-tetrahydro-1H-1,2,4-triazole[1,2-a]pyridazine-5(R)-carboxamide			Anaesthesia	Asthma
MOLO-6131					
Molindone	Synidone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)- [CAS]	7416-34-4			
molisindimine	Pegina-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dimethoxy-16-methyl-, (11S,16R)- [CAS]	25717-80-0 105102-22-5 83919-23-7	US 3769283	Vasodilator, coronary	
monometasone			EP 57401	Antipruritic/Inflamm, allergic	Pecoriasis
Monatepil		103377-41-9			
Monobenzene		103-16-2			
monolaurin	Dodecanic acid, monoisomer with 1,2,3-propanetriol [CAS]	27215-36-9	US 4885282	Dermatological	Ichthyosis
	Cyclopropanecarboxylic acid, 1-[[[1-[3-(2-7-Chloro-2-quinolinyloxy)phenyl]phenyl]-3-(2-(1-hydroxy-1,1-dimethylethyl)propyl)]thio]methyl-, (S)- [CAS]	156767-02-1 156666-62-8			
monolukast		122007-85-6		Anaesthesia	Asthma
Monoplease					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Meprobene		1050-79-9			
Mopidamol		13665-88-8			
Moprotol		5741-22-0			
moracizine	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]-, ethyl ester [CAS]	29560-58-5 31883-05-3	US 3984487	Antitarrhythmic	Tachycardia, ventricular
Morazone		6536-18-1			
Morizidine		31883-05-3			
Moroxidine		3731-59-7			
Morphazirnamide		952-54-5			
morphine		57-27-2			
morphine-6-glucuronide	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (6 α ,6 α h α h α), [CAS]	6055-08-7 64-31-3		Formulation, parenteral, other	Pain, cancer
	morphine-6-glucuronide			Formulation, inhalable, systemic	Pain, general
	Spiro[imidaz[1,2-a]pyridine-3(2H),4'-piperidin]-2-one, 1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[6,7-b]azepine-5-yl)propyl]hexahydro-, (4 <i>a</i>)- [CAS]	89419-40-9 89045-60-8	US 4337260	Neuroleptic	
mosapramine	Benzamide, 4-amino-5-chloro-2-ethoxy-N-[(4-(4-fluorophenyl)methyl)-2-morpholinyl]methyl-, [CAS]	112885-41-3 112885-42-4			
mosapride	Gadolinium, bis(acetate-kappaO)(9,10-dienyl-20,21-bis(2-(2-methoxyethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16,13-dinitro-1,1b-benzodiazacyclooctasine-5,14-dipropanoate-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-23324) [CAS]		EP 243959	GI inflammatory/bowel disorders	Gastritis
motexalin gadolinium		246262-86-2			
Motretinide		56281-36-8		Radiochemosensitizer	Cancer, brain
Movelipiril		85856-54-8			
Moxalactam		64952-97-2			
Moxastine		3572-74-5			
Moxaverfine		10539-19-2			
Moxestrol		34816-55-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
modifloxacin	3-Quinolincarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-2-(octahydro-9H-pyrido[3,4-b]pyridin-6-yl)-4-oxo-, hydrochloride (as-cis) [CAS]	186926-86-8 151096-09-2	DE 10546249	Quinolone antibacterial	Infection, respiratory tract, general
modisyllite	Pisagol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylpentyl), acetate (ester) [CAS]	964-52-3 54-32-0		Male sexual dysfunction	Impotence
moexidine	5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-5-methoxy-2-methyl- [CAS]	75438-57-2	DE 2949537	Antihypertensive, other	Hypertension, general
M-FGA	(-)-1S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isindol-2-yl)pentanedioic acid		US 5712291	Anticancer, other	Cancer, general
MPI-5010	Platinum diamminedichloro-, (S)-4,2) + (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol		US 6224883	Formulation, parenteral, other	Cancer, head and neck
MPI-6020	2,4-(1H,3H)-Pyrimidinadione, 5-fluoro- [CAS]	51-21-8	US 5750146	Formulation, parenteral, other	Cancer, breast
MPL		198076-81-2	US 6060481	Immunostimulant, other	Vaccine adjuvant
MRS-1754	1-Piperazineethanol, 4-(diphenylacetyl)-Alph-[5-quinolyl]oxy)methyl-, (2E)-2-butenedioate(2,3) (salt) [CAS]			Asthma	Asthma
MS-209	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino]methylbenzamide	158681-49-3		Radiochemosensitizer	Cancer, breast
MS-275					
MS-325		201688-00-8		Anticancer, antimetabolite	Cancer, lung, general
MS-377			EP 939805	Neuroleptic	Schizophrenia
Mupirocin		12650-69-0			
Muscarin		300-54-9			
Muzollimine		55294-15-0			
Mx-1013			US 6153591	Hepatoprotective	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mycophenolate mofetil	6-Hexanoic acid, 4-((1,3-dihydro-4-hydroxy-5-methoxy-2H-pyridin-2-ylideneamino)-4-oxo-2,4-morpholinyl)ethyl ester, (E)- [CAS] 116980-01-4 128794-94-5		WO 9119468	Immunosuppressant	Transplant rejection, general
mycophenolic acid	4-Hexanoic acid, 6-((1,3-dihydro-4-hydroxy-5-methoxy-2H-pyridin-2-ylideneamino)-4-oxo-2,4-morpholinyl)-4-methyl-,	37415-62-6 24280-93-1		Formulation, oral, enteric-coated	Transplant rejection, general
Myrophine		467-18-5			
N- (Hydroxymethyl)nicotina mide		3569-39-1			
N,N,N',N'- Tetraethylphthalamide		83-81-8			
N-Formylsulfonamide		795-13-1			
N-β-α- Glucosylsulfonamide		53274-53-6			
N- Sulfanilyl/sulfanilamide		547-52-4			
Nabifone		51022-71-0			
nabumetone	2-Bidlanone, 4-(6-methoxy-2-naphthalenyl) [CAS]	42924-53-9	GB 1476721	Anti-inflammatory	Arthritis, osteo
N-acetylcytostene	L-Cysteine, N-acetyl- [CAS]	616-91-1		Anticancer, other	Cancer, general
N-Acetylmethionine		65-82-7			
nadifloxacin	1H,5H-Benz[e][quinoxaline]-2-carboxylic acid, 6-fluoro-8,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (1-)- [CAS]	124869-35-1	US 4399134	Quinolone antibacterial	Acne
nadolol	2,3-Naphthalenediol, 5-[2-((1,1-dimethylethyl)amino)-2-hydroxypropyl]-1,2,3,4-tetrahydro- [CAS]	42200-33-9	US 4346106	Antihypertensive, adrenergic	
Nadoxolol		54063-51-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
naloxonolol	Benzoc acid, 4- (aminomethyl)amino-, 6- (aminomethyl)-2-naphthalenyl ester- [CAS]	80251-32-7 81525-10-2 82356-11-4	EP 450232	GI inflammatory/bowel disorders	Pancreatitis
naloxone	Lutealizing hormone-releasing factor (rg) 6-(3-(2-naphthalenyl)-D-alanine)-[CAS]	76932-56-4 86220-42-0	EP 21234	Releasing hormones	Endometriosis
Naloxonol		147-52-4			
Naloxonol		31329-57-4			
nalfedrone	2-Furanpropanoic acid, tetrahydro- α - (1-naphthalenyl)methyl-, 2- (diethylamino)ethyl ester	31329-57-4			
nalfine	1-Naphthalenemethanamine, N-methyl-N- (3-phenyl-2-propenyl)-, (E)-, [CAS]	63472-88-0 66473-14-5	US 4282251	Formulation, modified-release, other	Unspecified
nalfopidol	1-Piperazineethanol, 4-(2-methoxyphenyl)- α -(1-(1-naphthalenyl)oxy)methyl-, [CAS]	57149-07-2	US 3597666	Antihypertensive, adrenergic	Infection, dermatological
nalbuphine	Morphinan-3,6,14-triol, 17- (cyclobutylmethyl)-4,5-epoxy-, (5 α -Alfa)-[CAS]	20594-83-6 23277-43-2	US 3393197	Pain, general	Hypertension, general
Nalidixic Acid	Morphinan-3,14-diol, 17- (cyclopropylmethyl)-4,5-epoxy-6- methylene-, (5 α -Alfa)-[CAS]	388-08-2			
nalmecone		55096-28-9		Dependence treatment	Poisoning, drug
Nalorphine		62-57-9	JP 56167687		
naloxone	Morphinan-6-one, 17-allyl-4,5 α -epoxy- 3,14-dihydroxy-, hydrochloride [CAS]	337-08-4 465-65-6		Septic shock treatment	
naloxone	Morphinan-6-one, 17-(cyclopropylmethyl)- 4,5-epoxy-3,14-dihydroxy-, (5 α -Alfa)-[CAS]	16590-41-3 16676-29-2	US 3332950	Dependence treatment	Addiction, narcotic/psychiatric
NAMI	imidazolium trans-(imidazole)(dimethylsulfoxide)tetrachloro- borate (III)			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
namical	Guanidine, N-guanosyl-4-cyanophenyl-N'-[(R)-1,2,2-trimethylpropyl][CAS]	220641-11-2		Dermatological	Alopecia, general
Nandrolone		434-22-0			
Naphazoline		835-31-4			
Naphthalene		91-20-3			
naproxen betahlate	Meitanamium, 1-carboxy-N, N'-trimethyl-, salt with (R)-5-methoxy-Alpha-methyl-2-naphthalenesuccinic acid (1:1), sodium salt [CAS]	104124-26-7	US 4672077	Antiarthritic, other	Arthritis, rheumatoid
naproxen	2-Naphthalenesuccinic acid, 8-methoxy- [CAS]	267583-92			
naratriptan	Alpha-methyl-, [CAS]	22204-83-1	GB 1211134	Analgesic NSAID	Pain, general
Narcobarbital	(1H-Indole-5-yl)acetamide, N-methyl-, 5-(1-methyl-4-piperidinyl)-[CAS]	121679-13-8	EP 303507	Antimigraine	Migraine
Natamycin		131-28-2			
		125-55-3			
		7681-93-8			
netaglinide	D-phenylalanine, N'-(4-(1-methylethyl)cyclohexyl)carbonyl-, trans-[CAS]	105816-04-4	EP 196222	Antidiabetic	Diabetes, Type II
N-Butyldeoxynojirmycin		72589-27-0			
N-Butylscopolammonium Bromide		149-64-4			
NC-503			US 5643562	Anti-inflammatory	Amyloidosis
NC-531			US 5643562	Cognition enhancer	Alzheimer's disease
NCX-1003			WO 0061604	Hepatoprotective	Cirrhosis, hepatic
NCX-4016	Benzoic acid, 2-(acetoxy)-, 2'-(nitroxy)methylphenyl ester [CAS]	175033-38-0	WO 971605	Symptomatic antidiabetic	Insulin-related metabolic syndrome
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitroxy)butyl ester [CAS]	286499-26-0		GI inflammatory/bowel disorders	Inflammatory bowel disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NCX-950	Alpha-2-[(1,1-dimethylethylamino)propyl]-4-hydroxy-1,3-benzeneisothiazolidine nitrate			Antiasthma	Asthma
n-Docosanol	Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]	861-19-8 149409-57-4	WO 9307113	Neuroleptic	Schizophrenia
NE-100		561-83-1			
Nealbarbital	2H-1-Benzopyran-2-methanol, Alpha,Alpha'-[iminobis(methylene)]bis(6-fluoro-3,4-dihydro-1,2R(R'(R''S'''))-(1+)-[CAS]	118457-14-0 99200-09-6	EP 145067	Antihypertensive, adrenergic	Hypertension, general
nebirolol	N1-(4,4-Dimethylcyclohexyl)-L-leoglutamine	163000-63-3	EP 0683312	Cognition enhancer	Unspecified
nebostinel		97205-34-0			
Nebracetam	Platinun, diamminedihydroxyacetato(2-)-O1,O2H, (SP 4-3), [CAS]	95734-82-0	EP 216362	Anticancer, alkylating	
nedaplatin	4H-Pyran(3,2-b)quinoline-2,8-dicarboxylic acid, 8-methyl-6,5-dihydro-4,6-dioxo-10-propyl-, [CAS]	89049-73-6 89049-74-7	EP 555718	Antiasthma, Ophthalmological	Rhinitis, allergic, general, Ocular disorder, general
nedocromil	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-ethoxyphenyl)-1-piperazinylpropyl]-5-ethyl-2,4-dihydro-4-(2-phenoxylethyl)-, [CAS]	82762-99-6 83366-66-9	US 4398317	Antidepressant	Depression, general
nelazodone	1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo-, [CAS]	77191-36-7	US 4341790	Cognition enhancer	Dementia, senile, general
nefirocelam	TH-2,5-Benzoxazoline, 3,4,5,6-tetrahydro-5-methyl-1-phenyl-, [CAS]	13859-70-0 23327-57-3	US 3487153	Analgesic, NSAID	
nefopam		33404-76-3			
Negamycin	3-Isquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-phenylthio)butyl-, (3S- (2/2S',3S',3A(4a,8a)), [CAS]	159989-65-8 159989-64-7			
nefinavir		75272-39-8		Antiviral, anti-HIV	Infection, HIV/AIDS
Nemonapride		59-99-4			
Neostigmine					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
necaditant	Cyclo(5-amino-2-allyl-L-leucyl-H ₂ -L-leucylamino)-2-deoxy-5-D-glucopyranosyl-L-alaninyl-L-alanine-L-prolyl-L-phenylalanyl (4-1)-lactam [CAS]	183747-35-5	WO 9820487	Asthma	Asthma
neramexone	1,3,3,3-t-pentamethyl-5-(2-oxo-2-aminomethyl)-2-oxo-1,3-dioxolane-5-carboxamide	262807-80-5		Dependence treatment	Addiction, alcohol
neridronic acid	Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- [CAS]	79778-41-9		Musculoskeletal	Osteogenesis Imperfecta
Nerifolin		486-07-9			
N-Ethylamphetamine		457-87-4			
netconazole	1H-imidazole, 1-[2-(methylthio)-1,2-(phenyloxy)phenyl]ethenyl-, monohydrochloride, (E)- [CAS]	130773-02-3 130726-68-0	EP 445540	Antifungal	Infection, Candida, general
netilmicin	D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-6-L-arabinopyranosyl-(1-6)-O-12,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-glycero-hex-4-enopyranosyl-(1-4)-2-deoxy-N1-ethyl- [CAS]	56391-56-1 56391-57-2	GB 1473723	Aminoglycoside antibiotic	Infection, general
nevirapine	5H-Dipyrido[3,2-b:3'-q][1,4]diazepin-4-one, 11-cyclopropyl-5,11-dihydro-4-methyl- [CAS]	12618-40-2	EP 429987	Antiviral, anti-HIV	Infection, HIV/AIDS
NGD-99-2			WO 9656669	Antibiotic	Anxiety, general
Nitallamide		51-12-7			
Nlaprazine		27367-90-4			
Nicametate		3059-52-3			
nicaraven	3-Pyridinecarboxamide, N,N'-[1-methyl-1,2-ethanediyl]bis- [CAS]	79455-30-4	EP 29902	Neuroprotective	Haemorrhage, subarachnoid
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-oxo-1-phenyl-2-methyl-2-(methyl(phenylmethyl)amino)ethyl ester) [CAS]	54627-94-3 55985-32-5	US 3985756	Neuroprotective	Hypertension, general
nicargoline	Argaline-8-methanol, 10-methoxy-1,6-dimethyl-, (6R)-, 5-tromo-3-pyridinecarboxylate(ester)	27845-84-6		Formulation, modified-release, other	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nicetrol		5808053			
Niclosamide		50-65-7			
Niclosanate		10571-59-2			
Nicofuranose		15351-13-0			
Nicomol		27958-26-8			
Nicomorphine		639-48-5			
Nicorandil	5-(3-pyridinylcarboxamido, N12-nitrooxy)pyridine (CAS)	68141-46-0	US 4792564	Vasodilator, coronary	Hypertension, general
Nicotinamide		98-92-0			
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- (CAS)	54-11-5		Formulation, inhalable, other	Addiction, nicotine
Nicotinic Acid		59-67-6			
Nicotinic Acid Benzyl Ester		94-44-0			
Nicotinyl Alcohol		100-55-0			
nicotipine	4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarboximethoxy-1,4-dihydropyridine	21829-25-4	GB 1173862	Vasodilator, coronary	Hypertension, general
nifedipant	2,4-(1H,3H)-Pyrimidinone, 6-[[2-[(2-hydroxyethyl)(3-(4-nitrophenyl)propylamino)ethyl]amino]-1,3-dimethyl]-, (CAS)	130536-43-0 130556-51-8	EP 369627	Antiarhythmic	Arrhythmia, general
Nifenalol		7413-36-7			
Niflumic Acid		4394-00-7			
Nifuratel		4936-47-4			
Nifurtolone		3363-58-4			
Nifuroxazide		965-52-6			
Nifuroxime		6236051			
Nifurpirinol		13411-16-0			
Nifurpazine		1614-20-6			
Nifurtimox		23256-30-6			
Nifurtinolol		1088-92-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nitazoxanide	2-[1-hydroxy-2-nitro-2-(4-oxo-1,2,3,4-tetrahydro-2H-pyridin-5-ylidene)-5-oxo-1H-imidazo[4,5-b]pyridin-3-ylidene]propanoic acid, 5-nitro-3-(5-nitro-2-furanyl)-2-propenylidenehydrazide [CAS]	39978-42-2	US 3847911	Antidiarrheal	Infection, GI tract
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0		Formulation, other	Infection, general
Nikephamide		59-26-7			
nilutamide	2,4-bis[4-azolidinedione, 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)]-1,3,5-triazine-2,4-dione, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	63612-50-0	US 4472382	Anticancer, hormonal	Cancer, prostate
nilvadipine	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	75530-88-6	US 4338322	Antihypertensive, other	Hypertension, general
nitrasulide	Methanesulfonamide, N-(4-nitro-2-phenoxypheyl)- [CAS]	51803-78-2	US 3840597	Anti-inflammatory	Pain, general
Nimetazepam		2011-67-8			
nitrodiopine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	66085-59-4	EP 533014	Neuroprotective	
Nimorazole		6506-37-2			
nitruseline	Urea, N-[(4-amino-2-methyl-5-pyridinyl)methyl]-N-(2-chloroethyl)-N-nitroso- [CAS]	103745-00-2 42471-28-3 55661-38-6	GB 1374344	Anticancer, alkylating	Cancer, brain
Ninopterin	N-[(4S)-(Cyclopropylamino)-3-(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-benzopyran-5-yl]-4-methoxybenzenesulfonamide	2179-16-0			
NIP-142			WO 9804542	Antirhythmic	Fibrillation, atrial
NIP-531	N-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-[H-1-(4-fluorobenzyl)benzimidazol-2-yl]-aminopropyl]-N-methylurea hydrochloride			Antipruritic/anti-inflammatory, allergic	Eczema, atopic
nitrocecidine	N-[2-[(5-[(dimethylamino)methyl]furfuryl)bi(2-ethyl)-2-nitro-N-piperonyl-1,1-ethenediamine	84845-75-0	GB 2104071	Antitumor	Ulcer, GI, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nipradolol	2H-1-Benzoxan-3-d, 3,4-dihydro-8,7,2-hydroxy-3-[(1-methylethylamino)propoxy]-, 3-nitrate [CAS]	81486-22-8 86247-86-1	EP 42289	Formulation, mucosal, topical	Glaucoma
Nitrazole		61-57-4			
nesolipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]				
nitazoxanide	Benzanide, 2-(acetoxy)-N-(6-nitro-2-thiazolyl)- [CAS]	63675-72-9	GB 1616793	Antihypertensive, other	Hypertension, general
nitacinone	1,3-Dicyclohexanone, 2-(2-nitro-4-(trifluoromethyl)benzoyl)- [CAS]	55981-09-4	US 5387698	Protozoacide	Infection, GI tract
nitrazine	1,3-Propanediamine, N,N-dimethyl-N-(1-nitro-9-acridinyl)- [CAS]	104206-65-7 433539-5 6914-85-8	EP 186118	Metabolic and enzyme disorders	Cirrhosis, hepatic
Nitrazepam		146-22-5	FR 1458183	Anticancer, other	Cancer, ovarian
nitrazipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, [CAS]	39562-70-4	GB 1358951	Antihypertensive, other	Hypertension, general
nitrofuribiphen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitroxybutyl) ester [CAS]	158836-71-8	EP 670825	Urological	Incontinence
Nitrofurantoin		67-20-9			
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	59-87-0 55-68-0			
Nitromersol		133-58-4		Formulation, transdermal, patch	Angina, general
nitronaproxen	2-Naphtalenecarboxylic acid, 6-methoxy-Alpha-methyl 4-(nitroxy)butyl ester (Alpha) [CAS]	163133-43-5	WO 9509831	Analgasic, NSAID	Pain, post-operative
nitroazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-(3-(dimethylamino)propyl)-2-nitro-, monohydrochloride [CAS]	16398-39-3 4008-48-4	NL 6608671	Antidepressant	
Nitroxoline					
nitazidine	1,1-Ethenediamine, N-[2-[(2-(dimethylamino)methyl)-4-thiazolyl]phenyl]thiolethyl-N-methyl-2-nitro- [CAS]	76863-41-2	EP 49818	Antitumor	Ulcer, duodenal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nifedipine	3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isoumarin	54533-85-6			
NM-3			JP 08176138	Anticancer, other	Cancer, general
NM-702	4-Bromo-5-(3-pyridylmethylamino)-6-(3-(4-chlorophenyl)propoxy)-3(2H)pyridazinone hydrochloride			Antithrombotic	Peripheral vascular disease
N-Methylephedrine		552-79-4			
N-Methylepinephrine		554-99-4			
N-Methylglucamine		6284-40-8			
NH-414	8-chloro-3-(1-methylcyclopropylamino)-4H-benzol[3,2-e][1,2,4]triazine-1,1-dioxide			Antidiabetic	Diabetes, Type II
NNC-05-1869	(R)-1-(5-(10,11-dihydro-5H-dibenz[de][1,2,3-bisphosphin-5-ylidene)-1-propyl)-3-piperidine carboxylic acid			Symptomatic antidiabetic	Neuropathy, diabetic
Nogalamycin	4(1H-Quinazolinone, 2-amino-8-methyl-5-(4-pyridylthio), [CAS]	1404-15-5 132545-88-4			
nolafired	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+/-) [CAS]	147149-76-6	WO 9320055	Anticancer, antimetabolite	Cancer, liver
nolmole	1-Azobicyclo[2.2.2]octane, 1,2-[3-(3,4-dichlorophenyl)-1-[3-(1-methylthoxy)phenyl]acetyl]-3-piperidinylethyl-4-phenyl-, chloride, (S) [CAS]	138531-51-8	WO 9529147	Cardiosimulant	Heart failure
nolplanium	18-Norpregna-4(3-diene)-3,20-dione, 17-(acetyl)-5-methyl- [CAS]	153050-21-6	EP 591040	GI inflammatory/bowel disorders	Inflammatory bowel disease
nomegestrol		56652-20-3	DE 2522533	Menstruation disorders	Menstrual disorder, general
Nonifensine		24526-64-5			
Noprylsulfamide		576-97-6			
Norbolethone		1235-15-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nordazepam		1088-11-5			
Nordefrin		6539-57-7 (unspecified); 74812-63-8 (R*, S*)-(±)- form			
Nordihydroguaiaretic Acid		27686-84-6 (meso-form); 500-38-9 (unspecified)			
Norelgestromin, Ethinyl Estradiol					
Norepinephrine		51-41-2			
Norethandrolone		52-78-8			
Norethindrone		68-22-4			
Norethynodrel		68-23-5			
Norfenefrine		536-21-0			
norfloxacin	3-Quinolincarboxylic acid, 1-ethyl-6-fluoro- 1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	6807-27-0 70459-96-7	US 4146719	Quinolone antibacterial	Infection, general
Norgestosterone		13563-60-5			
Norgestimate		35189-28-7			
Norgestrel		6533-00-2			
Norgestronone		848-21-5			
Norevorphanol		1531-12-0			
Normethadone		467-85-6			
Normethandrone		514-61-4			
Normorphine		468-97-7			
Norphenazone		89-25-8			
Norplpanone		561-48-8			
Norpseudoephedrine		492-39-7			
Nortriptyline		72-69-5			
Norvinisterone		6795-60-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Noscapine		128-62-1			
Novembichin		1936-40-9			
Novobiocin		303-81-1			
Noxiptilin		3362-45-6			
Noxythiolin		15599-39-0			
NS-1209	Bulanic acid, 2-[[[5-(4-{(dimethylamino)sulfonyl}phenyl)-1,2,6,7,8-tetrahydro-6-methyl-2-oxo-3H-pyrido[3,2-b]isoquinolin-3-ylidene]amino]oxy-3-hydroxy-5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrido-[3,2-h]naphthalene-2,3-dione-3-oxime	254751-28-5	WO 9428747	Antiepileptic	Epilepsy, general
NS-1231				Neuroprotective	Ischaemia, cerebral
NS-126			US 5063222	Antiallergic, non-asthma	Rhinitis, allergic, general
NS-220	2-Methyl-5-(4-{5-methyl-2-(4-methylphenyl)-4-oxazoly]butyl-1,3-dioxane-1,2-carboxylic acid			Hypolipemic/Antiatherosclerosis	Atherosclerosis
NS-2330	NS 2330 [CAS]	402856-42-2		Cognition enhancer	Alzheimer's disease
NS5A inhibitors			US 6030785	Antiviral, other	Infection, hepatitis-C virus
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[[5-(1-piperidinyl)propyl]oxy]-monohydrochloride [CAS]		WO 9607641	Neuroprotective	Ischaemia, cerebral
NS-9	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrole-3-carbonitrile	178429-87-9		Urological	Incontinence
NSC-330507	17-Allylaminogeldanamycin			Anticancer, antibiotic	Cancer, general
NSC-619534	2-chloroethyl phenyl selenone			Anticancer, alkylating	Cancer, general
NSC-697726	2,6-diisindinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone			Anticancer, antibiotic	Cancer, general
N-Sulfamyl-3,4-xy/amide		120-34-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NU-5027	2,4-Pyrimidinediamine 1-(cyclohexylmethoxy)-5-nitroso- [CAS] 2,4,6-tris(1H,5H-pyridazinone, 5-ethyl)-5-oxo-pentyl-, 2-oxime [CAS]	220036-08-8		Anticancer, other	Cancer, general
NV-07	[(3R,4R,10aR)-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[gluino]line-3-carboxylic acid-4-(4-nitrophenyl)piperazine amide, hydrogen maleate	53745-16-7	US 6455032	Antipruritic/inflam. non-allergic	Keratosis
NVP-SPA880	(S)-(+)-2-[4-(2-fluorobenzoyloxy)benzyl]amino]propanamide methanesulfonate			Neurological	Unspecified
NW-1029	GPI 22 [CAS]				
NXY-059	1-imidazolidinacetic acid, 3-[[(2-nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	168021-79-2	US 5790510	Analgesic, other Neuroprotective	Pain, general Ischaemia, cerebral
Nylidrin		447-41-6			
NZ-314		128043-99-2	EP 353198	Symptomatic antidiabetic	Neuropathy, diabetic
NZ-419	5-hydroxy-1-methylimidazolidine-2,4-dione		EP 412940	Urological	Renal failure
Obidoxime Chloride	OC 108 [CAS]	114-90-9			
OC-108	Methanone, 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]- [CAS]	162602-62-2		Vasoprotective, topical	Venous insufficiency
ocetapion		99904-21-8	EP 125847	Anodytic	Generalized anxiety disorder
Octabenzonone		1343-05-6			
Octacaine		13912-77-1			
Octanoxin		4684-87-1			
Octaverine		549-68-8			
octenidine		70775-75-8			
Octodrine	1-Octanamine, N,N'-(1,10-decanediyl)-1,4(bis-pyridin-4-ylidene)bis- [CAS]	71261-02-0 89767-76-1	WO 8705501	Stomatological	Periodontitis
Octopamine		543-82-8			
Octotamine		104-14-3			
Octotianine		137-86-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
octroide	L-Cysteine, D-phenylalanine-L-cysteinyl-L-phenylalanine-D-phenyl-L-tyrosyl-thionyl-N,2-hydroxy-1-(hydroxymethyl)pyrrolidine-2,7-disulfide, [R*(R*)], [CAS]	83150-76-9		Formulation, fixed-dose combinations	Cancer, general
Octyl		5466-77-3			
Methoxycinnamate					
ofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+)-, [CAS]	82419-36-1	EP 47005	Quinolone antibacterial	
O-lodohippurate		133-17-5			
olanzapine	10H-Thieno[2,3-b](1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, [CAS]	132539-06-1	EP 454436	Neuroleptic	Schizophrenia
Oleandrin		465-16-7			
Oleic Acid		112-80-1			
olmesartan medoximil	1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(2-(1H-tetrazol-5-yl)(1,1-cyclopropyl)-4-ylmethyl)-, (S-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester, [CAS]	144689-63-4	EP 503785	Antihypertensive, renin system	Hypertension, general
olopatadine	11-(2,3-(Dimethylamino)propylidene)-6,11-dihydrobenzo[e]oxepin-2-carboxylic acid, monohydrochloride	113806-05-6 140462-76-6	EP 235796	Ophthalmological	Conjunctivitis
olpadronic acid	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	83132-39-8	WO 961998	Osteoporosis treatment	Osteoporosis
olelazine	Benzoic acid, 3,3'-azobis(6-hydroxy- [CAS]	75722-26-2			
olipraz	3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl-, [CAS]	53200-51-4 64224-21-1	US 4559330 DE 2705641	GI inflammatory/bowel disorders Anticancer, other	Colitis, ulcerative Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OM-294DP	2-[3(R)-(Dodecanoyloxy)tetradecanamido]-N-[4-(3(R)-hydroxytetradecanamido)-5-(phosphonoxo)pentyl]-4-(phosphonoxo)butylamide			Anticancer, immunological	Unspecified
	ethyl 6Z,8Z,11Z,14Z,17Z,elcisa-5,8,11,14,17-hexamethyl-2-ethyl-14Z,7Z,10Z,13Z,16Z,19Z-dodeca-4,7,10,13,16,19-hexaenoate	81996-94-5 88227-47-6			
Omacor	7H-Pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, octahydro-4-[(2-mercaptopropylamino)-5-oxo, (4S-[(4S)phatRY]alpha, (6aZ)]- [CAS]	167305-00-2	US 5508272	Antihypertensive, renal system	Hypertension, general
omeprazole	1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl- [CAS]	73590-58-6	US 4255431	Anticancer	Ulcer, GI, general
omiloxatine	Etlanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]	176894-08-0		Antidepressant	Depression, general
omnicorazole	1H-Imidazole, 1-[2-[2-(4-chlorophenoxy)ethoxy]-2-(2,4-dichlorophenyl)-1-methylethenyl]-, (2Z)- [CAS]	74512-12-2	EP 8804	Antifungal	Infection, dermatological
Onapristone	4H-Cardiazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- [CAS]	963346-61-1 99614-01-4 99614-02-5			
ondansetron	Benzoic acid, 4-[(1E)-3-[(2-ethoxy-2-oxoethyl)-2-propenylamino]-2-methyl-3-oxo-1-propanyl]-, 4- (aminomonomethylphenyl) ester, monomethanesulfonate [CAS]	US 4847281		Antiemetic	Chemotherapy-induced nausea and vomiting
ONO-3403		181586-07-2		GI inflammatory/bowel disorders	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ONO-4128	1-(4,9-Triazapolo[5,5-b]indole-2,5-dione, 1,3-bis[3,4-(epoxymethyl)-9-(2,3-dihydro-1,4-benzodioxin-5-yl)methyl]-[CAS]	342394-93-8		Antiviral, anti-HIV	Infection, HIV/AIDS
ONO-8815 Ly	L-lysine (2)-7-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E)-4-(1-ethoxydibutyl)-4-hydroxy-1-butenyl]cyclopentyl]-5-heptenoate				
ONT-088			US 5766527	Labour inhibitor Radio/chemosensitizer	Labour, preterm Cancer, general
OPC-14623	2-[(1H)-Quinolone, 1'-3'-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy- [CAS]	145989-30-8	EP 512525	Antidepressant	Depression, general
OPC-31260	Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-	137975-06-5	WO 9105549	Urological	Unspecified
OPC-51803	(SR)-2-[1-(2-chloro-4-(1-pyridinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide			Antidiabetic	Diabetes, insipidus
OPC-8535	2-Pyridinacetic acid, 6-[2-[3,4-diethoxyphenyl]-4-thiazoyl]- [CAS]	145739-56-6	WO 9205986	GI Inflammatory/bowel disorders	Inflammatory bowel disease
Opinazide	2-(4-(4-fluoromethylphenyl)-N-methyl-1-phenyl-2-(1-pyridinyl)ethyl)acetamide	2779-55-7			
opioid analgesics				Analgesic, other	Pain, general
Opipramol		315-72-0			
Orazamide		2574-78-9			
orazipone	2,4-Pentanedione, 3-[(4-methylsulfonyl)phenyl(methyl)ene]- [CAS]	137109-78-5	EP 440324	Antiasthma	Unspecified
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl], monohydrochloride [CAS]	210821-63-9		Antidepressant	Depression, general
Org-24448			US 5156008	Neuroleptic	Schizophrenia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ortavancin	Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-Alpha-L-arabinohexopyranosyl)-N3'-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-4-TR; [CAS]	171099-57-3	US 5840684	Peptide antibiotic	Infection, dermatological
	L-Leucine, N-formyl-, 1-[3-Hexyl-4-oxo-2-oxoethyl(methyl)decyl ester, [2S-2(Alpha(R),3(R))]; [CAS]	96828-58-2	EP 129748	Anorectic/Aniobesity	Obesity
orlistat	Pyridoline, 1-[2-(p-(7-methoxy-2,2-dimethyl-3-ethenyl)-4-chloranyl)phenoxylethyl], trans-[CAS]	31477-60-8	DE 2329201	Female contraceptive	Contraceptive, female
Ornidazole		16773-42-5			
	Ornithine	3397-23-7			
Ornithine		70-26-8			
	Prost-13-en-1-ol; acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70567-26-4	US 4276688	Prostaglandin	Ulcer, gastric
Orotic Acid		65-86-1			
	Orphenadrine	83-98-7			
Orphenadrine		536-25-4			
	Osalcaine	526-18-1			
Osalmid	Acetamide, N-[1-(3-(R)-1-benzoyl-3-(4-dichlorophenyl)-3-phenylpropyl)-4-phenyl]-4-piperidinyl-N-methyl; [CAS]	160492-56-8	EP 673928	Neuroleptic	Schizophrenia
osanelant	2-Oxopropyls-4,5-dioxo-3,20-dione, 17-(acetyl)-6-chloro- [CAS]	105149-00-6	EP 193871	Prostate disorders	Benign prostatic hyperplasia
osaterone	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethoxypropyl)-, ester, (3R,3a(R),4(R),5a(R))-; [CAS]				
oseltamivir	4'-Thio-5'-D-arabinofuranosylcytosine	196618-13-0	WO 9628933	Antiviral, other	Infection, influenza virus
OS-7636				Anticancer, anti-metabolite	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OSI-7904	Pentacyclic acid, 2-[6-[[1,2-dihydro-3-methyl-1-oxobenzofuran-5-yl]oxy]-2-hydroxy-2-yl], (S)- [CAS]	139987-54-5	WO 9119700	Formulation, optimized, liposomes	Cancer, general
sepiamifene	Etianol, 2-[4-[[1,2,4-trioxo-1,2-diphenyl-1-butenyl]phenoxy]- [CAS]	128607-22-7	WO 9807402	Menopausal disorders	Osteoporosis
edilium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[[4-[[2-(octyloxy)benzoyl]amino]benzoyl]oxy]-, bromide [CAS]	28095-59-0 630-60-4	GB 1181408	Antispasmodic	Irritable bowel syndrome
Guabain		33996-33-7			
Oxaceprol		66-79-5			
Oxacillin		26829-87-8			
Oxaflozane					
oxalipatin	Platinum, (1,2-cyclohexanediamine-N,N')[ethanedioate(2-)-O,O'], [SP-4-2 (1R,trans)]- [CAS]	61825-94-3	EP 393575	Anticancer, alkylating	Cancer, colorectal
Oxaly-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-67-5 15301-80-1	DE 2249274	Urological	
Oxamarin		27035-30-9			
Oxametacine		21738-42-1			
Oxaminiquine					
oxandrolone	2-Oxandrostane-3-one, 17-hydroxy-17-methyl-, (5 α ,17 β)- [CAS]	63-39-4 36531-28-7 541-66-2	US 3128283	Reproductive/gonadal, general	Sex-chromosome abnormality, Turner's syndrome
Oxantel					
Oxapropantium	2-Oxazolepropanoic acid, 4,5-diphenyl- [CAS]				
oxapropazin	2H-Benzimidazol-2-one, 1-[3-[4-(di-phenyl)methyl]-1-piperazinyl]propyl-1,3-dihydro- [CAS]	21256-18-8	GB 1206403	Antiarthritic, other	Arthritis, osteo
oxatolamide	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	90007-34-3	GB 1579365	Antiallergic, non-asthma	Rhinitis, allergic, general
oxazepam		904-75-1		Formulation, oral, orally-disintegrating	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Oxyfedrine	Ocdane, 1-bromo-1,1,2,2,3,4,4,5,5,6,6,7,7,8,8,8-hexadecafluoro- [CAS]	15687-41-9			
Oxygent		423-55-2		Haematological	Surgery adjunct
Oxymesterone		145-12-0			
Oxymetazoline		1491-59-4			
oxymetholone	Androsian-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α H, 17 β)- [CAS]	434-07-1		Hormone	Anaemia, general
Oxymethurra		140-95-4			
oxymorphone	(SAlph α)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	76-41-5		Formulation, modified-release, immediate	Pain, general
Oxypendyl		5585-93-3			
Oxypertine		153-87-7			
Oxyphenbutazone		129-20-4			
Oxyphenacylimine		125-53-1			
Oxyphenisatin		115-33-3			
Oxyphenonium		50-10-2			
Oxypinocampnone		10136-65-9			
oxypurinol	1H-Pyrazolo[3,2-g]pyrimidine-4(8H,7H)-dione [CAS]	2465-58-0		Antigout	Hyperuricaemia
Oxytetracycline		79-57-2			
oxagrel	2-Propenoic acid, 3-(4-(1H-imidazol-1-ylmethyl)phenyl)-, (E)- [CAS]	8371-45-3 8371-53-7	GB 2025946	Antithrombotic	Vasospasm, cerebral
P-(benzylsulfonamido)benzoic Acid		536-95-8			
P-100	Penitolic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]		US 6313177	Antiviral, anti-HIV	Infection, HIV/AIDS
P-1202	Ox-(3N) [(2S,3S)-2-amino-3-methyl-pentanoyl]-1,3-thiazolidine/thiuronate	79416-27-6	US 6034267	Dermatological	Keratosis
P22/98				Antidiabetic	Diabetes, Type II
PA-824			WO 9701562	Antimycobacterial	Infection, tuberculosis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PACAP 38	Pituitary adenylate cyclase-activating peptide-38 [CAS]	128606-20-2	US 5128242	Neuroprotective	Nerve injury, general
paclitaxel	5 β -20-Epoxy-12 α -alpha,4,7 α ,10 β ,13 α -hexahydroxy-14 α -methyl-1 α -oxo-1,10-diolate-2-benzoylate-13-(4 α -phenylthiopyrate)	33069-82-4		Formulation, optimized, nanoparticles	
PAURE	1H-Isindol-1-one, 2-(7-chloro-1,6-naphthyridin-2-yl)-2,3-dihydro-3,6-methyl-2-oxohexyl-, (R)- [CAS]		US 6413635	Immunostimulant, other	Cancer, breast
pagoclone		133737-32-3	US 4980779	Anaesthetic	Vaccine adjuvant
PAI inhibitor			WO 9404512	Antithrombotic	Penic disorder
palindore	8H-1,4-dioxino[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenylmethyl)amino]methyl-, 2(S)-, (2E)-2-butenedioate (1:1)	189681-71-8			Thrombosis, venous
Palivizumab	3aS,2'-(S)-1-Azabicyclo[2,2,2]oct-3-yl-, 2,3,3a,4,5,6-hexahydro-1-one-1H-benz[de]isoquinoline hydrochloride	188039-54-5		Neuroleptic	Schizophrenia
palonosetron		135729-82-3	US 5202333	Antiemetic	Chemotherapy-induced nausea and vomiting
Pamabrom		608-04-2			
Pamaquine		491-92-9			
pamocogrel	1H-Pyrole-1-acetic acid, 2,4,5-tris(4-methoxyphenyl)-2-thiozyl-, ethyl ester [CAS]	101001-34-7	EP 159677	Antithrombotic	Thrombosis, cerebral
panitronate	3-Amino-1-hydroxypropylidene(diphosphonic acid- [CAS]	40391-99-9		Formulation, implant	Hypocalcaemia of malignancy
p-Aminobenzoic Acid		150-13-0			
p-Aminopurpuric Acid		61-78-9			
p-Aminopropiophenone		70-69-9			
p-Aminosalicylic Acid		65-49-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Paravir	4-(4-isopropylphenyl)benzothio-2,8-di- <i>t</i> -butylphenol			Neuroprotective	Vasospasm, cerebral
Pancuronium		15500-86-0			
Paniphenem		87726-17-8			
Pantethine		16816-67-4			
paniprazole	1 <i>H</i> -Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]- [CAS]				
Pantothenic Acid		102825-70-7	EP 166287	Analgesic	Ulcer, duodenal
Papain		79-83-4			
Papaverine		58-74-2			
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2		Formulation, oral, other, modified-release	Pain, general
Paralutizide		1580-83-2			
Paraldehyde		123-63-7			
Paramethadione		115-67-3			
Paramethasone		53-33-8			
Paranyline		1729-61-9			
Parathyroid Hormone	Propanamide, N-[(4-{5-methyl-3-phenyl-4-isoxazolyl}phenyl)sulfonyl]-, sodium salt [CAS]	9002-64-6			
parecoidb		198470-85-8	WO 9738868	Analgesic, NSAID	Pain, post-operative
Parethoxycaine		94-23-5			
Pargyline		555-57-7			
paricalcitol	19-Nor-8,10-secoergosta-5,7,22-triene-1,3,25-triol, (1 α ,3 α ,7 α ,22 β)- [CAS]	131918-61-1	EP 387077	Hormone	Hyperparathyroidism
paromomycin	O-2-Amino-2-deoxy-Alpha-D-glucopyranosyl-(1 \rightarrow 4)-O-2,6-diamino-2,6-dideoxy-5-L-ribofuranosyl-(1 \rightarrow 3)-8-D-ribofuranosyl-(1 \rightarrow 6)]-2-deoxy-D-streptamine	7542-37-2		Proteoracide	Infection, leishmaniasis
paroxetine	Pipendine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3 <i>S</i> -trans)- [CAS]	61869-08-7	EP 223403	Antidepressant, formulation, oral, orally-disintegrating	Depression, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Paroxipropione		70-70-2			
Paralimide		30653-83-9			
ParTrin-2	4-Bromothienylguanine			Radiochemosensitizer	Cancer, melanoma
Pazfinacone		103255-66-9			
parafloxacin	7-[[4-(2,3-dichlorophenyl)-5-(4-benzoxazine-5-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-[CAS]	127045-41-4 127045-45-1 136905-87-9	DE 3913245	Quinolone antibacterial	Infection, general
p-Bromoacetanilide		103-88-8	US 4978063	Formulation, other	Arthritis, general
PC-NSAIDs	6-(2,6-Dichlorophenyl)-2-[4-(diethylaminoethoxy)phenylamino]-6-pyridyl-3-pyrimidine-7-one				
PD-0166285					
Peciloclin		19504-77-9			
pelofloxach	3-Quinolinesulfonyl-4-oxo-1-ethyl-5-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	70488-92-3	GB 1598915	Quinolone antibacterial	Infection, urinary tract
pegvisomant	Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine (human), pegylated [CAS]	218620-50-9		Somatostatin	Acromegaly
Pelletierine		4396-1-4			
pemetrexed	L-Glutamic acid, N-(4-(2-amino-4,7-dihydro-4-oxo-1H-pyrimidin-5-yl)ethyl)-4-oxo-1H-pyrimidin-2,3-diol [CAS]	137281-23-3 150389-23-8	US 5248775	Anticancer, antimetabolite	Cancer, mesothelioma
penmolast	4H-Pyrido[1,2-a]pyrimidin-4-one, 5-methyl-3-(1H-tetrazol-5-yl) [CAS]	107285-05-9 69372-19-6	US 4457932	Antisthma	Asthma
Penoline		2152-34-3			
Pemipidine		79-55-0			
PEN-203			US 5955446	Antiviral, other	Infection, human papilloma virus
Penamercillin		983-85-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
penbutolol	2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-(S)-, sulfate (2:1) (salt) [CAS]	38963-32-5 38963-40-5	GB 1215751	Antihypertensive, adrenergic	
pendocvir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39909-25-1	JP 60059982	Antiviral, other	Infection, herpes simplex virus
Penethamate		803-71-9			
penflutridol	4-Piperidino, 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl] [CAS]	26984-56-2	DE 2040231	Neuroleptic	
Penicillamine		52-87-5			
Penicillin G	81-33-6				
Penicillin G Benzathine	1538-09-6				
Penicillin G Procaine	6130-64-9				
Penicillin N	325-94-0				
Penicillin O	87-09-2				
Penicillin V	87-08-1				
Penimepicycline	4595-60-4				
Pentamides			US 4221778	Formulation, modified-release, other	Rhinitis, allergic, general
Pentaerythritol Chloral		78-12-6			
Pentaerythritol		2209-86-1			
Dichlorohydrin					
Pentaerythritol		597-71-7			
Pentagastrin		5634-95-2			
Pentagestone		7001-56-1			
Penulyls	Starch, 2-hydroxyethyl ether [CAS]	9005-27-0	US 5407428	Plasma substitute	Surgery adjunct
Pentamethonium		541-20-8			
pentamidine	Benzenehexa-carboximidamide, 4,4'-(1,5-pentamethyldiis(oxyl)bis- [CAS]	100-33-4		Formulation, inhalable, systemic	Infection, Pneumocystis jiroveci prophylaxis
Pentazocine		359-83-1			
Pentetate		12111-24-9			
Pentetic Acid		67-43-6			
Pentetreotide		138681-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Penthenate		60-44-6			
Pentifyline		1028-33-7			
Pentigetide		62087-72-3			
Pentisomide		78833-03-1			
Pentobarbital		76-74-4			
Pentolinum		52-62-0			
Pentorex		434-43-5			
pentosan	Xylan, [CAS]	37319-17-8	US 5180715	Urological	Inflammation, urinary tract
pentosatin	imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- β -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R), [CAS]	53910-25-1	US 3923785	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
pentoxifyline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-, [CAS]			Neuroprotective	Amniotic lateral sclerosis
Pentoxyl		147-61-5			
Pentifenitrol		1607-17-6			
Pentylmetetrazole		54-95-5			
peplomycin	Gleomycinamide, N1-[3-(1-phenylethyl)amino]propyl-, (S), [CAS]	68247-85-8	US 4195018	Anticancer, antibiotic	
Perazine		84-97-9			
Perflubron		423-55-2			
Perfosamide		62435-42-1; 39800-16-3 (unspecified)			
pergolide	Ergoline, 6-(((methylthio)methyl)-5-propyl-, (8S)-, monomethanesulfonate-, [CAS]	66104-22-1 66104-22-2	US 4797405	Antiparkinsonian	Parkinson's disease
Perhexiline		6621-47-2			
Pertivazine		2622-28-6			
perfosine	Hydridium, 4-[[[3-(2-deoxy-2-(phosphorylthio)propyl)-1,3-dioxol-5-yl]iminyl], inner salt [CAS]	157716-52-4	EP 594989	Anticancer, other	Cancer, prostate
perillyl alcohol	n-Cyclotrioxane-1-methanol, 4-(1-methylethenyl)-, [CAS]	536-39-4	US 5110832	Anticancer, other	Cancer, breast
Permethazine		13093-88-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]pyrrolidine, [2S-1-[[1-(1H-1,2,4)triazol-3-yl]amino]-2-methyl-2-propanamine (1:1)] [CAS]	107133-36-8 82834-16-0 98153-31-4	EP 49658	Antihypertensive, renin system	Hypertension, general
Perindyl	1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl), 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	53586-99-5 2139-25-5 2095-44-9			
perisoral		1977-11-3	JP 04217925	Anti-inflammatory	
Perlapine		52645-53-1			
Permethrin					
perospirone	1H-Isindole-1,3(2H)-dione, 2-[4-[4-(1,2-benzodisiazol-3-yl)-1-piperazinyl]butyl]hexahydro-, cis- [CAS]	129273-38-7 150915-41-6	CA 2157004	Neuroleptic	Schizophrenia
Perphenazine		58-39-9			
Petroleum Benzil		8030-30-6	US 6331286	Antipsoriasis	Psoriasis
PH-10		84-12-8			
Phanquinone			WO 9638462	Immunological	Unspecified
Pharmaprojects No. 4884			WO 9703986	Neuroleptic	Schizophrenia
Pharmaprojects No. 5323			WO 0204426	Anaesthesia	Asthma
Pharmaprojects No. 5972			US 6057346	Antiviral, anti-HIV	Infection, HIV/AIDS
Pharmaprojects No. 6362	(R)-N-[4-[2-[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide				
Pharmaprojects No. 6446				Anorectic/Anitobesity	Obesity
Pharmaprojects No. 6580			WO 0206223	Psychostimulant	Attention deficit disorder
Pharmaprojects No. 6586			US 6465026	Genomics-based drug discovery	Cancer, brain
Pharmaprojects No. 6691			US 6299600	Formulation, other	Pain, general
Pharmaprojects No. 6743	3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]acrylamide			Antibacterial, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pharmaprojects No. 6748	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methylidibenzoc[5,6]pyrazine[1,2-a]pyridine				
Phenacaine		520-99-5			
Phenacetamide		53-98-9			
Phenacetin		62-44-2			
Phenadoxone		467-84-5			
Phenalllylmal		115-43-5			
Phenacet		3819-34-9			
Phenazocine		127-35-5			
Phenazopyridine		136-40-3			
Phenbutamide		3149-00-6			
Phencyclidine		77-10-1			
Phendimetrazine		634-03-7			
Phenelzine		51-71-8			
Phenesterine		3546-10-9			
Phenetharbital		357-67-5			
Phenethicillin		132-93-4			
Phenetidine		90-49-3			
Phenformin		114-86-3			
Phenylglutamine		1156-05-4			
Phenindamine		82-88-2			
Phenindione		83-12-5			
Pheniprazine		55-52-7			
Pheniramine		86-21-5			
Phenmetrazine		134-49-6			
Phenobarbital		50-06-6			
Phenobutiodil		554-24-5			
Phenocodol		103-97-9			
Phenoclide		78-05-7			
Phenolphthalein		77-09-8			
Phenolphthalol		81-92-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenolsulfonphthalein		143-74-8			
Phenol	Phenoltetrachlorophthal	639-44-1			
Phenopertidine		562-26-5			
Phenosulfazole		515-54-8			
Phenoxybenzamine		59-98-1			
Phenoxypropazine		3818-37-9			
Phenprobamate		673-31-4			
Phenprocoumon		435-97-2			
Phenserine	Pyridol(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), (S,S'-di-), [CAS]	101246-66-6		Cognition enhancer	Alzheimer's disease
Phensuximide		86-34-0			
Phentermine		122-09-8			
Phentolthalein		18285-54-8			
Phenolamine	Phenol, 3'-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenylamino)-, monomethanesulfonate (salt) [CAS]	65-26-1 50-60-2		Formulation, oral, other	Impotence
Phenyl Acetyl/salicylate		134-55-4			
Phenyl Aminosalicylate		133-11-9			
Phenyl Salicylate		118-55-8			
Phenylbutazone		50-33-9			
Phenylephrine		61-76-7			
Phenylethanamine		7568-93-6			
Phenylmercury		102-98-7			
Phenylmethylbarbituric Acid		76-94-8			
phenylpropanolamine	Benzenemethanol, Alpha-(1-aminooethyl)-, (R*, S*)-(+/-), [CAS]	14838-15-4		Anesthetics/Anesthetics, formulation, optimized, microparticles	
Phenylpropylmethylamine		93-88-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenytobaxamine		92-12-6			
Phenylamidol	2,4-limidazolidinedione, 5,5-diphenyl- [CAS]	553-69-5			
phenytoin		57-41-0		Formulation, oral, other	Epilepsy, general
Phenethylate		510-34-9			
Phloroglucinol		108-73-6			
Pholcodine		509-67-1			
Photedrine		370-14-9			
Phosphocreatine		67-07-2			
Phosphorylcholine		5746-40-7			
Phthalylsulfacetamide		107-73-3			
Phthalylsulfathiazole		131-69-1			
p-Hydroxyvephedrine		85-73-4			
p-Hydroxyvephedrine		365-26-4			
Phylloquinone		84-80-0			
Physostigmine		57-47-6			
Phytic Acid		83-86-3			
PI-88	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)-hydrogen sulphate [CAS]	165077-23-0		Anticancer, other	Cancer, melanoma
Piberaline		39640-15-8			
piboserod	2H(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	152811-62-6	WO 93/18036	Antiarrhythmic	Fibrillation, atrial
Picilorex		62510-56-9			
Picloxydine		5636-92-0			
Picoperine		21755-66-8			
Picosulfate		10040-45-6			
Picotamide		32828-81-2			
Picumast		39577-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pidotimod	4-(1-methylimidazolidin-2-yl)-5-oxo-2-pyridinylcarboxylic acid, 3-[(5-oxo-2-pyridinyl)carboxyl]; [CAS]	121808-62-6	EP 276782	Immunomodulator, anti-infective	Infection, respiratory tract, lower
Pifamidine		56208-01-6			
pilocarpine	Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- [CAS]	60576-13-8	GB 1436502	Anti-inflammatory, topical	
Pildralazine	2-(3H)-Furanone, 3-ethylidihydro-4-[(1-methyl-1H-imidazo-5-yl)methyl]-, (3S-cis)- [CAS]	634000-73-3			
pilocarpine	2-Propanoic acid, 2-methyl-, dodecyl ester, polymer with 2-propanoic acid, compd. with (3S-cis)-3-ethylidihydro-4-[(1-methyl-1H-imidazo-5-yl)methyl]-2-(3H)-furanone [CAS]	92-13-7		Formulation, implant, Stomatological	
Pilopex	1H-Pyrolizine-7-[(6H)-acetamide, N-(2,6-dimethylphenyl)ketone], monohydrochloride [CAS]	62783-28-2	DE 2636559	Formulation, mucosal, topical	Glaucoma
pilocarpine		88069-49-2 88069-67-4	US 4564624	Antiarhythmic	Arrhythmia, general
Pimecrolime	15,19-Epoxy-3H-pyrido[2,1-c](1,4)oxazacyclotriosine-1,7,20,21-(4H,23H)-tetraone, 3-(2-(4-chloro-3-methoxyoxydihexyl-1-methylethenyl)-5-ethyl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26s-Hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S-(3R'E(1S',3S',4R'))), 4S'-9R',8S'-9E',12R',14R',5S',16R',18S',8,19S',26aR')- [CAS]	534-84-9			
pimecrolimus		137071-32-0	EP 626385	Antipruritic/anti-inflamm, allergic	Eczema, atopic
Pimefylline	Acetic acid, [2-(octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonyl)-2-pentanyloxy)ethoxy]-, methyl ester, [2R-(2 α),3 α ,4 α ,10 α](1E,3S',5S'),5 α ,6 α Alpha]; [CAS]	10001-43-1			
pimiprost		139403-31-9		Dermatological	Ulcer, general
Piminoindine		13495-09-5			
Pimobendan		74150-27-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pinazide	2H-Benzimidazole-2-one, 1-[1-(4,4-bis(4-chlorophenyl)butyl)-4-piperidinyl]-, 3-dihydro- [CAS]	2062-78-4	FR M3685	Neuroleptic	
Pinacidil		85371-64-8			
pinaverium	Morpholinium, 4-[2-bromo-4,5-dimethoxyphenyl]methyl-4-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl-, [CAS]	53251-94-8 59995-65-2	EP 406743	Antispasmodic	Irritable bowel syndrome
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propenyl)-[CAS]	52463-83-9	DE 2339790	Anxiolytic	
Pindolol		13523-86-9			
pioglitazone	2,4-Thiazolidinedione, 5-[4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl]methyl-, monohydrochloride (+/-) [CAS]	111025-46-9 112593-15-4	EP 193256	Antidiabetic	Diabetes, Type II
Pipacizine		1110-80-1			
Pipamperone		84-04-8			
Pipazethate		1893-33-0			
Piphehuzone		2167-85-3			
Pipeturium		27315-91-9			
	Piprazinium, 4,4'-[[26,34alpha,54beta,168,178]-3,17-bis(acetoxy)jandrostane-2,16-diyloxy]-1,1'-dimethyl-, [CAS]	52212-02-9	GB 1398050	Muscle relaxant	Anaesthesia, adjunct
pipecuronium	Pyrido[2,3-d]pyrimidine-5-carboxylic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)- [CAS]	66399-57-5			
pipecemic acid		51940-44-4	GB 1451911	Antibacterial, other	Infection, urinary tract
Pipenzolate Bromide		125-51-9			
Piperacetazine		3819-00-9			
piperacillin	4-Thia-1-arabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(4-ethyl-2,5-dioxo-1-piperazinyl)carbonyl]amino]phenyl]acetyl-aminol, 3,3-dimethyl-7-oxo-, [2S, (2Alpha,5Alpha,6S)]-, [CAS]	59703-84-3 61477-96-1	GB 1508062	Penicillin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Piperazine Adipate		142-88-1			
Piperidine		77-03-2			
Piperidolate		82-98-4			
Piperilate		4546-39-8			
piperine analogues			WO 002544	Dermatological	Vitiligo
Piperocaine		136-82-3			
Piperonal		120-57-0			
Piperoxan		59-39-2			
Piperylone		25-31-4-6			
Pipobroman		54-91-1			
Piposulfan		2608-24-4			
	Hexadecanoic acid, 2-[1-[3-[2-[(dimethylamino)sulfonyl]-10H-phenothiazin-10-yl]propyl]-4-piperidinylethyl ester [CAS]	37517-28-3 39980-99-6	US 4782077	Neuroleptic	
pipotizine					
Pipoxolan		18174-58-8			
Pipradrol		467-80-7			
piprozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene], ethyl ester [CAS]	17245-64-0	US 3971794	GI inflammatory/bowel disorders	Motility dysfunction, GI, general
Piracetam		7491-74-9			
	5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-xylo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[Alpha,10Alpha(S*)]]- [CAS]	72496-41-4	US 4303785	Anticancer, antibiotic	Cancer, breast
pirarubion					
Pirazolac		71002-09-0			
	2,6-Pyridinedimethanol, Alpha' [(1,1-dimethylethylamino)methyl]-3-hydroxy-, monoacetate (salt) [CAS]	38329-18-9 39877-81-5 65662-44-0			
pirbuterol			US 3786160	Antiasthma	Asthma
Prenoxline		1043-21-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pipecapine	6H-Pyrido[3,2-b]pyrazine-6-one, 5,11-dimethyl-1-(2-methyl-1-piperazinyl)acetyl- [CAS]	28797-61-7 29688-97-1	FR 1505795	Anticancer	
pirelande	Benzoic acid, 3-(aminoethyl)-4-phenoxyl-5-(1-pyridinyl)- [CAS]	55937-27-9	US 4010273	Antihypertensive, diuretic	Hypertension, general
pirfenidone	2-(1-pyridinyl)-6-methyl-1-phenyl- [CAS]	53179-13-8		Respiratory	Fibrosis, pulmonary
piribedil	Pyrimidine, 2,4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl- [CAS]	3605-01-4 87-21-8	US 3299067	Vasodilator, peripheral	Parkinson's disease
Piridocaine		55265-45-5			
Pirfratriate		302-41-0			
Pirfratriamde		72732-56-0			
Pirfraxim					
pirindole	1-H-Pyrazino[3,2-f]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU 270680	Antidepressant	Depression, general
pirimelol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-alpha-phenyl-, cis(+)- [CAS]	61477-94-9 66252-19-7	US 4112103	Antiarhythmic	Tachycardia, supraventricular
Piroctone		50650-76-5			
Piroheptine		16378-21-5			
Piromidic Acid		19552-30-2			
piroxtam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-(2-methyl-4-(2-pyridinyl)-1,1-dioxole [CAS]	36322-90-4	US 3862319	Anti-inflammatory	
piroxtam betadex	3-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N,2-pyridinyl-2H-1,2-benzothiazine-3-carboxamida 1,1-dioxole- [CAS]	121686-62-6 8684-38-8	EP 153988	Formulation, other	Pain, musculoskeletal
piroxtam cinnamate	2-Propanoic acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0			
Pirozadil		54110-25-7	EP 79639	Antiarthritic, other	Inflammation, general
Pirprofen		31793-07-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pilavastatin	6'-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-methyl-3,5-dihydroxy-1-phenyl)ethyl-1-oxopropoxy methyl ester, calcium salt (2:1), [S-(R ² , S'-E)]- [CAS]	147596-32-7	EP	Hypolipemic/Antiatherosclerosis	Hyperlipaemia, general
pivagabine	N-trimethylsilyl-L-aminobutyric acid	55542-35-4		Neurological	Anxiety, general
pivaloxymethyl	Biotinic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester [CAS]	122110-53-6	EP	Anticancer, other	Cancer, lung, non-small cell
Pivalybenzhydrazine		306-19-4			
Pivampicillin		33817-20-8			
pivampicillin/pivmecillinam		98445-47-7		Penicillin, oral	Infection, general
Pivcefalexin		53836-75-9			
	4-[Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 5-[[hexahydro-1H-azepin-1-yl)methyl]amino]-3,3-dimethyl-7-oxo-2-(2-aminomethyl-1-oxopropoxy)methyl ester, (2S,2'-alpha,3-alpha,6S)]- [CAS]	32886-97-8	GB	Penicillin, oral	Infection, general
pivmecillinam	Benzylisouquinoline-5,10-dione, 6,9-bis[(2-aminomethyl)amino]-, (2Z)-2-butenedioate(1:2)				
pixantone	4-[5-(10-dihydro-4H-benzo(4,5-f)pyrido[1,2-b]pyridine-4-ylidene)-1-methylpiperidine	144675-97-8	EP	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
pizotifen		15574-96-6	DE	Antimigraine	
Pizotylina		15574-96-6			
PK-188	Phenol, 4-((4-((1R)-1-phenylethyl)amino)-1H-pyrole(2,3-d)pyrimidin-6-yl))- [CAS]	187724-61-4		Anticancer, other	Cancer, general
p-Lactophenetide		539-08-2			
Plafibride		63394-05-8			
plasminogen activator	Plasminogen activator [CAS]	105913-11-9	EP	Fibrinolytic	Infarction, myocardial
Plasmocid		551-01-9			
Platonin		3571-88-8			
Plaunotol		154218-02-6			
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS]	198022-65-0	EP	Antifungal	Infection, Candida, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PLD-147	1,2,4-Oxadiazole-3-(3,5-dimethyl-4-(3-(3-oxo-4-oxo-1,2,4-oxadiazol-5-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-propan-1-ol				
Pleconaril				Anticancer, alkylating	Cancer, general
Plicamycin		153168-05-9	US 5464848	Antiviral, other	Infection, respiratory tract, general
P-Methylphenhydramine		18378-89-7			
PMS-301		19804-27-4			
Pneumococcal Vaccine, Diptheria Conjugate			WO 0001677	Antiviral, anti-HIV	Infection, HIV/AIDS
Pneumococcal Vaccine, Polyvalent					
PNU-28834	N-[(5S)-3-[[4(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide				
Podophyllotoxin		518-28-5		Antibiotic, other	Infection, general
Polaprezinc	Zinc, bis(N-[3-alanyl-L-histidinato-N3,O4]piv), (1-4), [CAS]	107687-60-7	EP 303380	Antituberc	Ulcer, duodenal
Polidine Methylsulfate		545-80-2			
Poliresulen		9011-2-3			
Polidexide		9064-92-0			
Polidocanol	Polyethylene glycol monododecyl ether	3355-38-0		Vasoprotective, systemic	Venous insufficiency
Poliovirus Vaccine Inactivated		9002-92-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
poly-ADPRT inhibitors					
Polyestradiol Phosphate		28014-46-2	WO 9843253	Anticancer, other	Cancer, general
Polyphenon E	Polyphenon E [CAS]	186265-33-0			
Polythiazide polymer	Phlorizin [CAS]	346-18-9 87665-31-3		Antiviral, other	Infection, human papilloma virus
Porifromycin		801-52-5	US 4682234	Anticancer, other	Cancer, lung, non-small cell
posaconazole	D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-((1S,2S)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-pyrazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)- [CAS]	171228-49-2			
Posatrelin		78664-73-0	US 5714490	Antifungal	Infection, fungal, general
potassium chloride	Potassium chloride [KCl] [CAS]	7447-40-7		Formulation, oral, enteric-coated	
Potassium Gluconate		289-27-4			
Potassium		1321-14-8			
Guaiacolsulfonate					
Potassium p-Aminobenzoate		138-84-1			
Potassium					
Pernanganate		7722-84-7			
Povidone		9003-39-8			
Povidone-Iodine		25655-41-8			
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]	92756-44-9	DE 2653028	Formulation, oral, other	Unspecified
PR-2699	(-)-(E)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)-1-imidazolylacetonitrile			Antifungal	Infection, fungal, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PR-608	(S)-(-)-1,4,4-bis(4-fluorophenyl)butyl-4-(2-hydroxy-3-phenylaminopropyl)pyrrolazine trifluoroborate			Antiparkinsonian	Parkinson's disease
Practolol		6673-35-4			
Pragmaline		35080-11-6			
Pralidoxime		51-15-0			
pralnacasan	8H-Pyridazino[1,2-a:1',2'-diazepine-1-carboxamide, N-(2R,3S)-2-carboxy-4-oxo-3-furanyl-4-hydroxy-9-(1-isopropyl-1-oxo-4-oxo-1,2-dioxo-1,2-dihydro-1,2,4-triazolo[4,3-b]pyridine-5-yl)-10-oxo-, (1S,9S)- [CAS]	192755-52-5		Antiarthritis, immunological	Arthritis, rheumatoid
pramipexole	terahydro-N6-propyl-, (S)- [CAS]	104632-26-0	EP 186087	Antiparkinsonian	Parkinson's disease
pramiracetam	1-Pyrrolidineacetamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-oxo-, monohydrochloride [CAS]	33787-82-1 72989-50-0 75733-50-5	US 4145347	Cognition enhancer	Amnesia
Pramiverin	1,2-Dihydro-5,8,11,14,17-pentazacyclodecane, cyclic peptide deriv. [CAS]	14334-40-8			
pramitidine		151126-32-8	US 5124314	Antidiabetic	Diabetes, Type I
Pramoxine		140-65-8			
prandipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl-, methyl 3-phenyl-2-propenyl ester, (E)- [CAS]	98522-79-9			
Pranlukast	SFH1-Benzoxypyrrol-2,3,5-pyridine-7-acetic acid, Alpha-methyl- [CAS]	103177-37-3	EP 173126	Antihypertensive, other	Hypertension, general
pranoprofen	Androst-5-en-17-one, 3-hydroxy-, (3R)- [CAS]	52549-17-4		Formulation, mucosal, topical	Ocular disorder, general
praslerone	4(3H)-Cycloheptadecalone, 5,6,7,8-tetrahydro-2-propyl-13,12-(1H,4H)-furan-2-ylidene-4-ylmethyl- [CAS]	53-43-0		Labour inducer	
prazosin	1-[1,1-bis(phenyl)-4-ylmethyl]- [CAS]	153804-05-8	US 5409947	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pravastatin	1-Naphthalenethiophenoic acid, 1,2,6,7,8,8a-hexahydro-3,4-delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobut-5-yn-1-yl)-, monosodium salt, [1S-]	81093-37-0 81131-70-6	US 4346227	Hypolipemic/Anthierosclerosis	Atherosclerosis
	[1'Alphai(S',delta(S'),2'Alpha,6'Alpha,8'Alpha)]	2955-38-6			
	4-[4-Pyrazinyl(2',1'-l)isouquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-] [CAS]	35268-74-1	US 4001411	Schistosomicide	
Pracizumab	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolin-4-yl)-(2-furanylcarbonyl)-[CAS]	19216-98-9 19237-84-4	US 4092315	Antihypertensive, adrenergic	Hypertension, general
Prednicarbate	Pregna-1,4-diene-3,20-dione, 21-(4-{4-[bis(2-chloroethyl)amino]phenyl}-1-oxobutyl)-1,17-dihydroxy-, (11b), [CAS]	73771-04-7			
Prednisolone	Pregna-1,4-diene-3,20-dione, 21-(4-{4-[bis(2-chloroethyl)amino]phenyl}-1-oxobutyl)-1,17-dihydroxy-, (11b), [CAS]	20695-24-7	GB 1272841	Anticancer, alkylating	
Prednisolone 21-Diethylaminoacetate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]-, [11b, 21(2E 6E)], [CAS]	50-24-8 5626-34-6			
Prednisolone farnesil	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]-, [11b, 21(2E 6E)], [CAS]	118244-44-3	EP 332143	Antiarthritic, other	Athritils, rheumatoid
Prednisolone Sodium Phosphate		125-02-0			
Prednisone		53-03-2			
Prednival		15180-00-4			
Prednylidene		599-33-7			
Pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S), [CAS]	148553-58-8		Aniepileptic	Epilepsy, general
Pregnan-3α,20-dione	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, (17β S), [CAS]	128-20-1			
Prenamin + timogestone		74513-82-6		Menopausal disorders	Hormone replacement therapy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
prenalterol	Phenol 4,2'-hydroxy-3,1'-methylethylamino]propoxy]-hydrochloride, (S)-[CAS]	57526-81-5 61260-05-7	GB 1470039	Cardio stimulant	
Prenoxdiazine		982-43-4			
Prenylamine		390-64-7			
prezatiside	Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L-lysinate)(N2-(N-glycyl-L-histidyl)-L-lysinate)(2-)-, hydrogen, [CAS]	130120-57-9			
Pridinolol		511-45-5		Vulnery	Wound healing
Prifinium		4630-95-9			
Prilocaine		721-50-6			
Primafloine		90-34-6			
Primidonone		125-33-7			
Prinomastat		192329-42-3			
PRO-2000			US 5614569	Antiviral, anti-HIV	infection, HIV prophylaxis
Probenecid		57-68-9			
Probutol		23288-49-5			
probutamide	Benzamide, 4-amino-N,2'-(diethylamino)ethyl]- [CAS]	51708-9 614-38-1		Formulation, other	Arrhythmia, general
Procaine		59-46-1			
Procarrbazine		671-16-9			
	2'-(1H-Quinolone, 8-hydroxy-5'-(1'-hydroxy-2'-(1-methyl-ethyl)amino)butyl)-monohydrochloride [CAS]	33282-07-8 60443-17-6			
procaraterol	10-[L-phenylthiazine,2'-chloro-5'-[3,5-(4-methyl-1,1'-biphenazyl)propyl]-, (2'-)-butanedicarboxylate	72332-33-3 58-38-8 64-06-6	GB 1498766	Antiasthma	
prochlorperazine				Formulation, oral, other	Nausea and vomiting, general
procodazol	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0	ES 407862	Anticancer, immunological	Cancer, general
Procydiline		77-37-2			
Procymate		13931-64-1			
Prodipine		31314-38-2			
Proflavine		92-62-6			
Progabide		62666-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
progesterone	Pregn-4-ene-3,20-dione [CAS]	57-48-0		Formulation, transmucosal, systemic	Amenorrhea
	1H-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-(4-(benzoylamino)-5-dipropylamino)-1,5-dioxopentyl)oxy)propyl-, 1,5-bis(aziridinylethylester, (+)- [CAS]	57132-53-3 59209-40-4	GB 1467668	Anti-inflammatory	Inflammation, general
progynon	pentanoic acid, 4-benzoylamino-5-(dipropylamino)-5-oxo-, (+)- [CAS]	6620-60-6	DE 1518125	Antitumor	Ulcer, gastric
Progestazine	77-14-5				
Prolactin	9002-62-4				
Prolinane	483-92-5				
Prolonum	123-47-7				
Promazine	58-40-2				
Promedol	64-39-1				
Promegestone	34184-77-5				
promestriene	estr-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17 β)- [CAS]	39219-28-8	GB 1337188	Reproductive/ovulation, general	Acne
Promethazine	60-87-7				
Promethalol	54-80-8				
propadimol	66532-85-2 66532-86-3		US 4127571	Formulation, parenteral, other	
	Glycine, N,N-diethyl-, 4-(acetylaminophenyl ester [CAS]				
	1-Propanone, 1-[2-(2-hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl- [CAS]	54063-53-5	GB 1307455	Antiarhythmic	Fibrillation, ventricular
propafenone	12758-40-6				
Propagermanium	545-93-7				
Propallylonal	104-32-5				
Propamidine	57-56-6			Formulation, dermal, topical	Infection, fungal, general
propand-1,2-diol	1421-14-3				
Propanidid	50-34-0				
Propantheline	499-67-2				
Proparacaine	2921-92-8				
Propatyl					
propandazole	ethyl/ trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76448-31-2		Antifungal	Infection, trichomoniasis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
propoxytyline	1-[1-Purine-2,6-dione, 3,7-adiene-3-methyl-1-(5-oxoheptyl)-7-propyl]-[CAS]	55242-55-2	GB 1470220	Neuroprotective	Ischaemia, cerebral
Propicillin		551-27-9			
Propiomazine		362-29-8			
Propionic Acid		79-09-4			
propionyl-L-carnitine	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, [R]-[CAS]	119793-66-7 20084-19-1			
Propipocaine		3670-68-6	GB 2008578	Vasodilator, peripheral	Peripheral vascular disease
Propiram		15686-91-6			
propivaine	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-8 60689-19-9			
Propizepine		10321-12-7		Urological	Incontinence
Propoxycaïne	Phenol, 2,6-bis(1-methylethyl)-[CAS]	2078-54-8	US 4056635	Anaesthetic, injectable	Anaesthesia
Propoxyphene		550-83-4			
proporanolol	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-[CAS]	469-82-5 378-88-9 923-66-6			
Propylhexedrine		101-40-6		Formulation, modified-release, <24hr	Hypertension, general
Propylidone		587-61-1			
Propylthiouracil		51-52-5			
Propyphenazone		479-92-5			
Proquazone		22760-18-5			
Proscillaridin		466-06-8			
Prostacyclin		35121-78-9			
Prostaglandin E ₁		745-65-3			
Prostaglandin E ₂		363-24-6			
Prostaglandin F _{2α}		551-11-1			
Prostutamine		59-58-5			
Protein C		60202-16-6			
Prothobromine		50-39-5			
Prothipendyl		303-69-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Protiofate		58418-00-5			
Protionamide		14222-60-7			
protizinc acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha,10-dimethyl-, (+)- [CAS]				
Protoanemolin		13799-03-6	US 3,450,698	Anti-inflammatory	
Protokylol		108-28-1			
Protoporphylin IX		136-70-9			
Protriplyline		563-12-8			
Pro-Urokinase		438-60-8			
Proxazole		82657-92-9			
Proxibarbal		5696-9-3			
proxigermanium	Propanoic acid, 3,3-(1,3-dioxo-1,3-digermoxanediyl)bis-, [CAS]	2537-29-3			
Proxyphylline		12758-40-6	FR 2,005,110	Antiviral, other	Infection, hepatitis-B virus
Prozapine		603-00-9			
Prucalopride		3426-6-2			
		179474-81-8			
prullifosacin	1H,4H,11,13Thiazolo[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-, [CAS]			Quinolone antibacterial	Infection, respiratory tract, general
Pseudococaine		123447-62-1	EP 315628		
		478-73-9			
	Benzazamethanol, Alpha,11-(methylamino)ethyl, hydrochloride, [S-(R* R*)], mixt. with (E-2,11,14-methylphenyl)-3-(1-pyrrolidinyl)-1-propenylpyridine monohydrochloride [CAS]				
pseudoephedrine + triprolidine	Benzazamethanol, Alpha,11-(methylamino)ethyl, hydrochloride, [S-(R* R*)], mixt. with (E-2,11,14-methylphenyl)-3-(1-pyrrolidinyl)-1-propenylpyridine monohydrochloride [CAS]	90-82-4, 8064-27-1, 346-76-6		Formulation, modified-release, other	Rhinitis, allergic, general
pseudoephedrine	Benzazamethanol, Alpha,11-(methylamino)ethyl, [S-(R* R*)], [CAS]	570-52-5		Formulation, oral, other	Infection, respiratory tract, general
Psilocybin	Benzonitrile, 4-[S-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-, [CAS]	154992-24-2		Dermatological	Alopecia, general
PSK-3841					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
p-Sulfamylbenzylamine		4393-19-5			
Px-141			US 6051555	Male sexual dysfunction	Impotence
Pteropterin		89-38-3			
Puromycin		53-79-2			
Px-12	1-Methylpropyl 2-mercaptimidazole disulfide				
Pyrantel					
Pyrazinamide		15686-83-8			
Pyridinol Carbamate		98-96-4			
Pyridostigmine Bromide		1882-26-4			
		101-26-8			
Pyridoxal 5-Phosphate		54-47-7			
Pyridoxine		58-56-0			
Pyridamine		91-84-9			
Pyrimethamine		58-14-0			
Pyrimidine		1740-22-3			
Pyrisuldeanol		33605-94-6			
Pyriithione		1121-30-8			
Pyriithydione		77-04-3			
Pyritinol		1098-97-1			
Pyrocatechol		120-80-9			
Pyrogallol		87-86-1			
Pyronaridine		74847-35-1			
Pyrovalerone		3563-49-3			
Pyroxilin		9004-70-0			
Pyrobutamine		91-82-7			
Pyrocaine		2210-77-7			
Pyrolnitrin		1018-71-9			
Pyvinium Pamoate		3546-41-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
quazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,2,2-dibenzofuran-9-yl-, (1S)-[CAS]	36735-22-5	US 3845039	Hypnotic/Sedative	Insomnia
Quercetin	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2	EP 240228	Neuroleptic	Schizophrenia
Quinacillin	N-(6-Chloro-2-methoxy-9-acidyl)-N,N-dimethyl-1,4-pentadiamine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl	1596-63-0 83-59-6			
quinacrine	Sulfamide, N,N-diethyl-N'-((1,2,3,4,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[ghi]peridin-3-yl)-3-phenyl-4a-phenyl, 10aB), (+)- [CAS]	87056-78-8 94424-50-7 97865-49-7	EP 77754	Neurological	Creutzfeldt-Jakob disease
quinagolide	3-Isquinolinecarboxylic acid, 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropylamino)-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-, [2R* (R*),3R*]]-, [CAS]	82566-55-9 85441-61-8 90243-99-5	EP 49605	Antihypertensive, renin system	Hypertension, general
quinapril	3-Isquinolinecarboxylic acid, 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropylamino)-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-, [2R* (R*),3R*]]-, [CAS]	82768-85-2	EP 46953	Antihypertensive, renin system	Hypertension, general
Quinaprylamine		20493-41-8			
Quinbolone		2487-63-0			
Quinestradiol		1169-79-5			
Quinestrol		162-43-2			
Quinethazone		773-49-4			
quinetamide	2-Furanecarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolyl ester [CAS]	62265-68-3	US 3987542	Anesthetic	
quinidine	Cinchonan-9-ol, 6'-methoxy-, (8S)-, sulfate [(1:1) (salt) [CAS]	56-54-2		Formulation, modified-release, other	Arrhythmia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Quinine		130-95-0			
Quinocidine		525-61-1			
Quinupramine		31721-17-2			
Quinupristin		120138-50-3			
R-107500	5S-2,3,3a-tetrahydro-N-(dimethylbenzylidene)-[5-oxazolo[2,3-a]azepine-2-methanamine		WO 96/14320	Anisolytic	Anxiety, general
R-567	1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfonyl], sodium salt		WO 1020439	COPD treatment	Emphysema, general
rabeprazole	117976-88-3 117976-90-6 [CAS]		EP 268956	Antulcer	Ulcer, gastric
racacalcatriol	Glycine, N-[2-[[acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (+/-)	112573-72-5 81110-73-8 [CAS]	EP 38758	Antidiarrhoeal	Diarrhoea, general
Racemethorphan	Methanone, [5-hydroxy-2-(4-hydroxyphenyl)benzob[thien-3-yl][4-(1-piperidinylethoxy)phenyl]-, hydrochloride	510-53-2			
raloxifene	1-glutamic acid, N-[[5-[[[1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-phenyl]carbonyl]- [CAS]	83640-04-8 84449-90-1 [CAS]	EP 62503	Osteoporosis treatment	Osteoporosis
ralitrexad	9H-Carbazole-9-propanoic acid, 3-[[[4-fluorophenyl]sulfonyl]amino]-1,2,3,4-tetrahydro-, (R), [CAS]	112887-88-0	EP 239362	Anticancer, antimetabolite	Cancer, colorectal
ramatroban	116640-85-5		EP 242518	Antiallergic, non-asthma	Rhinitis, allergic, perennial
Ramifenazone	3815-24-5				
	Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-phenylethoxy]methyl-, [2S]				
ramipril	[[[R- (2S,2aR,6aR,8aR)]-2-oxo-1-phenyl-3-phenylpropanoate]] [CAS]	87269-97-4 87333-19-5	EP 79022	Antihypertensive, renin system	Heart failure
ramosson	Methanone, (1-methyl-1H-indol-3-yl)[4-(5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3 132036-88-5	EP 381422	Antiemetic	Nausea and vomiting, general

Table IV

API Generic Name Remot project No. 1087	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ranitidine	1,1-Ethenediamine, N-[2-[[[5- [(dimethylamino)methyl]-2- furyl]methylthio]ethyl]-N-methyl-2-nitro- [CAS]	58994-96-0	US 1573082	Dermatological	Unspecified
ranitidine	1,1-Ethenediamine, N-[2-[[[5- [(dimethylamino)methyl]-2- furyl]methylthio]ethyl]-N-methyl-2-nitro- [CAS]	66357-35-5	US 4128658	Anticancer	Ulcer, duodenal
ranitidine bismuth citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy- bismuth(3+) salt (1:1), compd. with N-(2- [[[5-[(dimethylamino)methyl]-2- furyl]methylthio]ethyl]-N-methyl-2-nitro- ethenediamine (1:1)-[CAS]	128345-62-0	EP 533281	Anticancer	Ulcer, duodenal
ranolazine	1-Piperazinecarboxamide, N-[2,6- dimethylphenyl]-4-[2-hydroxy-3-(2- methoxyphenoxy)propyl], (+)-[CAS]	95635-55-5 95635-56-6	EP 126449	Antianginal	Angina, general
Rapirnasase		133737-96-9			
Rapacuronium		156137-99-4			
rasagiline	1H-Inden-1-amine, 2,3-dihydro-N-2- propenyl-, (R)-, [CAS]	161735-79-1 483-04-5	US 5457133	Antiparkinsonian	Parkinson's disease
Raubasine					
ravuconazole	Benzonitrile, 4-[2-[(1R,2R)-2-(2,4- difluorophenyl)-2-hydroxy-1-methyl-3-(1H- 1,2,4-thiazol-1-yl)propyl]-4-thiazolyl]-[CAS]	182760-06-1		Antifungal	Infection, meningitis, general
raxofelast	2-Benzotriazacetic acid, 5-(acetoxy)-2,3- dihydro-4,6,7-trimethyl-, (+)-[CAS]	128232-14-4	US 4993550	Symptomatic antidiabetic	Nephropathy, diabetic
razoxane	2,5-Piperazinedione, 4,4'-(1-methyl-1,2- ethanediyl)bis-, [CAS]	21416-97-1, 21416- 87-5	GB 1234935	Anticancer, other	Cancer, general
RC-529	Tetradeconoic acid (1R)-1-(2-(2-deoxy- 3-O-(9R)-1-oxo-3-(1- oxotetradecyl)tetradecyl)amino)-4-O- phosphono-5-O- glucopyranosyl)oxy)ethyl)amino)-2- oxoethyl)decyl ester, compd. with N,N- diethylethanamine (1:1)[CAS]	216014-46-9		Immunostimulant, other	Vaccine adjuvant
retamipide	4-Quinolinaspropionic acid, Alpha [(4- chlorobenzyl)amino]-1,2-dihydro-2-oxo- [CAS]	90089-04-7	DE 3324034	Anticancer	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
repotrolol	[1-H]-Purine-2,6-dione, 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3,1,3,5-tetrazolo[4,5-d]pyrimidin-4-ylidene-1,3-dimethyl- [CAS]	13055-82-8 54063-54-6	FR M5969	Antiasthma	Asthma
Rescimetrol		73573-42-9			
Rescinamine		24815-24-5			
Reserpiline		131-02-2			
Reserpine		50-55-5			
Resibufogenin		465-39-4			
resiquimod	[1H-imidazo[4,5-c]quinoxaline-1-ethanol(ethoxymethyl)-Alpha, Alpha-dimethyl- [CAS]	144875-48-9	US 5389640	Antiviral, other	Infection, hepatitis-C virus
Resorcinol		108-46-3			
Reteprese		133652-38-7			
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester [CAS]	190812-12-7	DE 4200259	Antiepileptic	Epilepsy, general
retinoic acid	Retinoic acid [CAS]	302-79-4		Formulation, parenteral, other	Cancer, leukaemia, acute myelogenous
Revimid	[[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl		US 6281730	Anticancer, other	Cancer, myeloma
R-flurbiprofen		5104-49-4		Anticancer, other	Cancer, prostate
Rho (D) Immune Globulin (Human)					
Rho-kinase inhibitors					
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1,3-D-ribofuranosyl- [CAS]	36791-04-5	WO 0156883	Antiasthma	Unspecified
Riboflavin		146-17-8	US 4211771	Antiviral, other	Infection, haemorrhagic fever
ribostamycin	D-Streptamine, O-2,6-diamino-2,6-dideoxy-Alpha-D-glucopyranosyl-(1-4)-O-beta-D-ribofuranosyl-(1-5)]-2-deoxy- [CAS]	25546-65-0			
Ritidoleic Acid		141-22-0	GB 1254683	Aminoglycoside antibiotic	Infection, general
Ridogrel		110140-89-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rifabutin	Rifampicin XIV, 1',4'-dichloro-1'-deoxy-1,4'-dihydro-5'-(2-methylpropyl)-1-oxo-[CAS]	72559-06-9	US 4219478	Antimycobacterial	Infection, Mycobacterium avium complex
rifalazil	Rifampicin VIII, 1',4'-dichloro-1'-deoxy-1,4'-dihydro-5'-hydroxy-5'-(4-(2-methylpropyl)-1-piperazinyl)-1-oxo-[CAS]	128791-92-0 128791-94-2 133633-12-2	EP 366914	Antimycobacterial	Infection, tuberculosis
rifameterane	Rifampicin, 3-[[1-(4-aminophenyl)idene]hydrazono]methyl-[CAS]	94168-98-6	EP 119571	Antimycobacterial	Infection, general
Rifamidine	Rifampicin, 3-[[4-methyl-1-piperazinyl]imino]methyl-, mixt. with 5-[[3,4,5-trimethoxyphenyl]methyl]-2,4-pyrimidinediamine [CAS]	2750-76-7 61498-94-0			
rifampicin + trimethoprim					
Rifampin		13292-46-1		Formulation, fixed-dose combinations	Infection, general
Rifampycin SV		6998-60-3			
rifapentine	Rifampicin, 3-[[4-cyclopentyl-1-piperazinyl]imino]methyl-[CAS]	61379-85-5	DE 2008218	Antibiotic, other	Infection, tuberculosis
rifaximin	Epoxypentadeca[1,11,13]trienimino]benzo[b]qud, 4,5-epyrdo[1,2- <i>ab</i>]benzimidazole, 1,15(2H)-dione, 25-(<i>isocycloxy</i>)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, [2S-(2R*,16Z*,18E*,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]	80621-81-4	GB 2079270	Antibiotic, other	Infection, GI tract
rifaximine cream	4-deoxy-4'-methylpyrdo[1',2'-1,2]imidazo[5,4- <i>c</i>]rifampicin SV	80621-81-4 99593-25-6	BE 888895	Formulation, dermal, topical	Infection, dermatological
Rilmazafone					
rilmendine	2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-[CAS]	54187-04-1 51249-57-9	DE 2362754	Antihypertensive, adrenergic	Hypertension, general
riluzole	2-Benzothiazolamine, 6-(trifluoromethoxy)-[CAS]	1744-22-5	EP 50551	Neuroprotective	Amniotrophic lateral sclerosis
Rimantadine		13392-28-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
flmazolium	4H-Pyridol[1,2-a]pyrimidin-3-ylmethyl-4-oxo-1,6-bis(4-hydroxyphenyl)-5-(1-methyl-1H-piperidin-4-yl)-1H-pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl, monohydrochloride [CAS]	28610-84-6 35815-72-6	DE 2461349	Analgesic, NSAID	
flmexolone	Androst-14-en-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl), (11S, 16S)isomer, (11R, 16R)-[CAS]	46987-38-3 32953-89-2	DE 2301317	Ophthalmological	Inflammation, ocular
Rimitecil	1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl, monohydrochloride [CAS]	156881-13-1 19403-92-0	US 5624841 US 3755251	Anorectic/Antiobesity Antiviral, other	Obesity
Riprostilil	1,3-Benzenediol, 2,4,6-trifluoro- [CAS]	77287-05-9			
risedronate	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethyl)ene]bis-, monosodium salt	115436-72-1 105462-24-6	EP 304961	Osteoporosis treatment	Paget's disease
Risedronic Acid	4H-Pyridol[1,2-a]pyrimidin-4-one, 3-[2-(4-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinylethyl]-6,7,8,8-tetrahydro-2-methyl-, [CAS]	106266-06-2 87051-43-2	EP 196132	Neuroleptic, formulation, optimized, microencapsulate	Schizophrenia
Ritanerfin	Benzeneethanol, 4-hydroxy-Alpha-[1-[2-(4-hydroxyphenyl)ethylamino]ethyl], (R*, S*)-[CAS]	84845-57-8 23239-51-2			
Ritipenem	2,4,7,12-Tetraazadecan-13-ic acid, 10-hydroxy-2-methyl-5-(1-methyl-1H-piperidin-4-ylthio)-3,8-dioxo-8,11-bis(phenylmethyl)-5-thiazolyl ester, (5S, (6R*, 8R*, 10R*, 11R*))-[CAS]	26652-09-5	US 3410544	Labour inhibitor	Labour, preterm
ritonavir	2,4,7,12-Tetraazadecan-13-ic acid, 10-hydroxy-2-methyl-5-(1-methyl-1H-piperidin-4-ylthio)-3,8-dioxo-8,11-bis(phenylmethyl)-5-thiazolyl ester, (5S, (6R*, 8R*, 10R*, 11R*))-[CAS]	155213-67-5 174722-31-7	WO 9414436	Antiviral, anti-HIV	Infection, HIV/AIDS
Rituximab	Carbamic acid, ethylmethyl, 3'[(1-dimethylamino)ethyl]phenyl ester, (S)-[CAS]	123441-03-2 129101-54-8			
ritavagline			DE 3805744	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ziziprian	1H-indole-3-ethanamine, N,N-dimethyl-5-((1H-1,2,4-triazol-1-ylmethyl)-, [CAS]	14202-88-0 19377-6-7 144034-80-0	EP 487512	Antimigraine	Migraine
RJR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-, (E)-, (E)-2-butenedicate (1:1) [CAS]	183288-88-5		Cognition enhancer	Alzheimer's disease
RNA Stealth Nucleosides	5-Formyluridine			Antiviral, other	Infection, hepatitis-C virus
Ro-0094889	2'-O-(3'-O-acetyl-5'-vinyl)cytidine			Anticancer, antineoplastic	Cancer, general
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl]-5-methyl-, [CAS]	180384-56-9	WO 9619459	Cardiovascular	Haemorrhage, subarachnoid
Rociverine	Pyrrolidinium, 1- [(2S,3Alpha,5Alpha,16S,17B)-17-(acetoxy)-3-hydroxy-2-(4-morpholinyl)androstane-16-yl]-1-(2-propenyl)-, bromide, [CAS]	53716-44-2			
rocuronium	2-(5H)-Furanone, 4-(4-(methylsulfonylphenyl)-3-phenyl-, [CAS]	104855-17-6 104884-91-5 118302-91-9 143558-00-3	EP 287150	Muscle relaxant	Muscle spasm, general
rofecoxib	benzamide, 3-(5-(diisopropylmethoxy)-1-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-, [CAS]	162011-90-7	US 5474995	Analgesic, NSAID	Arthritis, osteo
rolimast	Leucosmycin V, 7d-Eutanoate 3B-propanoate [CAS]	182401-32-3	WO 9901338	COPD treatment	Chronic obstructive pulmonary disease
rolitetracycline		74014-51-0	US 4242504	Macrolide antibiotic	Infection, general
Rolipram		51413-54-5			
Rolitetraacycline		751-87-3			
Ronitride		78113-36-7			
Ronifibrate		42587-57-9			
ropinirole	2H-indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, monohydrochloride, [CAS]	91374-20-8 91374-21-9	EP 266033	Antiparkinsonian	Parkinson's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
propocaine	2-propionylcarbazamide, N-(2,4-dimethylphenyl)-1-propyl-, (S)- [CAS]	98357-36-4 98717-19-8	EP 239710	Anaesthetic, local	Anaesthesia
Roquintex	Cyclopentanepentanoic acid, 2-hexyl-5-hydroxy- [CAS]	84088-42-6			
rosaprostol		66995-66-9			
Rosaramicin		35834-26-5	GB 1523355	Prostaglandin	
Ross Bengal		632-68-8			
rosiglitazone	2,2'-thiazolidinedione, 5'-(4-{2-(methyl-2-pyridinylamino)ethoxy}phenyl)methyl-, (Z)- 2,5-bisulfinylate (1:1) [CAS]	122320-73-4 155141-29-0	US 5002953	Antidiabetic	Diabetes, Type II
rosuvastatin	3-Quinolincarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- [CAS]	40034-42-2	US 3753993	Quinolone antibacterial	Infection, gonorrhoea
rosuporfin	Tin, dichloro[ethynyl 3,4,20,21-tetrahydro-4,8,14,19-tetraethynyl-18,19-dihydro-3,6,13,16-tetramethyl-20-probucylcarboxylato(2-)-protonated]nickel(II) complex, kappaN2, S ² , (OC-8-19)- [CAS]	11494-17-6		Ophthalmological	Macular degeneration
rosuvastatin	6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyridinyl)-3,5-dicycloxy-, (S-(R*, S*-(E))) [CAS]	147098-20-2	JP 2648897	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general
rotigotine	1-Naphthalenol 5,6,7,8-tetrahydro-6-propyl[2-(2-thienyl)ethyl]amino]-, (S)- [CAS]	99755-59-6	US 4554628	Antiparkinsonian	Parkinson's disease
Rotaxate		92071-51-7			
Roxarsone		121-19-7			
roxatidine	Acetamide, 2-(acetyloxy) N-[3-(1-piperidinylmethyl)phenyl]propyl-, [CAS]	78628-28-1 95793-83-0	EP 24510	Anticancer	Ulcer, gastric
roxiblan	L-Alanine, 3-(((2-(4-(4-methylphenyl)-4,5-dihydro-5-isoxazolethyl)amino)-N-sulfonylcarboxyl-, methyl ester, (R), [CAS]	176022-59-6		Antithrombotic	Thrombosis, general
Roxindole		112192-04-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
roxithromycin	Erythromycin 9-[O]-(2-methoxyethoxy)methylloxime [CAS]	80214-88-1 80214-89-4	EP 33255	Macrolide antibiotic	Infection, general
RPR-106881A	Benzeneopropionic acid, 8-((1,1-dimethylethoxy)carbonylamino)-Alpha-hydroxy 1,3,3,3-tetrafluoro-1-(benzyloxy)-7,7,7,7-tetrafluoro-1-(benzyloxy)-1,3,4,7,8-pentakis(1,1,2,2,2,2-hexafluoroethyl)-8-oxo-2,8-dimethyl-2H-chromene-6-carboxylic acid (4,5) benz (1,2,3)-oxadiazole ester, dihydrate Alpha R, Teles [CAS]	192573-38-9		Anticancer, other	Cancer, lung, general
RPR-130401	4,9-Ethano-3aH-benz[1]isoxazole-3a-carboxylic acid, 1,2,3,4,9a-hexahydro-2-oxo-2-(propenyl)-1-oxo-2-propenyl-9-(4-methylphenyl)-, (S)-R,4S,5S,9aR)-tri- [CAS]	210282-89-2	WO 9829390 US 6316456	Anticancer, other Anticancer, other	Cancer, general Cancer, lung, non-small cell
RS-0408	NN-516(3-hydroxyphenyl)pyridazine-3,6-diamine			Neuroprotective	Alzheimer's disease
RSR-13	[1H-Pyran(3',4',5')indolizin(1,2'-b)quinoline-3,14(4H,12H) dione, 4-ethyl-4-hydroxy-10-ethoxy-, (S)- [CAS]	131179-95-8 79-58-3			
Rubi/gervine	8H,19H,5,21,12,17-hexaazabenzocyclopentadiene-18,20(13H)-dione-3-(dimethylamino)methyl-6,7,10,11-tetrahydro-, (S)- [CAS]	91421-42-0	US 6485514	Anticancer, other	Cancer, pancreatic
ruboxestaurin		166939-94-0		Symptomatic antidiabetic	Retinopathy, diabetic
Rufnamide		106308-44-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
luloxacin	7-[[4-pyridyl]-1,2,3-oxe]-1,4-benzothiazine-6-carboxylic acid, 5-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 102052-47-1 106017-08-7	EP 155375	Quinolone antibacterial	Infection, general
lupatadine	5H-Benz[5,6]pyrido[3,2-b]pyridine, 8-chloro-6,11-dihydro-11-[[1-(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene], tritylhydrochloride- [CAS]	156611-76-6	EP 0577957	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Rutin		1553-18-4			
RMJ-54428	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[2Z]-(2-amino-5-chloro-4-thiazolyl)(hydroxymino)acetyl(amino)-3-[[3-[[2-aminobenzyl(methylamino)methyl]-4-pyridinylthio]-5-oxo-, (6R, 7R)- [CAS]	189445-35-9	WO 9713772	Cephalosporin, injectable	Infection, beta-lactamase resistant
S-0139	Olean-12-en-28-olc acid, 27-[[3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-butenyl)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS]	193969-54-9	WO 9727314	Cardiovascular	Ischaemia, cerebral
S-15535	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS]	146995-34-7		Cognition enhancer	Cognitive disorder, general
S-16866	1-Naphthalenesulfonylpropanoic acid, 6-[[[4-chlorophenyl)sulfonyl(amino)-5,6,7,8-tetrahydro-2-methyl [CAS]	165537-73-5		Analthrombotic	Thrombosis, general
S-34730	7-Chloro-6-sulfamoyl-2-[1H-quinoline-3-yl]phosphonic acid			Neuroprotective	Unspecified
S-3578	7-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2Z-ethoxymino]naphthalenyl-3-[[1-(N-methylamino)propyl]-1H-imidazo[4,5-b]pyridin-4-ylmethyl]-3-septam-4-carboxylate monosulfate			Cephalosporin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
S-38486	2-[N(4-{4-Chlorophenylsulfonylamino}butyl)-N-(3-{4-isopropylthiazol-2-yl}methoxy)benzyl)sulfamoyl]benzoic acid			Antiashma	Asthma
	2-[N(4-{4-Chlorophenylsulfonylamino}butyl)-N-(2-{4-cyclobutylthiazol-2-yl}ethyl)benzyl)sulfamoyl]benzoic acid			Antiashma	Asthma
S-38527	(1R,2R,3S,5S)-7-[2-{5-Hydroxy-1-methyl-3-(carboxamido)-2,6-dimethylpiperidin-3-yl}propyl]-5-(2-heptenoic acid				
S-5751	imidazo[4,5-d]pyrido[4,3-b]pyridine, 1,6,7,8-tetrahydro-2-(3-oxo-2-oxo-2-yl)-, phosphina (1:1) [CAS]	151466-23-8	EP 0596008	Antiallergic, non-asthma	Allergy, general
S-8510	2-Naphthalene carboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS]	151165-96-7	WO 8308155	Cognition enhancer	Alzheimer's disease
S-8921		159912-53-5			
Sabcomeline		104383-17-7			
Sabeluzole		29908-03-0			
S-Adenosylmethionine					
salinamide	(S)-(+)-2-(4-{3-fluorobenzoyl}benzylamino)propanamid e methanesulfonate	153865-80-1	AU 711309	Antiepileptic	Epilepsy, general
Sabatamide		487-48-9			
Salazosulfamidine		2315-8-4			
salbutamol	1,3-Benzenedimethanol, Alpha 1,[[[1,1-dimethyl-2-(4-hydroxy-1-methyl-1-oxopentyl)-4-hydroxy-1,3-benzenedimethyl]amino]methyl] (CAS)	16559-94-9	EP 451745	Formulation, inhalable, topical, dry powder	Asthma
Salicin		138-52-3			
Salicyl Alcohol		90-01-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Salicylamide		65-45-2			
Salicylamide O-Acetic Acid		25395-22-6			
Salicylanilide		37-17-2			
Salicylic Acid		69-72-7			
Salicylsulfonic Acid		39-45-2			
Salinazid		495-84-1			
salmeterol	1,3-Benzenedimethanol, 4-hydroxy-Alpha-1-[[[6-(4-phenylbutoxy)hexylamino]methyl], (4S)-1-hydroxy-2-naphthalenecarboxylate [CAS]	89385-50-4 94749-08-3	WO 9008775	Antiasthma	Asthma
Salisolate		552-94-3			
Salverine		6376-26-7			
Samarium ¹⁴⁹ Sm		154427-93-5			
Lexidronam	L-Tyrosine, N2-(methylsulfonyl)-L-tyr-1-[(2S)-5-amino-2-carboxypropyl]pyclopentane-carboxyl- [CAS]	12981-36-8 808-26-4	EP 358398	Antihypertensive, renin system	Hypertension, general
samparilat					
Sancycline		110588-57-3			
Saperconazole	4-(1H)-Pteridinone, 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydrochloride, [BR-6R*(1R',2S')]- [CAS]	69056-38-8 62989-33-7	EP 191335	Antidepressant	Hyperphenylalaninemia
sapropterin	Bucanadimide, N1-[3-{3-[[1,1,4-dimethyl-4-((methylcarboxyl)butylideneoxy-2(1H)-pyridin-2-yl)-2-oxo-1-phenylmethyl]propyl]-2-(2-sulfonylcarboxyl)amino]-3S-[21H(R',2S')-3alpha,4aa,8aH]- [CAS]	12779-20-8	EP 432695	Antiviral, anti-HIV	Infection, HIV/AIDS
saquinavir		34273-10-4			
Saralasin					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sareclant	Benzamide, N-[4-(4-(acetylamino)-4-phenyl-1-piperidinyl)-2-(3,3,4,4-tetrachlorophenyl)butyl]-N-methyl-, (S)- [CAS]	432001-63-6	EP 474561	Antiasthma	Asthma
sarizolan	3,5-bis(4-methoxyphenyl)-N-(3,3,4-dihydro-2H-1-benzopyran-2-yl)methyl-5-(4-fluorophenyl)-[CAS]	177975-08-5		Antiparkinsonian	Parkinson's disease
saricogrelate	Butanedioic acid, mono(2-(dimethylamino)-1-[2-(2-(3-methoxyphenyl)ethyl)phenoxy]methyl)ethyl ester [CAS]	129928-17-2	EP 398328	Antithrombotic	
Sattigrel	Platinum, bis(acetato-O)ammine(dichloro(cyclohexanamine)), (OC-4-43)- [CAS]	111753-73-2	EP 338274	Anticancer, alkylating	Cancer, prostate
Sattumomab	N-[3-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl-4-nitrobenzamide, HCl	129980-63-8		Anticancer, other	
SB-237376	5-(2-phenylamino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole	144058-40-2		Anticancer, other	Cancer, general
SB-238039	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydro-6-oxo-3-pyridazinyl)-5-ethyl]-4-quinolinecarboxamide			Neuroleptic	Schizophrenia
Scarlet Red		85-83-6			
SCH-00013	Benzonitrile, 4-[2-(3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1(2H)-pyridinyl)-1-hydroxyethyl]-[CAS]	217983-18-3	EP 618204	Cardioinulant	Heart failure
Sch-22663	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo[5,6-d]cyclohepten-5-yl]-N, N-dimethylethanamine			Immunosuppressant	Inflammation, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sch-57760	1-[4-piperazin-2-yl]-4-cyclohexyl- alpha-4-[(S)-4- methoxyphenyl]butylphenyl- [CAS]	221660-80-6		Cognition enhancer	Alzheimer's disease
Sch-53390	7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5- c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3- phenylpropyl)- [CAS]	174648-45-4		Antiparkinsonian	Parkinson's disease
Scillarelin		465-225-5			
Scopolamine		51-34-3			
Scopolamine N-Oxide		97-75-6			
scopolamine	Benzeneacetic acid, Alpha- (hydroxymethyl)-, 9-methyl-3-oxa-9- azabicyclo[3.3.1]non-7-yl ester, [7(S)- (1Alpha,2B,4B,6Alpha,7B)]- [CAS]	51-34-3	US 4262003	Formulation, transdermal, other	Nausea and vomiting, general
SCS technology			US 6046188	Antiasthma	Unspecified
secalcitol	9-[10-Secocholesta-5,7,10(19)-triene- 3,24,25-triol, (3S,5Z,7E,24R)- [CAS]	55721-11-4	EP 301167	Osteoporosis treatment	Osteocytrophy
seclizadole	1H-imidazole-1-ethanol, Alpha,2-dimethyl- 5-nitro- [CAS]	3366-95-8	FR M3270	Protozoicide	Infection, trichomoniasis
Secobarbital		309-43-3			
selegiline	benzenesulfonamide, N,Alpha-dimethyl-N- 2-propynyl-, (R)- [CAS]	14811-51-9	GB 1153578	Antiparkinsonian	
Selenomethionine		1464-42-2			
Sematiide		101526-83-4			
Semotiadil		116476-13-2			
	1,3-Cyclohexanediol, 5-((1-(6-allyl-6- hydroxy-1-methyl-2,4-octadienyl)oxahydro- 7a-methyl-4H-inden-4-ylidene)ethylidene)- 4-methylene-, (1R- (1Alpa,1a1',2'E,4E),3aB,4E(1R',3S',5Z),7 aAlpha')- [CAS]				
secalcitol		13404-52-7	WO 9108855	Anticancer, other	Cancer, liver
Seipimostat		103926-64-3			
seratrodast	Benzenesulphonic acid, zeta (2,4,5- trimethyl-3,6-diboro-1,4-cyclohexadien-1-yl)- (N-)- [CAS]	003187-07-1 112665-49-7	EP 232089	Antiasthma	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sericonazole	1H-Indazole, 1,3,4-trichloro-5-phenyl-3-[(methyl)-2-(4-chlorophenyl)ethyl]-[CAS]	99592-32-2	EP 151477	Antifungal	Infection, dermatological
serindole	2-Indazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-phenyl]-ethyl]-[CAS]	108515-24-9	EP 332359	Neuroleptic	Schizophrenia
sertraline	1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)-[CAS]	79559-37-0 79617-96-2 79617-97-3	EP 30081	Antidepressant	Depression, general
Sotastine	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	64294-95-7			
sevelamer	Propane, 1,1,1,3,3,3-hexafluoro-2-[(fluoromethyl)-[CAS]	152751-57-0 52757-95-6	US 5498545	Urological	Renal failure
sevoflurane	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-(4,5,7-trifluoro-2-benzothiazolyl)methyl)-[CAS]	28523-98-6	DE 1954268	Anaesthetic, inhalation	Anaesthesia
SG-210	Cyclooctanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-Alpha-(2-methylpropyl)-[CAS]	143162-65-6		Symptomatic antidiabetic	Neuropathy, diabetic
sibutramine	4aS: 4aAlpha,6aAlpha,11bAlpha,13aR,13bUp,ha)-1,2,3,4,4a,5,5a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzofluoro[2,3,4-m]naphthen-11-ol	106650-56-0 84485-00-7	GB 2088902	Anorectic/Anitobesity	Obesity
siccanin	Piograzine, 1-[(3,4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]ethoxy)-4-methyl-2-hydroxy-1,2,3-propanetricarboxylate: (1:1)	22733-60-4	JP 37003548	Antifungal	
slidenafil	Piograzine, 1-[(3,4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]ethoxy)-4-methyl-2-hydroxy-1,2,3-propanetricarboxylate: (1:1)	171599-83-0 139755-63-2	WO 9428902	Male sexual dysfunction	Impotence
slidodisin	1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[(2-2,2,2-trifluoroethyl)phenoxy]ethyl]amino]propyl-, [CAS]	160970-54-7	EP 800675	Urological	Dysuria
Silver Lactate		128-00-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Silver Picrate	N-(2-pyrimidinyl)sulfanilamide monosilver salt	146-84-9 22789-08-2			
silver sulfadiazine		108-33-9		Anti-infective, other	Infection, general
Simetride		154-82-5			
Simfibrate		14929-11-4			
simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8-bis-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-] (1 α ,3 α ,3 α ,7 α ,8 α)(2S*,4S*,8S*)	79902-63-9	US 4444784	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general
Sinicalide		25125-32-3			
Sintropium Bromide		79467-19-9			
Siromicin		32385-11-8			
slarilofacin	3-Quinolonecarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-5-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, [1R-(1 α ,3 α ,5 α ,2 α)]-, hydrate	127354-12-0	EP 341493	Quinolone antibacterial	Infection, general
sltamaquine	1,6-Hexanediamine, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolinyl)-, [CAS] 53307-29-9	57695-04-2		Protozoacide	Infection, leishmaniasis
sltaxsentan	N-(4-Chloro-3-methyl-5-oxoazoyl)-2-[(1,5-methyleneoxy)-o-tolyl]acetyl-3-biophenylsulfonamide	184036-34-8	US 5464553	Antihypertensive, other	Hypertension, pulmonary
sivelesat	Glycine, N-[2-[(4,2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl-], [CAS]	127373-66-4	EP 347168	Respiratory	Systemic inflammatory response syndrome
SUA-6017	Butanamide, 2-[(4-fluorophenyl)sulfonyl]amino]-N-[(1S)-1-formyl-3-methylbutyl]-, 3-methyl-, (2S)-, [CAS]	190274-53-4	EP 771565	Ophthalmological	Cataract
SL-65-1498	5-Fluoro-3-methyl-2-phenyl-4-pyrrolidin-1-ylcarbonyl-2,9-dihydro-1H-pyridin-3,4-biindole-1-one		EP 607076	Anxiolytic	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SLV-306	(3S,2R)-3,11-bis[2-ethoxycarbonyl-4-phenylbutyl]-cyclopentan-1-carboxylamino-2,3,4,5-tetrahydro-2-oxo-1H-benzazepin-1-acetic acid			Antihypertensive, diuretic	Hypertension, general
SLV-308	2-(3H)-Benzoxazolo[5,4-b]pyridine-7-(4-methyl-1-piperazinyl)-, monohydrochloride	269718-83-4		Antiparkinsonian	Parkinson's disease
Sm153 leixidronam	Samarate (5->155Sm, (((1,2-aminoadipylbis(nitrolob(methylene)))tetraalkylammonio)ato(1-6-)))N,N'-bis[2-(2,6-dimethyl-4-oxo-1H-imidazo[1,2-a]pyridin-3-yl)perfluorooctyl]pentasodium, (COC-6-21)- [CAS]	160360-75-8		Analgic, other	Pain, cancer
S-Methylmethionine	N-(Aminomimomethyl)-11-chloro-5,6,7,8-tetrahydro-8-oxo-4H-pyrrolo[3,2,1-b][1,2,4]benzoxazine-2-carboxamide monomethanesulfonate monohydrate	4727-40-6			
SNP-300	(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyran-3',4',8,7'-indolizino[1,2-b]quinidin-8-yl			Antianginal	Angina, general
SN-38	((+)-methyl (4S)-3-((3-(4-(3-(acetylaminophenyl)-1-piperidinyl)propylamino) carbonyl)-4-(3-(4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinocarboxylate hydrochloride)	100286-90-6		Formulation, optimized, liposomes	Cancer, colorectal
SNAP-7941	2-Naphthalenecarboxamide, N-[2-(4-(diphenylmethoxy)-1-piperidinylethyl)-3-hydroxy-5-(3-pyridinylmethoxy)] [CAS]			Anxiolytic	Anxiety, general
SOA-132		143964-80-1		Formulation, inhalable, topical	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
solidolin	[<i>o</i> -calixarene, N,N-dimethyl-L-valyl-N-[2-methoxy-4-(2,4,1-methoxy-2-methyl-5-oxo-3-(2-phenylethyl)imino)propyl]-L-proline]-(1,2-methylpropyl)-4- <i>o</i> -butyl-N-methyl-12S-[11R(R'),2S',2R(1S',2S')]]-[CAS]	149606-27-9	WO 9303054	Anticancer, other	Cancer, lung, non-small cell
Sobrenol		498-71-5			
sebozoxane	Carbonic acid, 1,2-ethanedithylele[(2,6-dioxo-4,1-piperazinethy)(methylene)bis(2-methylpropyl) ester [CAS]	98631-95-9	EP 140327	Anticancer, other	Cancer, lymphoma, T-cell
Sodium Arsanilate		127-85-5			
Sodium Arspenamine		1936-28-3			
<i>Sodium Chloride</i>					
Sodium Dibunate		14592-59-7			
Sodium Folate		6484-39-5			
Sodium Formaldehydesulfoxylate		149-44-0			
Sodium Glycerophosphate		1334-74-3			
<i>Sodium Hyaluronate</i>					
Sodium Iodomethanide		519-26-6			
Sodium Nitrite		7632-00-0			
Sodium Nitroprusside		14402-89-2			
sodium oxalate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2		Psychostimulant	Narcoplepsy
Sodium Phenolsulfonate		1300-51-2			
sodium phenylbutyrate	Butyric acid, 4-phenyl-, sodium salt- [CAS]	1716-12-7		Formulation, other	Hyperammonaemia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
sodium phosphate	Sodium phosphate monobasic anhydrous		US	6162464	Formulation, oral, other	Surgery adjunct
sodium prestarone sulfate	3-(4-hydroxy-5-androst-17-one(sodium sulfate chrylate)		EP	380036	Formulation, mucosal, topical	Labour, induction
Sodium Propionate		137-40-6				
sodium salicylate	Benzoic acid, 2-hydroxy-, monosodium salt [CAS]	54-21-7			Formulation, oral, solubility-enhanced	Pain, general
Sodium Tetradecyl Sulfate		139-88-8				
sotalone	Acetic acid, [5-(3-methyl-2-butenyloxy)-2-(3,4-(3-methyl-2-butenyloxy)phenyl)-1-oxo-2-propenyl]phenoxyl- [CAS]	64506-49-6	GB	1523241	Antitumor	
Solasulfone		133-66-3				
solfenacin	Butanedioic acid compd with (1S)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isouquinolinecarboxylate (1:1) [CAS]	212478-38-2			Urological	Overactive bladder
Sorbinolate	D-Glucitol, 1,6a-3-pyridinecarboxylate [CAS]	6184-06-1	BE	883352	Hypotensive/Antiatherosclerosis	
Sorbitol		50-70-4				
Sorvudine		77181-69-2				
sotalol	Methanesulfonamide, N-[4-(1-hydroxy-2-[(1-methylethyl)amino]ethyl)phenyl]- [CAS]	3930-20-9 699-24-0			Antiarrhythmic	
Soterenol		13642-52-9				
Szoloiodolic Acid		554-71-2				
spaglumic acid	L-Glutamic acid, N-[N-acetyl-L-Alpha-aspartyl]- [CAS]	3105-85-2 80619-64-3			Formulation, mucosal, topical	Conjunctivitis
sparfloxacin	3-Quinolonecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis- [CAS]	110871-86-8	EP	221463	Quinolone antibacterial	Infection, respiratory tract, general
Sparteine		90-39-1				

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SR-146131	1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyanoethyl)-2-(4-methoxyphenyl)-2-(4-methoxyphenyl)amino]carbonyl]-5,7-dimethyl-1H-indol-1-yl]-N-methylformamide	221671-61-0	WO 9915525	Anorectic/antibesity	Obesity
SR-271425	N-[1-(2-(diethylamino)ethylamino)-7-methoxy-3-oxo-9H-thioxanthen-4-ylmethyl]formamide			Anticancer, alkylating	Cancer, general
SR-27897	1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolylamino]carbonyl]-136381-95-6	136381-95-6	EP 432040	Anticancer, other	Cancer, pancreatic
SR-31747	Cyclohexanamine, N-(3-(8-chloro-4-cydoxethylphenyl)-2-propenyl)-N-ethyl-, hydrochloride, (2)- [CAS]	132173-07-0	EP 376850	Anticancer, other	Cancer, myeloma
SR-58611 SS732	Acetic acid, [[[(7S)-7-[[[2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-ethyl ester, hydrochloride [CAS]	121524-09-2	EP 303546 US 5385900	GI inflammatory/bowel disorders Formulation, mucosal, topical	Irritable bowel syndrome Infection, ocular
SS-750	[R]-(-)-2,4-difluorophenyl-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol		US 6083968	Antifungal	Infection, fungal, general
9-a-lephine	Propanamide, N'-N'[[[thio]-2,1-ethanedyl]bis(3-amino)-] [CAS]	646-08-2		Anticancer, immunological	Cancer, myeloma
SSR-149415	(2S,4R)-1-[5-chloro-1-[2,4-dimethylphenyl]sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,5-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide				
SSR-160575	2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazinol[4,5-b]indol-1-yl)-N,N-dimethylacetamide		WO 0155130	Antidepressant	Depression, general
				Neuroprotective	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SSR-181507	(3-Exo)-8-benzoyl-N-[(2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-ylmethyl]-8-azabicyclo[3.2.1]heptane-3-methanamine HCl		US 6221879	Neuroleptic	Schizophrenia
SSR-561813	(6aS,8S,10aR)-5a,6,9,10-tetrahydro-7H,11H-8,10a-methanopyrido[2',3':5,6]pyrrolo[2,3-d]azepine			Dependence treatment	Addiction, nicotine
SSR-101	D-Glucitol, 1,4:3,6-dianhydro-, dimtrate [CAS]	87-33-2		Formulation, transdermal, other	Angina, general
SSY-726	(-)-[(R)-3-Methyl-3-(methylsulfonyl)-1-(2,4-triazol-1-yl)-2-(4-(trifluoromethyl)phenyl)-2-butanol		US 5147886	Antifungal	Infection, fungal, general
ST-200	1-Propanaminium, 2-(ecyleoxy)-3-carboxy N,N,N-trimethyl-, chloride, (R)- [CAS]	5090-50-2	DE 3019535	Cognition enhancer	Dementia, senile, general
Stachylin			WO 9711947	Antiviral, other	Infection, influenza virus
Stannous		638-47-5	US 6350738	Antiviral, anti-HIV	Infection, HIV/AIDS
Pyrophosphate		15578-26-4			
Stannoporphin	(OC-6-13)-Dihydrogen dichloro(7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropionate(4-)-N21,N22,N23,N24)stannate(2-)	106344-20-1		Hepatoprotective	Hyperbilirubinaemia
Stanolone		521-18-6			
Stanozolol		10418-03-8 (2'H form); 302-96-5 (1'H form)			
Staph aureus ther			US 6376652	Genomics-based drug discovery	Infection, MRSA
STAT4 inhibitors			WO 9629341	Immunosuppressant	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sulbactam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S-cis) [CAS]	68373-14-8	GB 2000138	Antibiotic, other	Infection, general
sulbactam + ampicillin		117060-71-8	US 4234679	Antibiotic, other	Infection, general
sulbenicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[phenylsulfonamido]vinyl]-, [2S-[2Alpha,5Alpha,6(S*)]]- [CAS]	28002-18-9 41744-40-5			
Sulbentine		350-12-9		Penicillin, injectable	Infection, pseudomonal
sulbutamine	Propanoic acid, 2-methyl-, dihydro[3-(1-[[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]ethylidene]-3,1-propanediyl] ester [CAS]	3286-46-2 67-16-3			
sulconazole	1H-imidazole, 1-[2-[[4-chlorophenyl]methyl]-2,12,4-dichlorophenyl]ethyl-, (+)- [CAS]	61318-90-9 61316-91-0		Neurological	Unspecified
Sulesomab		167747-19-5	US 4056652	Antifungal	Infection, fungal, general
Sulfabenzamide		127-71-9			
Sulfacetamide		144-80-9			
Sulfachlorpyridazine		80-32-0			
Sulfachrysoidine		485-41-6			
Sulfacycline		17784-12-2			
Sulfadiazine		68-35-9			
Sulfadiazine		115-68-4			
Sulfadimethoxine		122-11-2			
Sulfadoxine		2447-57-6			
Sulfathiazole		94-19-9			
Sulfaguanidine		57-67-0			
Sulfaguanole		27031-08-9			
Sulfalene		152-47-6			
Sulfaloxice Acid		14376-16-0			
Sulfamerazine		127-79-7			
Sulfamer		651-06-9			
Sulfamethazine		57-68-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfamethizole		144-82-1			
Sulfamethomidine		3772-76-7			
Sulfamethoxazole		723-46-6			
Sulfamethoxypyridazine		80-36-3			
Sulfametrole		32909-92-5			
Sulfamidochrysoidine		103-12-8			
Sulfamoxole		729-99-7			
Sulfanilamide		63-74-1			
Sulfanilic Acid		121-67-3			
Sulfanilylurea		547-44-4			
Sulfaperine		599-88-2			
Sulfaphenazole		526-08-9			
Sulfaproxyline		116-42-7			
Sulfapyrazine		116-44-9			
Sulfapyridine		144-83-2			
Sulfarside		1134-98-1			
Sulfarsphenamine		618-82-6			
sulfasalazine	Benzolic acid, 2-hydroxy-5-[(4-(2-pyridinylamino)ethyl)phenyl]azo]- [CAS]	599-79-1			
Sulfasomizole		632-00-8		Formulation, oral, enteric-coated	Arthritis, rheumatoid
Sulfasymazine		1984-94-7			
Sulfathiazole		72-14-0			
Sulfathiourea		515-49-1			
Sulfinalol		66264-77-5			
Sulfingyrazone		57-96-5			
Sulfiram		95-05-6			
Sulfisomidine		515-64-0			
Sulfisoxazole		127-69-6			
Sulfobromophthalein		71-67-0			
Sulfonethymethane		76-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfonizacide		3691-81-4			
Sulfonmethane		115-24-2			
Sulfonidiazine		14759-06-9			
Sulfoxone		144-75-2			
sulfidac	6is-6-fluoro-2-methyl-1,1,1-(p-methylsulfonyl)benzylidene]idene-3-acetic acid	38194-50-2	US 3725548	Anti-inflammatory	Inflammation, general
Sulfisatin		54935-03-4			
Sulfisobenzonone		4065-45-6			
Sulmarin		29334-07-4			
Sulmazole		73384-60-8			
Subotidil		54063-56-8			
Sulphan Blue		129-17-9			
supiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-[CAS]	16676-16-1		Alimentary/Metabolic, other	
suplostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-(methylsulfonyl)-, [1R-1[Alpha](Z),2B(1E,3R),3[Alpha]]-[CAS]	60325-46-4	US 4024179	Prostaglandin	Abortion
sulfamicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-((aminopropyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-1-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ylidene)amino)oxy)methyl ester, S, S-dioxide, [2S,3S]-[CAS]	117060-71-6 78497-13-7 61-56-3	GB 2044255	Penicillin, oral	Infection, general
Sulthiame	Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]	53583-79-2	FR IM5916	Neuroleptic	Psychosis, general
Sulfosilic Acid		57775-26-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sumatriptan	4H-indolo[4,3-f]quinolin-2-(1H)-one, 5,6-dihydro-5-methyl-, (S)-, (2Z)-2-butenediate (1:1) [CAS]	175386-44-8	WO 9514020	Antiparkinsonian	Parkinson's disease
sumatriptan	1H-indole-3-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-46-2 103628-48-4	EP 147107	Antimigraine	Migraine
SUN-18075	1-(4-amino-2,3,5-trimethylphenoxy)-3-[4-(4-fluorobenzyl)phenyl]piperazin-1-ylpropan-2(1s)-ol dimethanesulfonate			Neuroprotective	Infection, cerebral
suplatal	Sulfonium, 3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, [CAS]	94055-76-2	JP 59167564	Antiasthma	Asthma
Suramin		40828-46-4 128-46-4			
surfactant TA	Bereciant [CAS]	108778-82-1	WO 9117766	Lung Surfactant	Respiratory distress syndrome, general
Suriclone		53813-83-5			
Suxibuzone		27470-51-5			
SYM-1010			US 5530998	Antiepileptic	Epilepsy, general
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3		Analgesic, other	Pain, general
SYM-2207	4-(Aminophenyl)-1-methyl-8,7-(methylenedioxy)-N-butyl-1,2-dihydropyridazine-2-carboxamide			Neuroprotective	Ischaemia, cerebral
Synchosene		87-90-1			
Syn-1253	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid			Quinolone antibacterial	Infection, peritoneum
Syn-2150	1-Axalidinesulfonic acid, 3-[[[2(E)]][(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]amino]-2-thienylacetyl]amino]-2-methyl-4-oxo-, (2S,3S)- [CAS]	214983-75-4	WO 9947895	Antibacterial, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Syn-2869	3H-1,2,4-Triazol-3-one, 4-(4-(4-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazinyl)phenyl)-2,4-dihydro-2-(4-(trifluoromethoxy)phenyl)methyl-, [CAS]	210552-98-4	US 6153616	Antifungal	Infection, Aspergillus
Synephrine		94-07-5			
Syrosingopine		84-36-6			
T-1095	1-Propanone, 3-(5-benzotrianyl)-1-(2-hydroxy-6-(6-O-methoxycarbonyl)-5-D-glucopyranosyl)oxy-4-methylphenyl-, [CAS]	209746-59-8	EP 860648	Antidiabetic	Diabetes, general
T-1249	L-Phenylalaninamide, N-acetyl-L-typtophyl-L-glutaminyl-L-Alpha-glutamyl-L-typtophyl-L-Alpha-glutamyl-L-glutaminyl-L-tyryl-L-Isoleucyl-L-theonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-Isoleucyl-L-glutaminyl-L-glutaminyl-L-Alpha-glutamyl-L-tyryl-L-Alpha-glutamyl-asparaginy-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminyl-L-tyryl-L-leucyl-L-Alpha-aspartyl-L-tyryl-L-typtophyl-L-ananyl-L-seryl-L-leucyl-L-typtophyl-L-Alpha-glutamyl-L-typtophyl-, [CAS]	251562-00-2	WO 9959615	Antiviral, anti-HIV	Infection, HIV/AIDS
T-3912	1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid				
T-588	3-azoc(2)thiophene-5-sulfonamide, Alpha-(2-(diethylamino)ethoxy)methyl-, hydrochloride, (R), [CAS]	142935-03-3	EP 965985	Quinolone antibacterial Cognition enhancer	Infection, dermatological Alzheimer's disease
T-67	Benzocyclohexanone, 2,3,4,5,6-benzocyclohexanone-N-(3-fluoro-4-methoxyphenyl)-, [CAS]	196553-53-0		Anticancer, other	Cancer, liver
T-82			US 5190951	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TA-2005	2-[(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[(2,4-methoxyphenyl)-1-methylamino]ethyl], monohydrochloride, [R-(R', R'')] [CAS]	137888-11-0	US 4579854	Antiasthma	Asthma
TA-2005	2-[1H]-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[(2,4-methoxyphenyl)-1-methylamino]ethyl], monohydrochloride, [R-(R', R'')] [CAS]		WO 189480	Formulation, inhalable, solution	Asthma
TA-693	1,5-Benzothiazepin-4(5H)-one, 3-(acetoxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel-(+), (2Z)-2-butenediate [CAS]	122024-98-0	JP 01045376	Antithrombotic	Peripieral vascular disease
tabimorelin	(R)-Alpha-[(E)-S-Amino-N,5-dimethyl-2-hexenamido]-N-methyl-N-[(R)-Alpha-(methylcarbamoyl)phenethyl]-2-naphthalenepropionamide	170851-70-4 193075-99-5		Releasing hormones	Growth hormone deficiency
tacalcitol	9,10-Secodicholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,38,5Z,7E,24R), [CAS]	57333-96-7 88129-94-3	EP 129003	Antiporiasis	Keratosis
tacedinaline	Benzanide, 4-(acetylamino)-N-(2-aminophenyl)- [CAS]	112522-64-2	DE 3613571	Anticancer, other	Cancer, pancreatic
tacrine	S-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	188440-5 321-04-2	EP 332147	Cognition enhancer	Alzheimer's disease
Tacrolimus	Pyrazolo(1,2-f:1,6-b')pyrido(3,4-b)indole 1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (8R-, trans) [CAS]	104987-11-3			
tadalafil	1,4-Phenanthrolamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]- [CAS]	171595-29-5 100635-80-7 106635-81-9 80065-55-0	US 6143746	Male sexual dysfunction	Impotence
tafenoguin	(S)-N-[2-(1,6,7,8-tetrahydro-2H-benzo-[5,4-b]furan-5-yl)propionamide	19387-42-6	US 4617394	Antimalarial	Infection, malaria
taliposide			WO 9612727	Anticancer, other	Cancer, general
TAK-375				Hypnotic/Sedative	Insomnia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TAK-427	2-[6-[3-(4-(Diphenylmethoxy)-piperidin-1-yl)-2,3-pyridazin-2-yl]-2-methylpropionic acid dihydrate			Anti-puritic/inflamm, allergic	Eczema, atopic
TAK-569	(E)-4-[4-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzoxyoxymino-4-phenylbutyric acid	9001-19-8		Antidiabetic	Diabetes, general
Taka-Diastase					
talampicillin	7H-1,3-Dioxolo[4,5-h][2,3]benzodiazepine, 7-acetN-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (8R)-[CAS]	161832-65-1	US 5639751	Antiepileptic	Epilepsy, general
Talampicillin	N-[(2S,3S)-18-Carboxy-2-(2-carboxy-ethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl porphyrin-20-yl]acetyl-L-aspartic acid	47747-56-8			
talapofin		220201-34-3			
Talastine		16188-61-7		Radiochemosensitizer	Cancer, lung, general
Talbutal		115-44-6			
Talinolol		57460-41-0			
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)-[CAS]	101625-70-4 36085-73-1	DE 3503963	Antiparkinsonian	Schizophrenia
talirelant	4-Quinolinesulfonylcarbamate, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-[CAS]	174696-32-9	WO 9532948	GI Inflammatory/bowel disorders	Irritable bowel syndrome
tariflumate	3-Pyridinecarboxylic acid, 2-[[3-(dihydro-3-oxo-1-isobenzofuran-1-yl)ester][CAS]	96898-62-2	BE 865864	Anti-inflammatory	Inflammation, ocular
talirelan	L-Prolineamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidinyl-, (S)-[CAS]	103300-74-9	JP 61033197	Neurological	Dyskinesia, general
temoxifen	Ethoxamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	10540-29-1	US 4536516	Anticancer, hormonal	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tamisulcin	Benzene sulfonamide, 5-[2-[2-(2-ethoxyphenoxy)ethyl]amino]propyl-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0	EP 34432	Prostate disorders	Benign prostatic hyperplasia
tendosphone	4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (3 α Alfa,4 β ,7 β ,7 α Alph α), 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	112457-95-1 87760-53-0	EP 82402	Analgesic	Anxiety, general
Tamoxifen		9010-29-1			
Tamoxifen		108945-35-3			
Tamoxifen	3-Quinolincarboxamide, N-[2-[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isochinolyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl] [CAS]	206873-63-4	WO 9817648	Radiochemosensitizer	Cancer, lung, non-small cell
Tamoxifen	5-[[2-(Dimethyl-amino)ethyl]amino]-3-hydroxy-7H-inden[2,1-g]quinolin-7-one dihydrochloride	174634-09-4 145733-36-4 81-24-3 19388-87-5	WO 9532187	Anticancer, other	Cancer, lung, non-small cell
Tamoxifen	Acetic acid, oxo[3-(1H-tetrazo-5-yl)phenyl]amino-, butyl ester [CAS]	82989-25-1	US 4779816	Asthma	
Tamoxifen	3-Pyridinecarboxylic acid, 6-[3,4-dihydro-4,4-dimethyl-2H-1-benzothiofuran-6-yl]ethyl-, ethyl ester [CAS]	118292-40-3 89786-04-9	EP 284288	Anipsoisias	Psoriasis
Tamoxifen					
Tamoxifen	N-Methyl-N-propargyl-10-aminomethyl-dibenzo(c,h)oxepin	374680-51-0	JP 58225091	Antibiotic, other	Infection, general
Tamoxifen	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethenyl-1H-imidazole [CAS]	82200-24-6		Neuroprotective	Heart failure Amyotrophic lateral sclerosis
Tamoxifen				Beta-lactam antibiotic	Infection, streptococcal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
lecadenoson	Adenosine, N[(3H)-tetrahydro-3-furanyl]- [CAS]	204512-90-3	WO 9800855	Antiarrhythmic	Tachycardia, supraventricular
lecarnitide	1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- [CAS]	75970-99-9 121281-41-2	US 4219559	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Technetium ^{99m} Tc Blicisate					
Technetium ^{99m} Tc Meritride		125224-05-7; 104348-91-6			
Technetium ^{99m} Tc Sestamibi		109581-73-9			
Technetium ^{99m} Tc Teboroxime		104716-22-5			
Tecothiazide					
Teclozan		4287-5-4 5560-78-1			
tedisamil	Spiro[cyclopentane-1,3'- (3,7)diazabicyclo[3.3.1]nonane], 3',7'-bis(cyclopropylmethyl)- [CAS]	90981-53-8	EP 102833	Antiarrhythmic	Fibrillation, atrial
Teflurane		124-72-1			
tegafur	2,4-(1H,3H)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)- [CAS]	17902-23-7	GB 1165391	Anticancer, antimetabolite	Cancer, general
tegafur + uracil	2,4-(1H,3H)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, mix. with 2,4-(1H,3H)-pyrimidinedione- [CAS]	74578-38-4	EP 224885	Anticancer, antimetabolite	Cancer, breast
tegaserod	Hydrazinecarboximidamide, 2-[(6-methoxy-1H-indol-3-yl)methyl]ene)-N-pentyl-, (Z)-2-butenedioate [CAS]	189188-57-8 145158-71-0		GI inflammatory/bowel disorders	Irritable bowel syndrome
Telcoplanin		61036-64-4			
telivudine	15-L, 2'-deoxythymidine	3424-98-4		Antiviral, other	Infection, hepatitis-B virus
Telenzepine		80880-90-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
telithromycin	3-De(2,6-dideoxy-3-C-methyl-3-O-methyl- Alpha-L-ribo-hexopyranosyl)-11,12- dideoxy-5-O-methyl-3-oxo-12,11- (oxycarbonyl)(4-(4-(3-pyridinyl)-1H- imidazol-1-yl)butyl)imino)-[CAS]	191114-48-4	EP 680967	Macrolide antibiotic	Infection, respiratory tract, general
telmisartan	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (R)- [CAS]	122946-43-4		COPD treatment	Bronchitis, chronic
telmisartan telomerase inhibitor	(1,1-Biphenyl)-2-carboxylic acid, 4'-(1,4- dimethyl-2-propyl(2,6-di-1H- benzimidazol-1-yl)methyl)- [CAS]	144701-48-4	EP 502314 WO 9941261	Antihypertensive, renin system Anticancer, other	Hypertension, general Cancer, general
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5- phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US 3197467	Hypnotic/Sedative	Insomnia
temiverine	Benzeneacetic acid, 4-(alpha-cyclohexyl- Alpha-methoxy-4-(4-ethylamino)-1,1- dimethyl-2-butenyl ester), [CAS]	129927-33-9	US 3197467	Urological	Poliakiduria
temocapril	1,4-Thiazepine-4(8H)-octic acid, 6-[[1- (ethoxycarbonyl)-3- phenylpropylamino]tetrahydro-5-oxo-2-(2- phenyl)-, [2S-[2Alpha,6B(R)]]- [CAS]	102090-90-4 110221-44-8 111902-57-8 66148-78-5	US 4495188	Antihypertensive, renin system	Hypertension, general
Temocillin					
temoporphin	Phenol, 3,3',3''-(2,3-dihydro-2H,23H- porphine-5,10,15,20-tetrayl)tetraakis-, [CAS]	122341-38-2	EP 337601	Radiochromensitizer	Cancer, head and neck
temozolomide	Imidazo[5,1-c][1,2,3,5-tetrazine-8- carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]	85622-93-1	DE 3231255	Anticancer, alkylating	Cancer, brain, general
tenalaprazole	1H-Imidazo[4,5-b]pyridine, 5-methoxy-2- [(4-methoxy-3,5-methyl-2- pyridinyl)methyl]butyl-, [CAS]	113712-98-4	US 4808996	Antulcer	Ulcer, gastric
Tenecteplase		191588-94-0			
Tenidap		120210-48-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
teniposide	Furo[3,4':6,7]naphtho[2,3-dj-1,3-dioxol-8(6aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[4-(6-O-(2-phenylmethylene)-6-D-glucopyranosyl)oxy]-[5R-[5Apha,5aB,8aAlpha,9C(R)]]	23787-20-2	US 3524844	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)- [CAS] 147127-20-6			Antiviral, anti-HIV	Infection, HIV/AIDS
tenofovir disoproxil	2,4,6,8-tetraoxa-5-phosphorane-3,4-dicarboxylic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl) bis(1-methylethyl)ester, 5-oxide (R), (E)-2-butenedioate	202138-50-9			
Tenonitroazole	2H-Thieno[2,3-ej]-2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	3810-35-3			
tenoxicam	carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	59804-37-4	GB 1519811	Antiarthritic, other	
Tentazonic Acid	5,9,13,17-Nona-decatrien-2-one, 6,10,14,16-tetramethyl- [CAS]	610-88-8			
teprenone	Piprazine, 1-(4-amino-8,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]- [CAS]	3795-63-2 6809-52-5 63074-03-8 63590-64-7 70024-40-7		Antitumor	
terazosin	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hapten-4-ynyl)-N-methyl-, (E)- [CAS]	78628-90-5 81161-71-6	US 4112097	Antihypertensive, adrenergic	Hypertension, general
terbinafine	1,3-Benzoxazole, 5-[2-(1,1-dimethylethyl)amino]-1-hydroxyethyl]- [CAS]	EP 24687		Antifungal	Infection, dermatological
terbutaline		23031-25-6		Formulation, mucosal, topical	Dysmenorrhea
terconazole	Piprazine, 1,4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-thiazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylphenyl]-4-(1-methylethyl)-, Cs- [CAS]	67915-31-5	US 4398449	Antifungal	Vaginitis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
terfenadine	1-[4-(piperidin-4-yl)-1-(4-dimethylphenyl)-4-(hydroxydiphenylmethyl)-phenyl]-N,N-dimethyl-N'-[6-(alpha)-5-methylergolin-8-yl]-[CAS]	50679-08-8	US 3878217	Antiallergic, non-asthma	
tergicide		37696-84-3	EP 159522	Antiprolactin	Hyperprolactinaemia
Teripressin		14636-12-5			
Terdoline		15793-40-5			
Terfenamate		29088-15-5			
Terpin		80-53-5			
tertiolol	2-Propanol, 1-[3,4-dihydro-2H-1-benzothio[pyran-8-yl]oxy]-3-[1,1-dimethylethyl]amino], hydrochloride, (+)- [CAS]	33580-30-2 83688-84-0 34784-64-0			
tert-Pentyl Alcohol	2S)-2-ethoxy-3,4,4,4-tetramethyl-1-phenylpropanoic acid	75-85-4	GB 1308191	Antihypertensive, adrenergic	Hypertension, general
tesaglitazir				Antidiabetic	Diabetes, Type II
tesmilone	Ethanamine, N,N-Diethyl-2-(4-[(methylsulfonyl)oxy]phenyl)ethoxy [CAS]	92981-78-7 958-93-4		Radiochromosensitizer	Cancer, breast
Testolactone					
Testosterone	androst-4-en-3-one, 17-hydroxy-, (17 β) - [CAS]	58-22-0 5949-44-0		Formulation, transdermal, systemic	Hormone replacement therapy
terabamate		60763-47-5	DE 2748794	Audiolytic	Addiction, alcohol
Tetrabartital		76-23-3			
Tetrabenazine		58-46-8			
Tetracaine		136-47-0			
Tetrachloroethylene		127-18-4			
tetracine	Benzoic acid, 4-(substituted)-2-(dimethylamino)ethyl ester [CAS]	94-24-6		Formulation, transdermal, systemic	Pain, general
tetracycline	2-Naphtho[1,2-b:6-b']bis(4-[(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12-tetrahydro-6-methyl-1,11-dioxo-, [4S]-[4A]phthal-5a-yl]-5a,6,12a-phenyl)-[CAS]	60-54-8		Formulation, oral, other	Infection, oral

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tetrahydrozoline		84-22-0			
Tetrandrine		518-34-3			
Tetrantoin		52094-70-9			
Tetrazepam		10379-14-3			
Tetrolfosmin		127502-08-1			
tertoprim					
Tevenel®	2,4-Pyrimidinediamine, 5-[3,5-dimethoxy-4-(2-methoxyethoxy)phenyl]methyl-[CAS]	53808-87-0 74515-38-1	US 3892378	Trimethoprim and analogues	Infection, general
tezacitabine	Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)- [CAS]	4302-95-8			
		130306-02-4	US 5616702	Anticancer, antimetabolite	Cancer, colorectal
	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridyl)-4-pyrimidinyl)-5-(1-methylethyl)- [CAS]	180384-57-0		Cardiosimulant	Oedema, general
tezosentan	1H-isoxazole-1,3,4-trihydro-dione, 2,7,2,8-tetraoxo-3-piperidinyl- [CAS]	50-35-1		Dermatological	Infection, dermatological
thalidomide		86-12-4			
Thenaldine		91-79-2			
Thenyldiamine		83-67-0			
Theobromine		54504-70-0			
Theofibrate		3655-3			
theophylline	1H-pyrimine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	5867-84-0		Formulation, modified-release, other	Asthma
Thiabendazole		148-79-8			
Thiacetazone		104-06-3			
	Carbamic acid, (4-(1-methylethyl)phenyl)-, (9aS,8aS)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]				
thiacymserine		145209-51-4			
Thiobarbital		467-36-7		Cognition enhancer	Alzheimer's disease
Thiamine		59-43-8			
Thiamine		154-87-0			
Thiamine		67-16-3			
Thiamiprine		5581-32-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thiamphenicol		15318-45-3			
Thiamylal		77-27-0			
Thiazesim		5845-26-1			
Thiazinamium		58-34-4			
Thiazolnibutazone		54749-86-9			
Thiazolsulfone		473-30-3			
Thibenzazoline		6028-35-9			
Thiethylperazine		1420-55-9			
Thimerfonate		5964-24-9			
Thimerosal		54-64-8			
Thiobarbital		77-32-7			
Thiobutabarbital		2095-57-0			
Thiocarbamizine		91-71-4			
Thiocarbazono		120-02-5			
Thiocolchicine		2730-71-4			
Thiocresol		26445-03-4			
Thioctic Acid		62-46-4			
Thioglycerol		96-27-5			
Thioguanine		154-42-7			
Thiomeg	L-Thiodycetyl-glycyl-glycine			Anticancer, immunological	Cancer, general
Thiopental		71-73-8			
Thiopropazate		84-06-0			
Thiopropazine		316-81-4			
Thioridazine		50-52-2			
Thiothixene		5591-45-7			
Thiovir	Thiophosphoradamic acid			Antiviral, anti-HIV	Infection, HIV/AIDS
Thiophenamil		82-99-5			
Thiram		137-26-8			
Thonzylamine		63-56-9			
Thozalinone		655-05-0			
Thromboplastin		9035-58-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thurifyl Nicotinate		70-19-9			
Thymecacon			US 6245750	Anticancer, other	Cancer, colorectal
Thymol		89-83-8			
Thymopentin		69553-55-0			
Thymyl N-		578-20-1			
Isoamylcarbamate					
Thyroxine		51-26-3			
Thyroxine		51-48-9			
Thiadenol		6964-20-1			
Thiagabine	3-Piperidinecarboxylic acid, 1,4,4-bis(3-methyl-2-thienyl)-3-butenyl-, (R)-, [CAS]	115103-54-3	WO 8700171	Antiepileptic	Epilepsy, general
Thiamendiline		31423-61-2			
Thienopine	Heptanoic acid, 7-[(3-chloro-6,11-dihydro-6-methylbenzo[c][1,2]thiazepin-11-yl)amino]-, S,S-dioxide [CAS]	72787-41-2 66981-73-5			
Thiopic	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)-, [CAS]	51012-32-9	GB 1269551	Antidepressant	Depression, general
Thioprofenic acid	2-Thiophenecarboxylic acid, 5-benzoyl- α -methyl-, [CAS]	33005-95-7	GB 1394563	Neuroleptic	
Thiaramide		32527-55-2	GB 1331505	Antiarthritic, other	
Thiazoturin	4-Thiazolocarboxamide, 2,4-D-thiofuranosyl-, [CAS]	60084-10-8	EP 54432	Anticancer, antimetabolite	Cancer, leukæmia, chronic myelogenous
Thibezontum	19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7 α), [CAS]	54663-47-7			
Thibolone		5630-53-5	EP 389035	Menopausal disorders	Hormone replacement therapy
Thiarcillin		34787-01-4			
Thiodipine	Thienod(3,2-g)pyridine, 5-(2-chlorophenyl)methyl-4,5,6,7-tetrahydro-, [CAS]	53895-35-1 55142-85-3			
Thienafan	4-(3-hydroxy-5-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium	40180-04-9 6252-32-2 144-12-7	GB 1554424	Antithrombotic	
Thiomium				Antispasmodic	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tigecycline	2-Naphthoicacetic acid, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethyl-2-phenyl-2-oxoethyl)amino]-1,4,4a,5,6a,6,11,12a-octahydro-3,10,12,12a-tetrahydro-1,11-dioxo-, (4S,4aS,8aR,12aS)-], [CAS]	220920-08-7	EP 582229	Tetracycline	Infection, general
Tigemonam		102507-71-1			
Tigilidine		495-83-0			
Tilidine		20380-58-9			
Tilisolol		85136-71-6			
tilmascorb	Benzene sulfonamide, 4-(4-cyanoethoxy-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-88-4	WO 9619463	Alimentary/Metabolic, other	Polyp
fluoronic acid	Phosphonic acid, [[4-chlorophenyl]thio]methylene]bis- [CAS]	89987-06-4	EP 100718	Osteoporosis treatment	Page's disease
Timentin		86482-18-0		Antibiotic, other	Infection, general
timopidum	Piperidinium, 3-[(2-2-phenylmethyl)ene]-5-methoxy-1,1-dimethyl-, [CAS]	35035-05-3	GB 1358446	Antispasmodic	
Timperone		57648-21-2			
timolol	(S)-1-(4-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanolmaleate (1:1) salt	28839-75-8 28921-17-5	GB 1253709	Antihypertensive, adrenergic, antiglaucoma	
Timonacid		444-27-9			
Tin Ethyl Etio purpurin		113471-15-1			
tinazoline	1H-indole, 3-[(4,5-dihydro-1H-midazo-2-yl)thio], [CAS]	62882-99-9	US 3376311	Vasodilator, peripheral	
Tindazole		19387-81-8			
Tiofirdine		24237-54-5			
Tiocarlide		910-86-1			
Tiocloमारol		22619-35-8			
ticomazole	1H-midazole, 1,2-[(2-chloro-3-thienyl)methoxy]-2,12,4-dichlorophenylthyl- [CAS]	61675-64-7 66889-73-2	US 4052866	Antifungal	Infection, fungal, general
tiopronin	Glycine, N-(2-mercaptopropyl)- [CAS]	1983-02-2	US 3246025	Urological	Hemorrhoids

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Isotretinoin	9-Oxo-9-azabicyclo[3.3.1]nonane, 7-(4-hydroxy-2-methylacetoxy)-9-amine, [CAS]	138310-93-5	EP 418716	COPD treatment	Chronic obstructive pulmonary disease
Tioxolone		4931-65-5			
Tipecidine		5169-78-8			
Tipifarnib	21H-Quinolone, 8-(amino-4-chlorophenyl)-(1-methyl-1H-imidazol-5-yl)methyl-4-(3-chlorophenyl)-1-methyl, [CAS]	192185-68-5 192185-72-1	WO 9718443	Anticancer, other	Cancer, breast
Tipranavir	N-[8-[[[R]-[4-Hydroxy-2-oxo-5(R)-[2-phenylethyl]-6-propyl]-5,6-dihydro-2H-pyran-3-ylidene]amino]-5-(trifluoromethyl)pyridine-2-sulfonylamide	174484-41-4		Antiviral, anti-HIV	Infection, HIV/AIDS
Tiqizium	2H-Quinoxalinium, 3-(di-2-(2-methyl-2-phenylethyl)ethyl)-5-methyl-, [CAS]	71731-58-3	US 4205074	Antispasmodic	
Tirapazamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxide-, [CAS]	20028-80-2 27314-97-2 5424-06-6	DE 2204574	Radio/chemosensitizer	Cancer, lung, non-small cell
Tritacrol		51-24-1			
Tritilazad	Pregna-1,4,8(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methyl-, (16Alpha), [CAS]	110101-65-0 110101-67-2 110101-66-1	WO 8701706	Neuroprotective	Haemorrhage, subarachnoid
Tirofiban	L-Tyrosine, N-(butylsulfonyl)-O-(4-(piperidinyl)butyl-, [CAS]	182973-69-2 144494-66-5	EP 478363	Antithrombotic	Infarction, myocardial
Tiropramide	Benzenehexopropanamide, Alpha-(benzylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropyl-, (+)-, [CAS]	56637-29-1	DE 2803992	Antispasmodic	Muscle spasm, general
Titanium Sulfate		138275-74-6			
Tibacortol	Pregna-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropyl)thio]-1,17-dihydroxy-, (11B)-, [CAS]	55560-96-8 61951-99-3	GB 1475795	Antiasthmatic, non-asthma, mucosal, topical	Rhinitis, allergic, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Israndine	2,1,3-Benzothiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl) [CAS]	51322-75-9	GB 1429926	Muscle relaxant	Spastic paralysis
TLK-199	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenyl-diethyl ester, (2R)- [CAS]	169882-53-9	US 5679643	Immunostimulant, other	Myelodysplastic syndrome
TLK-288	Glycine, L-Gamma-glutamyl-3-[(2-chloroethylamino)phosphoryloxy]ethylsulfonyl-L-alanyl-2-phenyl-, (2R)- [CAS]	193982-37-7	US 5545621	Anticancer, other	Cancer, ovarian
TNP-470	TNP-470	129288-91-5	RU 2035185	Anticancer, immunological	Cancer, general
TCO-186	Propas-1, 4-diene-3,20-dione, 9-fluoro-11,13,17,21-tetrahydro-16-beta-methyl-, 17-butyrate 21-propionate [CAS]	5534-02-1		Antipruritic/anti-inflam., allergic	
tolbramycin	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1,6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4)-2-deoxy- [CAS]	32986-66-4		Formulation, inhalable, topical	Infection, respiratory tract, general
tolcalide	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	41708-72-9	US 4218477	Antiarrhythmic	Fibrillation, ventricular
Tocamphyli		5634-42-4			
tocadafeline	8-Chloroadenosine 3'5'-cyclic phosphate	41941-56-4		Anticancer, other	Cancer, colorectal
Tocoretinate		40516-48-1			
Tofentalazine		14679-73-3			
Tofenacin		15301-93-6			
tofmilast	5H-Pyrazolo[3,4-d]-1,2,4-triazolo[4,3-a]pyridine, 8-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-phenyl)-	185954-27-2		Anticellulite	Asthma
tolisopam	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl- [CAS]	22345-47-7	GB 1394271	Anxiolytic	Anxiety, general
Tolazamide		11156-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolazoline		59-98-3			
Tolbutamide		64-77-7			
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	EP 237929	Antiparkinsonian	Parkinson's disease
tolcidate	Carbamothioic acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS]	50838-36-3			
Tolcyclamide		664-95-9	GB 1364407	Antifungal	Infection, dermatological
toleramer	Benzenesulfonic acid, 4-ethenyl-, homopolymer,				
toleramic acid	Benzoic acid, 2'-(3-chloro-2'-methylphenyl)amino)- [CAS]	28038-50-8		Antibacterial, other	Infection, Clostridium, general
Tolindate		13710-19-5	DE 1543295	Anti-inflammatory	Inflammation, general
Toliprolol		27677-51-6			
Tolmetin		2933-94-0			
Tolmetin		26171-23-3			
Tolnate		2398-96-1			
Tolonidine		4201-22-3			
Tolonium		92-31-9			
toloxatone	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	28218-27-7	GB 1250538	Antidepressant	
Tolperisone		728-88-1			
Tolpropamine		5632-44-0			
Tolrestat		82964-04-3			
tolerine	Carbamic acid, (2-methylphenyl)-, (3aS,6aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-30-9			
tolterodine	Phenol, 2-[3-bis(1-methyl(ethyl)amino)-1-phenylpropyl]-4-methyl-, (R)-, [CAS]	124937-61-5	EP 324571	Cognition enhancer	Alzheimer's disease
	Benzanilide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5H-1-benzazepin-1-yl)acetyl]-3-methylphenyl]-2-methyl-, [CAS]			Urological	Incontinence
tolvaptan		160683-30-0	EP 450087	Cardiovascular	Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolycaine	Beta-D-Fructopyranose, 2,3,4,5-bis-O-(1-methylethylidene), sulfamate [CAS]	3686-58-6 97240-79-4	EP US	Antiepileptic Anticancer, other	Epilepsy, generalized, tonic-clonic Cancer, general
topiramate	1H-Pyranol[4,5-f]indolizino[1,2-b]quinoline-3,14-dihydro-9-[[dimethylamino]methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]				
topotecan	3-Pyridinesulfonamide, N-[[1-methylethylamino]carbonyl]-4-[[3-methylphenyl]amino]- [CAS]	123948-87-8	EP	Anticancer, other	Cancer, ovarian
torasemide	ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]([methoxycarbonyl]amino)-2-ethyl-4-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	56211-40-6	US	Antihypertensive, diuretic	Hypertension, general
torcetrapib	8-L-2'-Deoxycytidine	262352-17-0		Hypolipemic/Antiatherosclerosis	Atherosclerosis
torclatbine				Antiviral, other	Infection, hepatitis-B virus
tormentilene	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-ethyl-1-phenyl)-N,N-dimethyl-, (Z)-[CAS]	88778-36-7 88778-27-8	EP	Anticancer, hormonal	Cancer, breast
Torsemide		56211-40-6			
Tositumomab		208921-02-2			
tosufloxacin	1,8-Naphthylidine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, [CAS]	100490-36-6 115964-29-9	US	Quinolone antibacterial	Infection, urinary tract
tramadol	Cyclohexanol, 2-[[dimethylamino]methyl]-1-(2-methoxyphenyl)-, (S)-(+)-[CAS]	147203-92-5 36282-47-0		Analgasic, other	Pain, general
Tramazoline	1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-, [2S-][1R-(1',1'')] 2Alph,3alpha,7alpha-, [CAS]	1082-57-1			
trandolapril		87679-71-8 87679-37-6 92-53-9	DE	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
trans-aminic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- [CAS]	1197-18-8	US 3950405	Antifibrotic	Menstrual disorder, general
trans-aminic acid	Benzoic acid, 2-[(3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino]- [CAS]	53902-12-8	US 3940422	Vulnary	Wound healing
trans-aminic acid	Retinoic acid [CAS]	302-79-4		Anticancer, other	Cancer, general
Tranylcypromine	[1,2,4]triazol[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	155-09-9			
trapidil		15401-84-8	DD 55956	Vasodilator, coronary	
Trastuzumab		180288-68-1			
travoprost	5-Hydroxy acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethylester (1R(1Alpha(Z),2E(1E,3R)),3Alpha,5Alpha) [CAS]	157283-68-6		Formulation, mucosal, topical	Glaucoma
Traxanox	1-Piperidineethanol, 4-hydroxy-Alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-, (AlphaS,1S)- [CAS]	58712-69-9			
traxoprolil	1,2,4-Triazol[4,3-a]pyridin-3(2H)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)- [CAS]	134234-12-1 188591-67-5		Anaesthetic, other	Pain, general
trezodone		19794-93-5 25332-38-2	US 4215104	Antidepressant	
Trenacamra		155578-46-7			
Trenbolone		10161-33-8			
Trengestone		5192-84-7			
treosulfan	1,2,3,4-Butanetriol, 1,4-dimethanesulfonate, [S-(R'-R'')] [CAS]	299-75-2	WO 8401506	Anticancer, alkylating	
treptibulone	Benzenesulfonic acid, 2,4,5-trifluoro-gamma-oxo- [CAS]	41826-92-0	GB 1387733	Antiparasitic	
treprostinil	Prosta-5,13-diol-6-oleic acid, 6,8-epoxy-11,15-dihydroxy-, [5Z,9Alpha,11Alpha,13E,15S]- [CAS]	35121-79-9 61849-14-7		Formulation, parenteral, other	Hypertension, pulmonary
treprostinil	Retinoic acid [CAS]	302-79-4	US 6054486	Formulation, dermal, topical	Acne

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
haloquinol	6,7-bisquinolinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-, (S)- [CAS]	18555-55-6 30418-38-3 21650-42-0	ZA 6802416	Antiasthma	
TRH	TRI 50b [CAS]	24305-27-9			
		22824-49-9		Antithrombotic	Thrombosis, general
Triacetin		102-76-1			
Triamcinolone Acetonide		76-25-5			
Triamcinolone		31002-79-6			
Benetonide		5611-51-8			
Triamcinolone Hexacetonide					
Triamcinolone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydro-16,17-{(1-methylethylidene)bis(oxo)}, (11b,16a) [CAS]	76-25-5 124-94-7		Formulation, inhalable, topical	Asthma
Triamterene		396-01-0			
Triazine	Triazine [CAS]	23832-58-6	US 6458816	Anticancer, antimetabolite	Cancer, leukæmia, general
Triaziquone		68-76-8			
triazolam	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-1,2,4-triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	US 3980790	Hypnotic/Sedative	Insomnia
Tribenoside		10310-32-4			
Trichlorfon		52-68-6			
Trichloromethiazide		133-67-5			
Trichloromethine		555-77-1			
Trichloroethylene		79-01-6			
Triclobonium		79-80-3			
Triclocarban		101-20-2			
Triclofenol Piperazine		5714-82-9			
Triclofos		306-52-5			
Triclosan		3380-34-5			
Tricromyl		85-90-5			
Tridhexethyl Iodide		125-99-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Trifluorine	1,2-Ethanediamine, N,N-bis(2-aminoethoxy)- [CAS]	38260-01-4 112-24-3		Metabolic and enzyme disorders	Wilson's disease
Triethanolamine		102-71-6			
Triethylenemelamine		51-18-3			
Triethylenephosphoramide		545-55-1			
Triethylenethiophosphoramide		52-24-4			
Trifluoperazine		117-89-5			
Trifluoperidol		749-13-3			
Triflupromazine		146-54-3			
Trifluoridine	Thymidine, Alpha, Alpha-trifluoro- [CAS]	70-00-8	US 3201387	Antiviral, other	Infection, herpes virus, general
Trifluasal	Benzoic acid, 2'(acetoxy) 4'- (trifluoromethyl)- [CAS]	322-79-2	US 4096252	Antithrombotic	Thrombosis, general
Trifluorophenidyl		52-49-3			
Trifluraline	Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4Alpha,5Alpha,17E)- [CAS]	13647-35-3	US 3298255	Anticancer, hormonal	Cancer, breast
Trimazosin		35795-16-5			
Trimelbine	Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylethyl ester, (2S,2S)-butenedioate (1:1) [CAS]	34140-89-5 39153-31-8	DE 2151716	Antispasmodic	
Trimecaine		616-68-2			
Trimeprazine		84-96-8			
Trimezadine		5011-34-7			
Trimethadione		127-48-0			
Trimethaphan		68-91-7			
Trimethobenzamide		138-56-7			
Trimethoprim		738-70-5			
Trimetozine		635-41-6			
Trimevalate	2,4-Quinoxalinediamine, 5-methyl-6-[[[3,4,5-trimethoxyphenyl]amino]methyl]- [CAS]	52129-35-5 82982-64-5	US 4391809	Antifungal	Infection, Pneumocystis jirovecii

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
trifluoromethine	5H-Dibenz[b,f]azepine-5-propionamide, 10,11-dihydro-N-6-(dimethyl- (2,2-butenedioate (1:1) [CAS]	521-78-8 739-71-9		Antidepressant	
Trimoprostil		69900-72-7			
Troxosalen		3902-71-4			
trpamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-((cyclohydro-4,7-methano-2H-isindol-2-yl)-(3aAlpha,4Alpha,7Alpha,7aAlpha), [CAS]	73803-48-2	JP 7305585	Antihypertensive, diuretic	Hypertension, general
Triptanol		78-41-1			
Triptelenamine		91-81-6			
Triptolidine	Luteinizing hormone-releasing factor (LHRH), 124508-68-3	486-12-4			
triprathin	6-D-typtophan- [CAS]	57773-63-4	US 4010125	Releasing hormones	Cancer, prostate
trifluazone	Morpholine, 4-[[[oxo(3,4,5-trimethoxyphenyl)methyl]- [CAS]	35619-65-9	US 3862138	Antifolator	
Trifluqualine	Phosphonic acid, [[[(4-(methylthio)phenyl)methyl]ene]bis, disodium salt [CAS]	14504-73-5			
TRK-530		151425-92-2	WO 9410181	Antiarthritic, other	Arthritis, rheumatoid
TRK-820	2-Propionamide, N-[(5Alpha,8beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydrooxymorphinan-6-yl]-[3-(3-furanyl)-N-methyl-, monohydrochloride, (2E)- [CAS]	125658-17-8	WO 9315081	Antipruritic/antiinflamm, non-allergic	Pruritus
Trosclozene	3,2-(chloroacetyl)-2-[bis(2'-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide	2244-21-5			
trosclofenamide		22089-22-1	GB 1188159	Anticancer, alkylating	
Troglitazone		97322-87-7			
Troloandromycin		2751-9-9			
Trolointrate		588-42-1			
trontamandine	NH(1-(adamantyl)-2-(2-dimethylamine ethoxy)acetamide	53783-83-8	DE 1941218	Antiviral, other	Infection, herpes simplex virus
Tromethamine		77-86-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tuaminoheptane		123-82-0			
Tubercidin		69-33-0			
Tubocurarine Chloride		57-94-3			
tubocurclol	Benzenehexanol, 2-chloro-Alpha-[(1,1-dimethylethyl)amino]methyl-; [CAS]	41570-61-0	DE 2244737	Antiasthma	Asthma
TV-3326	N-[Pipargyl-(8R)aminocyclopentyl]ethyl methyl carbamate			Cognition enhancer	Alzheimer's disease
TY-11223	Acetic acid, [2-[2,3,3a,6,7,7a-hexahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadimethyl)-1H-inden-5-yl]ethoxy]-, [1S-1']-Alphal(1'')2b,3aAlphal(1'')Alphal(1'')- [CAS]	140994-49-5	US 4837342	Antithrombotic	Unspecified
TY-12533	6,7,8,8-Tetrahydro-2-methyl-5H-cyclohepta[b]pyridine-3-carbonylguanidine maleate				
TYB-3215	D-Glucitol, 1',4',3',6'-dianhydro-, dimaleate [CAS]	87-33-2		Antiarhythmic	Unspecified
Tybamate	4-[(1,1,3,3-tetramethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	4268-36-4		Formulation, modified-release, other	Angina, general
tycoxopol		25301-02-4			
Tynazoline		24243-97-8			
Tyramine		51-67-2		Formulation, inhalable, topical	Cystic fibrosis
Tyropanoate		7246-21-1			
Ubanimex		58970-76-6			
ufenamate	Benzoic acid, 2-[(3-trifluoromethylphenyl)amino]-, butyl ester [CAS]	67330-25-0			
Undecylenic Acid		112-38-9	DE 861852	Antipruritic/antiinflamm, non-allergic	
Unoprostone		120373-36-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
UR-8880	4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide [CAS]				
Uracil Mustard	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:6), hydrate [CAS]	66-75-1		Anti-inflammatory	Inflammation, general
Uraly-U	2,2'-(1,1',3,3'-Pyrimidinodione, 6-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino)-1,3-dimethyl- [CAS]	55049-48-4	US 4400535	Urological	
urapidil urea	Urea [CAS]	34661-75-1	GB 1305324	Antihypertensive, adrenergic	Hypertension, general
Uredopa		57-13-6		Antiparkinson	
Urethan		302-49-8			
Uridine 5'-Triphosphate		51-79-6			
Uridine		63-35-8			
Urinastatin		30449-31-6			
ursodeoxycholic acid	3 α hydroxy-7 β ,12-dihydroxy-5 β -cholestan-24-oic acid [CAS]	128-13-2		Formulation, other, Cirrhosis, primary biliary, hepatic dysfunction, biliary calculus	Cirrhosis, primary biliary
Ursodiol		128-13-2			
Ushercell					
Uzarin			US 6063773	Formulation, mucosal, topical	Contraceptive, female
valaciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester [CAS]	20231-81-6			
Valacyclovir		124832-28-4	EP 308065	Antiviral, other	Infection, herpes simplex virus
valdecoxib	Benzenesulfonamide, 4-[5-methyl-3-phenyl-4-isoxazolyl]- [CAS]	124832-28-4			
Valdeketamide		181695-72-7			
Valdeketamide		512-48-1	US 5655257	Antianthratic, other	Arthritis, rheumatoid
Valdeketamide		90-22-2			
valganciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy-3-hydroxypropyl ester [CAS]	175865-59-5 175865-60-8			
Valnoctamide		4171-13-5	EP 694547	Antiviral, other	Infection, cytomegalovirus

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
valomacidevir	L-Valine (3R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-8-ylmethyl)-4-((1-oxooctadecyl)oxy)butyl ester [CAS]	195156-77-5 76594-70-8		Antiviral, other	Infection, herpes simplex virus
valproate	Pentanoic acid, 2-propyl-, [CAS]	1069-65-5 99-66-1	US 4988731	Antiepileptic	Epilepsy, generalized, tonic-clonic
Valproic Acid					
Valpromide		2430-27-5			
valtocoamide	Pentamamide, N-(2-amino-2-oxoethyl)-2-propyl- [CAS]	92262-58-3	US 5585358	Antiepileptic	Epilepsy, general
valubutin	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-5,11-dioxo-4-((2,3,5-trimethoxy-5-(trifluoroacetyl)amino)-4-oxo-1,4-dioxacyclopratrioxyl)-2-naphthylacetyl)-2-oxoethyl ester (2S-cis)-[CAS]	56124-62-0	US 4035568	Anticancer, antibiotic	Cancer, bladder
valsartan	L-Valine, N-(1-oxopropyl)-N-[2'-(H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-[CAS]	137862-53-4 121584-18-7	EP 443983	Antihypertensive, renin system	Hypertension, general
Valspodar					
varidenafil	Piparazine, 1-[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo(6,1-f)(1,2,4)-triazin-2-yl)-4-ethoxyphenyl]sulfonfyl)-4-ethyl- [CAS]	224785-90-4		Male sexual dysfunction	Sexual dysfunction, male, general
varicelidib	Acetic acid, ((3-(aminooctacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- [CAS]	1172732-66-2 172733-42-5	EP 675110	Septic shock treatment	Sepsis
<i>Varicella Virus</i>					
<i>Vaccine</i>					
valandipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-bis(methyl-4-(3-aminophenyl)-2,4-fu-(4-aminophenyl)-piperazinophenyl)methyl methyl ester, [CAS]	116308-55-5 133743-71-2	EP 257618	Neuroprotective	Hypertension, general
VFA			US 6007817	Radiocontrast sensitizer	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
vecuronium	Piperidinium, 1- [20,3,6,10,16,17,18]-3,17- bis[4-(oxo)-2-(1-piperidinyl)endostan- 10-yl]-1-methyl-, [CAS]				
Velnacrine					
venlafaxine	Cyclohexanol, 1-[2-(dimethylamino)-1-(4- methoxyphenyl)ethyl]-, [CAS]	50700-72-6 104675-29-8 93413-69-5 99300-78-4	US 4237128	Muscle relaxant	Anaesthesia, adjunct
Verapipride					
verapamil	Benzeneacetone, 1-[2-(dimethylamino)-1-(4- dimethoxyphenyl)ethyl]methanobipropyl-]-3,4-dimethoxy-Alpha-(1-methylethyl)- [CAS]	66644-81-3	GB 2227743	Antidepressant	Depression, general
verteporfin	23H-2H-Benz[20,19]pyrroline-9,13- dipropionic acid, 18-ethyl-14-oxo-4-hydro- 3,4-bis(methoxycarbonyl)-4a,8,14,19- tetramethyl-, monomethyl ester, trans- [CAS]	52-53-9		Formulation, modified-release, other	Hypertension, general
vesnarinone	Piazazine, 1-[3,4-dimethoxybenzoyl]-4- (1,2,3,4-tetrahydro-2-oxo-6-quinolyl)- [CAS]	129497-78-5	US 5238940	Ophthalmological	Macular degeneration
Vetrabutine					
VF-233	Benzene carboximidamide, N,3,4,5- tetrahydro-, [CAS]	81840-15-5	GB 2086896	Cardioinulant	Heart failure
VF-0134		3735-45-3			
vidarabine	Benzene carboximidamide, N,3,4,5- tetrahydro-, [CAS]	95933-74-7	US 4623659 GB 6403597	Cardiovascular Male sexual dysfunction	Reperfusion injury Premature ejaculation
vigabatrin	9H-Purin-6-amine, 9-β-D-arabinduranosyl- [CAS]	24356-66-9 5636-17-4 68506-86-5 60043- 86-9	US 1159280 GB 1472525	Antiviral, other Antiepileptic	Infection, herpes virus, general Epilepsy, partial (focal, local)
vilazodone	5-Hexenoic acid, 4-amino-, [CAS]	163521-12-8	EP 648767	Antidepressant	Depression, general
Vinoxazine	2-Benzofuran-3-carboxamide, 5-(4-(4-(5- cyano-1H-indol-3-yl)butyl)-1-piperazinyl)- [CAS]	46817-91-8			
Vimanol		21363-18-8			
Vinbarbital		126-44-0			
Vinblastine		865-21-4			
vinburnine	Ebumenine-14(15H)-one, (3A,16A,16B)-[CAS]	474-00-0 4680-88-0	DE 1932245	Cognition enhancer	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Vincamine		1617-90-9			
Vincamate		70704-03-9			
Vincristine	Vincaluticristine, 22-oxo-, sulfate (1:1) (salt) [CAS]	2068-78-2 57-22-7	EP	Formulation, paraneural, other	Cancer, general
Vindesine	Vincaluticristine, 3-(aminocarbonyl)-O4-deacetyl-5-de(methoxycarbonyl)- [CAS]	53643-48-4 59917-39-4	GB	Anticancer, other	Cancer, leukaemia, acute lymphocytic
Vinflunine	Aspidospermidine, 3-carboxylic acid, 4-(azepylprop)-4,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecin-9(4,3-b)indol-3-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2S,3R,4S,5A,12B,19A)-, [CAS]	162652-95-1	FR	Anticancer, other	Cancer, general
Vinorelbine	C-Norvinorelbine, 3',4'-didehydro-4'-deoxy-, [CAS]	71486-22-1	EP	Anticancer, other	Cancer, lung, non-small cell
Vinopocetine	Etumemine-14-carboxylic acid, ethyl ester, (3A,16A)-, [CAS]	42971-09-5	GB	Cognition enhancer	Cognitive disorder, general
Vinyl Ether		109-93-3			
Vinybital		2430-49-1			
Viquidil		84-55-9			
Viridin		3306-52-3			
Vismadine		477-32-7			
Vitamin A		68-26-8			
Vitamin B12	Vitamin B12 [CAS]	68-19-9		Formulation, transmucosal, nasal	Anaemia, general
Vitamin C	L-Ascorbic acid [CAS]	50-81-7		Formulation, modified-release, <=24hr	Nutrition
Vitamin D2		50-14-6			
Vitamin D3		67-97-0			
Vitamin K2		83-70-5			
Vitamins, Prenatal					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
VLA-4 antagonists	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-((4-biphenyl)-methyl)-4-methyl-2,5-dioximidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP 842943	Antiasthma	Asthma
VNP-40101M	1,2-Bis((methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine				
voglibose	D-apl-Inositol, 3,4-dideoxy-4-[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- [CAS]	83480-29-9	US 6040338	Anticancer, alkylating	Cancer, general
voriconazole	4-Pyridinethanol, Alphas-(2,4-difluorophenyl)-5-fluoro-6-methyl-Alpha-(1H-1,2,4-triazol-1-yl)methyl-, (R-(R', S')) [CAS]	137234-62-9	EP 56194	Antidiabetic	Diabetes, Type II
Vorozole	7-[3-[4-(2-Quinoliny)methyl]-1-piperazinyl]propoxy]-3,4-dihydro-2H-1,4-benzothiazine-5-one	129731-10-8	EP 440372	Antifungal	Infection, fungal, general
VUF-K-6788					
Warfarin		81-81-2		Antiasthma	Asthma
WF-10	Tetrachloro-dioxole [CAS] 2-(3-[4-(3-oxo-6H-2,10b-diazacanthrenyl)-5-(amino)propyl]-piperazin-1-yl)propyl-5-nitro-2-azaphenylene-1,3-dione	92047-76-2		Radio/chemoprotective	Chemotherapy-induced injury, bone marrow (general)
WMC-79					
WP-170	wound healing matrix		US 5697880	Anticancer, other	Cancer, colorectal
xaliproden	Pyridine, 1,2,6-tetrahydro-1-(2-(2-naoxyphenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)- [CAS]	90494-79-4 135354-020-8	US 6531121	Formulation, transdermal, patch	Ulcer, diabetic
xamoterol	4-Morpholinylacetoamide, N-[2-[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl-, (+-) [CAS]	73210-73-8 81801-12-9	EP 101381 GB 2002748	Cyloine Neuroprotective Cardio stimulant	Unspecified Amyotrophic lateral sclerosis Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Xanomeline		131986-45-3			
Xanthinol Niacinate		437-74-1			
Xenilofiban		149820-74-6			
Xenibucin		959-10-4			
Xibenolol		81584-06-7			
xibonol	Phenol, 4,5-dimethyl-2-(4,7,7-trimethyl-2-oxobicyclo[2.2.1]hept-2-yl)-, exo- [CAS]	13741-18-9	GB 126774	Antibacterial, other	Infection, general
ximelagatran	Glycine, N-(R)-cyclohexyl-2-(2S)-2-(((4-(hydroxyamino)imino)ethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl ethyl ester [CAS]	192939-46-1			
Ximoprofen		56187-89-4		Antithrombotic	Thrombosis, venous
xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,8-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US 356777	Antihypertensive, diuretic	
xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-8-methyl-6-methylene-, (8S)- [CAS]	77287-89-9		Analgesic, other	Pain, cancer
	2,5-Piperazinedione, 3-[[5-[[2-(dimethylamino)ethyl]thio]-2-(dimethylamino)ethyl]pheno]-2-methoxydichloride, (3Z,6Z)- [CAS]	174766-49-5	WO 9632190	Anticancer, other	Cancer, general
XR-5118	N,N'-1,1,2-Ethanesulfonylbis(amino-2,1-ethanediy)bis(9-methylphenazine-1-carboxamide)				
XR-5944		526-36-3	EP 934278	Anticancer, other	Cancer, general
Xylometazoline		58-86-6			
Xylose					
YH-1685	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoxolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	178307-42-1	WO 9605177	Antitumor	Ulcer, GI, general
YM-511	Benzoic acid, 4-[[[4-bromophenyl)methyl]-4(1-1,2,4-triazol-4-ylamino)- [CAS]	148869-05-0	WO 9505027	Anticancer, hormonal	Cancer, breast

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
YM-698	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl]pyrimidin-4-yl-2-phenylethanesulfonamide				
Yohimbine					
YT-146	Adenosine, 2-(1-octynyl)- [CAS] Thiazolidine, 3-(2,3-dihydro-1H-imiden-2-yl)acetate 4-(1-pyrrolidinylcarboxyl)- (R)- [CAS]	146-48-5 90586-75-1	US 5270304	Anticancer, other	Cancer, prostate
Z-321	(1H-imidazo-5-acetic acid, 2-[[[(4-chlorophenyl)sulfonylamino]methyl]-2,3-dihydro, monosodium salt] [CAS]	130945-58-0	EP 372484	Cognition enhancer	Dementia, senile, general
Z-335	Carbamic acid, [8-[(2-methoxy-4-[[[(2-methylphenyl)thio]amino]methyl]phenoxy]methyl]-1-methyl-1H-imidazol-5-yl)-cyclopentyl ester [CAS]	146731-14-8	JP 92506077	Antithrombotic	Peripheral vascular disease
zafirlukast	Carbamic acid, [8-[(2-methoxy-4-[[[(2-methylphenyl)thio]amino]methyl]phenoxy]methyl]-1-methyl-1H-imidazol-5-yl)-cyclopentyl ester [CAS]	10753-79-6	EP 199543	Anticesthma	Asthma
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	7481-89-2	US 4879277	Antiviral, anti-HIV	Infection, HIV/AIDS
Zalcidrine					
zaleplon	Acetamide, N-[3-(5-cyanoprazolyl)-5-alpyrimidin-7-yl]phenyl-N-ethyl- [CAS]	109826-26-8	EP 199543	Anticesthma	Asthma
zaltoprofen	Dibenzol[b,f]thiophen-2-acetic acid, 10,11-dihydro-Alpha-methyl-10-oxo- [CAS]	151319-34-5	EP 776898	Hypnotic/Sedative	Insomnia
zanamivir	5-Acetamido-2,6-amino-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid [CAS]	74711-43-6	JP 55953282	Anti-inflammatory	Infection, Influenza virus
zanapezil	1-Propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl)- [CAS]	139110-80-8	WO 9116320	Antiviral, other	Infection, Influenza virus
Zatebradine					
ZD-3473	Platinum, aminomethylchloro(2-methylpyridine), (SP-4-3)- [CAS]	142852-50-4	EP 487071	Cognition enhancer	Alzheimer's disease
ZD-1947	Platinum, aminomethylchloro(2-methylpyridine), (SP-4-3)- [CAS]	142852-50-4	EP 487071	Cognition enhancer	Alzheimer's disease
ZD-6126	N-acetylcichloro-O-phosphate	85175-67-3	EP 727430	Anticancer, alkylating	Cancer, ovarian
		181630-15-9	WO 9526388	Urological	Overactive bladder
				Anticancer, other	Cancer, general
ZD-9331	1H-Tetrazole-5-butanolic acid, Alpha-((4-((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propionylamino)-2-fluorobenzoate)amino) (S)- [CAS]	153837-73-6	GB 2264946	Anticancer, antimetabolite	Cancer, pancreatic

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zebularine	2(1H)-Pyrimidinone, 1,6-D-ribofuranosyl- [CAS]	3690-10-6		Anticancer, other	Cancer, general
zelandopam	7,8-Isosquindiolide, 4,13,4, dihydroxyphenyl)-1,2,3,4-tetrahydro-, [CAS]	138065-00-7	JP 03190818	Vasodilator, renal	Hypertension, general
Zenarestat	Thymidine, 3'-acetyl-3'-deoxy- [CAS]	112733-06-9			
Ziconotide	Urea, N-(1-benzobiphen-2-ylmethyl)-N- hydroxy- [CAS]	107452-89-1			
zileuton		30516-97-1	US 4724232	Antiviral, anti-HIV	Infection, HIV/AIDS
Zimeldine		111406-87-2	EP 279263	Antiepileptic	Asthma
zinc acetate	hexakis(m-acetato)-m4-oxotetrazinc [2:1]- [CAS]	12129-82-7		Antiviral, other	Infection, herpes simplex virus prophylaxis
zinc ascorbate	Hexanoic acid, 6-(acetylamino)-, zinc salt [2:1]- [CAS]	70020-71-2	EP 369088	Anticancer	Ulcer, duodenal
zinc bupropionate		78416-80-5		Anti-inflammatory, topical	Inflammation, dermal
Zinc p-Phenolsulfonate		127-82-2			
Zinc Salicylate		16283-36-6			
Zinostatin		9014-2-2			
zincethal stimalmer		123760-07-6	EP 136791	Anticancer, antibiotic	Cancer, liver
Zipeprol		34758-83-3			
zfrasinidone	2H-Indol-2-one, 5-(2-(4-(1,2- benzodiazol-3-yl)-1-piperazinyl)ethyl)-6- chloro-1,3-dihydro- [CAS]	122883-93-6 146939-27-7	EP 281309	Neuroleptic	Schizophrenia
zoferopril	L-Proline, 1-(3-benzoylthio)-2-methyl-1- oxopropyl-4-(phenylthio)- [1(R*),2Alpha,4Alpha]- [CAS]	75176-37-3 81872-10-8 81838-43-4	GB 2028327	Antihypertensive, renin system	Hypertension, general
zoferopril + HCTZ	L-Proline, 1-(3-benzoylthio)-2-methyl-1- oxopropyl-4-(phenylthio)- [1(R*),2Alpha,4Alpha]- + 6-Chloro-3,4- dihydro-2H-1,2,4-benzoxiazole-7- sulfonamide, 1,1-dioxide [CAS]				
zoleconic acid	Phosphonic acid, 1'-hydroxy-2-(1H- imidazol-1-yl)ethylidene]bis- [CAS]	118072-93-8 165800-06-6	EP 631253	Formulation, fixed-dose combinations Osteoporosis treatment	Hypertension, general Hypercalcaemia of malignancy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zolmidine	2-(p-methylsulfonylphenyl)imidazo[1,2-a]pyridine	1222-57-7	US 3318880	Antitumor	Gastritis
zolmitriptan	2-Oxazolidinone, 4-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl-, (S)- [CAS]	139264-17-8	WO 9118897	Antimigraine	Migraine
zolpidem	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R-(R', R''))-2,3-dihydroxybutanedioate (2:1) [CAS]	99294-93-6 82626-48-0	EP 50563	Hypnotic/Sedative	Insomnia
Zomepirac		33369-31-2			
zonampanel	1-(2H-Quinoxaline-3-carboxylic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo- [CAS]	210245-80-0		Neuroprotective	Ischaemia, cerebral
zonitopride	1H-pyrazole-4-carboxamide, N-(aminomino methyl)-5-cyclopropyl-1-(5-quinolinyl)- [CAS]	249296-45-5		Cardiovascular	Unspecified
zonisamide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	68291-97-4 68291-98-5	GB 2025931	Antiepileptic	Epilepsy, generalized, tonic-clonic
zopidone	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-8,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2	GB 1356680	Hypnotic/Sedative	Insomnia
Zoplorestat		110703-94-1			
Zorubicin		54083-22-6			
zosuquidar	1-Piperazineethanol, 4-(1,1-difluoro-1,1a,6,10b-tetrahydroindeno[5,6-e]cyclopropa[cyclohepten-6-yl)-alpha-[(5-quinolinyl)oxy)methyl]-, [B(R)-1(a)alpha,6(Alpha,10a)Alpha]- [CAS]	167465-36-3		Radiochemosensitizer	Cancer, leukemia, acute myelogenous
zolepine ZP-123	Ethanamine, 2-[(8-chlorobenzoyl)phenyl-10-yloxy]-N,N-dimethyl- [CAS]	28615-21-4	GB 1247067	Neuroleptic	Schizophrenia
2-tamoxifen	Ethanamine, 2-(4-{1,2-diphenyl-1-butenyl}phenoxy)-N,N-dimethyl-, (Z)- [CAS]	10540-29-1	WO 0162775	Antianthrhythmic	Arrhythmia, general
				Anticancer, hormonal	Cancer, colorectal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zuclopenthixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthin-9-ylidene)propyl]-, [Z]-[CAS]	53772-83-1 982-24-1 85721-05-7 64053-00-5	EP 270282	Neuroleptic	Psychosis, general

CLAIMS:

1. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein both the API and the co-crystal former are solids at room temperature and the API and co-crystal former are hydrogen bonded to each other.
2. The pharmaceutical co-crystal composition according to claim 1, wherein the co-crystal former is selected from a co-crystal former of Table I or Table II.
3. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from an API of Table IV.
4. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.
5. A pharmaceutical co-crystal composition, comprising: an API, a co-crystal former, and a third molecule, wherein the API and the co-crystal former are solids at room temperature, and wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.
6. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein the API is liquid and the co-crystal former is solid at room temperature, and wherein the API and the co-crystal former are hydrogen bonded to each other.
7. The pharmaceutical co-crystal composition according to claim 6, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.
8. A pharmaceutical co-crystal composition, comprising: two APIs, wherein one or both of the APIs are solids at room temperature, and wherein the two APIs are hydrogen bonded to each other.

9. The pharmaceutical co-crystal composition according to claim 8, wherein each API is selected from an API of Table IV.
-
10. A pharmaceutical co-crystal composition, comprising: two co-crystal formers, wherein both co-crystal formers are solids at room temperature, and wherein both co-crystal formers are hydrogen bonded to each other.
11. The pharmaceutical co-crystal composition according to claim 10, wherein each co-crystal former is selected from a co-crystal former of Table I or Table II.
12. The pharmaceutical co-crystal composition according to claim 1, wherein the API and the co-crystal former form an inclusion complex.
13. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former; wherein the API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine, and the co-crystal former has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine, such that the drug and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions and a hydrogen bond is formed between a hydrogen bond donor and a hydrogen bond acceptor.
14. The pharmaceutical composition according to claim 1, wherein (i) one of the API and co-crystal forming compound has at least one hydrogen bond donor group and (ii) the other has at least one hydrogen bond acceptor group.

15. The pharmaceutical composition according to claim 14, wherein the difference in pKa between the API and the co-crystal forming compound does not exceed 2.

16. The pharmaceutical composition according to claim 1, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate and modafinil.

17. The pharmaceutical composition according to claim 1, wherein the API is selected from 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, and ibuprofen.

18. The pharmaceutical composition according to claim 1, which further comprises a pharmaceutically acceptable diluent, excipient or carrier.

19. A co-crystal comprising carbamazepine and saccharin.

20. A co-crystal comprising carbamazepine and nicotinamide.

21. A co-crystal comprising carbamazepine and trimesic acid.

22. A co-crystal comprising celecoxib and nicotinamide.

23. A co-crystal comprising olanzapine and nicotinamide.

24. A co-crystal comprising celecoxib and 18-crown-6.

25. A co-crystal comprising itraconazole and succinic acid.

26. A co-crystal comprising itraconazole and fumaric acid.

27. A co-crystal comprising itraconazole and tartaric acid.

28. A co-crystal comprising itraconazole and malic acid.

29. A co-crystal comprising itraconazoleHCl and tartaric acid.
30. A co-crystal comprising modafinil and malonic acid.
31. A co-crystal comprising modafinil and benzamide.
32. A co-crystal comprising modafinil and mandelic acid.
33. A co-crystal comprising modafinil and glycolic acid.
34. A co-crystal comprising modafinil and fumaric acid.
35. A co-crystal comprising modafinil and maleic acid.
36. A co-crystal comprising topiramate and 18-crown-6.
37. A co-crystal comprising 5-fluorouracil and urea.
38. A co-crystal comprising hydrochlorothiazide and nicotinic acid.
39. A co-crystal comprising hydrochlorothiazide and 18-crown-6.
40. A co-crystal comprising hydrochlorothiazide and piperazine.
41. A co-crystal comprising acetaminophen and 4,4'-bipyridine.
42. A co-crystal comprising phenytoin and pyridone.
43. A co-crystal comprising aspirin and 4,4'-bipyridine.
44. A co-crystal comprising ibuprofen and 4,4'-bipyridine.
45. A co-crystal comprising flurbiprofen and 4,4'-bipyridine.

46. A co-crystal comprising flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene.
47. A co-crystal comprising carbamazepine and p-phthalaldehyde.

48. A co-crystal comprising carbamazepine and 2,6-pyridinecarboxylic acid.
49. A co-crystal comprising carbamazepine and 5-nitroisophthalic acid.
50. A co-crystal comprising carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid.
51. A co-crystal comprising carbamazepine and benzoquinone.
52. A process for the production of a pharmaceutical co-crystal composition, which process comprises:
 - (1) providing an API which has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (2) providing a co-crystal former which has at least one complementary functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (3) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions; so as to form a solid phase;
 - (4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition; wherein the API is a liquid or solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and co-crystal former are hydrogen bonded to each other.

53. The process according to claim 52, wherein:

- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (b) the API is selected from an API of Table IV;
- (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (d) the API and the co-crystal former form an inclusion complex;
- (e) (i) one of the API and co-crystal forming compound has at least one hydrogen bond donor group; and
(ii) the other has at least one hydrogen bond acceptor group;
- (f) the difference in pKa between the API and the co-crystal former does not exceed 2;
- (g) the API is selected from the group consisting of celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, and modafinil;
- (h) the API is selected from the group consisting of 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, and ibuprofen; or
- (i) the pharmaceutical co-crystal composition further comprises a pharmaceutically acceptable diluent, excipient, or carrier.

54. The process for the production of a pharmaceutical co-crystal composition, which process comprises:

- (3) providing an API which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (4) providing a co-crystal former which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (3) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions; so as to form a solid phase;
- (4) isolating co-crystals formed thereby; and
- (5) incorporating the co-crystals into a pharmaceutical composition; wherein the API is a liquid or solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and a third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.

55. The process according to claim 52, wherein the API is a liquid at room temperature.

56. The process according to claim 55, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.

57. A process for the production of a pharmaceutical co-crystal composition, which process comprises:

- (1) providing an API which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (2) providing another API which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone,

thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (3) grinding, heating, or contacting in solution the APIs under crystallization conditions; so as to form a solid phase;
- (4) isolating co-crystals formed thereby; and
- (5) incorporating the co-crystals into a pharmaceutical composition; wherein one or both of the APIs are solids at room temperature, and wherein the two APIs are hydrogen bonded to each other.

58. The process according to claim 57, wherein each API is selected from an API of Table IV.

59. A process for the production of a pharmaceutical co-crystal composition, which process comprises:

- (1) providing a co-crystal former which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (2) providing another co-crystal former which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (3) grinding, heating, or contacting in solution the co-crystal formers under crystallization conditions; so as to form a solid phase;
 - (4) isolating co-crystals formed thereby; and
 - (5) incorporating the co-crystals into a pharmaceutical composition; wherein both co-crystal formers are solids at room temperature, and wherein both co-crystal formers are hydrogen bonded to each other.
-

60. The process according to claim 59, wherein each co-crystal former is selected from a co-crystal former of Table I and Table II.

61. The process according to claim 52, wherein the co-crystal is selected from the group consisting of carbamazepine:saccharin, carbamazepine:nicotinamide, carbamazepine:trimesic acid, celecoxib:nicotinamide, olanzapine:nicotinamide, celecoxib:18-crown-6, itraconazole:succinic acid, itraconazole:fumaric acid, itraconazole:tartaric acid, itraconazole:malic acid, itraconazole:HCl:tartaric acid, modafinil:malonic acid, modafinil:benzamide, modafinil:mandelic acid, modafinil:glycolic acid, modafinil:fumaric acid, modafinil:maleic acid, topiramate:18-crown-6, 5-fluorouracil:urea, hydrochlorothiazide:nicotinic acid, hydrochlorothiazide:18-crown-6, hydrochlorothiazide:piperazine, acetaminophen:4,4'-bipyridine, phenytoin:pyridone, aspirin:4,4'-bipyridine, ibuprofen:4,4'-bipyridine, flurbiprofen:4,4'-bipyridine, flurbiprofen:trans-1,2-bis(4-pyridyl) ethylene, carbamazepine:p-phthalaldehyde, carbamazepine:2,6-pyridinedicarboxylic acid, carbamazepine:5-nitroisophthalic acid, carbamazepine:1,3,5,7-adamantane tetracarboxylic acid, and carbamazepine:benzoquinone.

62. A process for the production of a pharmaceutical composition, which comprises:

- (1) contacting in solution an API with a co-crystal forming compound, under crystallization conditions, so as to form a solid phase;
- (2) isolating the solid phase;
- (3) testing the solid phase for the presence of co-crystals of the API and the co-crystal forming compound; and
- (4) incorporating the co-crystals when formed in step (3) into a pharmaceutical composition.

63. A process for the production of a pharmaceutical composition, which comprises:

(1) providing (i) an API or a plurality of different APIs, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at least one of the API and the co-crystal forming compound is provided as a plurality thereof;

(2) screening for co-crystals of APIs with co-crystal forming compounds by subjecting each combination of API and co-crystal forming compound to a step comprising

(a) contacting in solution the API with the co-crystal forming compound under crystallization conditions so as to form a solid phase;

(b) isolating the solid phase; and

(c) testing the solid phase for the presence of co-crystals of the API and the co-crystal forming compound; and

(3) incorporating the co-crystals when formed in step (c) into a pharmaceutical composition.

64. A process for modulating the solubility of an API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal;

(3) testing the co-crystal for modulated solubility as compared to the API; and

(4) incorporating the co-crystal having modulated solubility into a pharmaceutical composition.

65. A process for modulating the dose response of an API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal;

(3) testing the co-crystal for modulated dose response as compared to the API; and

(4) incorporating the co-crystal having modulated dose response into a pharmaceutical composition.

66. A process for modulating the dissolution of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated dissolution as compared to the API; and
- (4) incorporating the co-crystal having modulated dissolution into a pharmaceutical composition.

67. A process for modulating the bioavailability of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated bioavailability as compared to the API; and
- (4) incorporating the co-crystal having modulated bioavailability into a pharmaceutical composition.

68. A process for increasing the stability of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal, wherein the co-crystal has increased stability as compared to the API; and
- (3) incorporating the co-crystal having increased stability into a pharmaceutical composition.

69. A process for the incorporation of a difficult to salt or unsaltable API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal;

(3) incorporating the co-crystal having a difficult to salt or unsaltable API into a pharmaceutical composition.

70. A process for decreasing the hygroscopicity of an API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal, wherein the co-crystal has decreased hygroscopicity as compared to the API; and

(3) incorporating the co-crystal having decreased hygroscopicity into a pharmaceutical composition.

71. A process for crystallizing an amorphous API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal;

(4) incorporating the co-crystal into a pharmaceutical composition.

72. A process for decreasing the form diversity of an API for use in a pharmaceutical composition, which process includes:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal wherein the co-crystal has decreased form diversity as compared to the API; and

(3) incorporating the co-crystal having decreased form diversity into a pharmaceutical composition.

73. A process for modulating the morphology of an API for use in a pharmaceutical composition, which process includes:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal, wherein the co-crystal has a different morphology as compared to the API; and
- (3) incorporating the co-crystal having modulated morphology into a pharmaceutical composition.

74. The co-crystal of claim 1, specifically excluding co-crystals selected from the group consisting of: nabumetone:2,3-naphthalenediol, fluoxetine HCl:benzoic acid, fluoxetine HCl:succinic acid, acetaminophen:piperazine, acetaminophen:theophylline, theophylline:salicylic acid, theophylline:p-hydroxybenzoic acid, theophylline:sorbic acid, theophylline:1-hydroxy-2-naphthoic acid, theophylline:glycolic acid, theophylline:2,5-dihydroxybenzoic acid, theophylline:chloroacetic acid, bis(diphenylhydantoin):9-ethyladenine acetylacetone solvate, bis(diphenylhydantoin):9-ethyladenine 2,4-pentanedione solvate, 5,5-diphenylbarbituric acid:9-ethyladenine, bis(diphenylhydantoin):9-ethyladenine, 4-aminobenzoic acid:4-aminobenzonitrile, sulfadimidine:salicylic acid, 8-hydroxyquinolinium 4-nitrobenzoate:4-nitrobenzoic acid, sulfaproxyline:caffeine, retro-inverso-isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-(N-(2R)-2-morpholinocarbonylmethyl)-3-(1-naphthyl)propionyl)-L-histidylamino)butyrate:cinnamic acid monohydrate, benzoic acid:isonicotinamide, 3-(2-N',N'-(dimethylhydrazino)-4-thiazolylmethylthio)-N''-sulfamoylpropionamide:maleic acid, diglycine hydrochloride ($C_2H_5NO_2 \cdot C_2H_4NO_2^+Cl^-$), octadecanoic acid:3-pyridinecarboxamide, cis-N-(3-methyl-1-(2-(1,2,3,4-tetrahydronaphthyl)-piperidin-4-yl)-N-phenylpropanamide hydrochloride:oxalic acid, trans-N-(3-methyl-1-(2-(1,2,3,4-tetrahydronaphthyl)-piperidin-4-yl)-N-phenylpropanamide oxalate:oxalic acid dihydrate, bis(1-(3-(4-(2-isopropoxyphenyl)-1-piperazinyl)methyl)benzoyl)piperidine succinate:succinic acid, bis(p-cyanophenyl)imidazolymethane:succinic acid, cis-1-((4-(1-imidazolylmethyl)cyclohexyl)methyl)imidazole:succinic acid, (+)-2-(5,6-dimethoxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline:(+)-dibenzoyl-D-tartaric acid, raclopride:tartaric acid, 2,6-diamino-9-ethylpurine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:bis(2-

aminopyridine), 5,5-diethylbarbituric acid:acetamide, 5,5-diethylbarbituric acid:KI₃, 5,5-diethylbarbituric acid:urea, bis(barbital):hexamethylphosphoramide, 5,5-diethylbarbituric acid:imidazole, barbital:1-methylimidazole, 5,5-diethylbarbituric acid:N-methyl-2-pyridone, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine:5,5-diethylbarbituric acid, bis(barbital):caffeine, bis(barbital):1-methylimidazole, bis(beta-cyclodextrin):bis(barbital) hydrate, tetrakis(beta-cyclodextrin):tetrakis(barbital), 9-ethyladenine:5,5-diethylbarbituric acid, barbital:N'-(p-cyanophenyl)-N-(p-iodophenyl)melamine, barbital:2-amino-4-(m-bromophenylamino)-6-chloro-1,3,5-triazine, 5,5-diethylbarbituric acid:N,N'-diphenylmelamine, 5,5-diethylbarbituric acid:N,N'-bis(p-chlorophenyl)melamine, N,N'-bis(p-bromophenyl)melamine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:N,N'-bis(p-iodophenyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(p-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-chlorophenyl)melamine, N,N'-Bis(m-methylphenyl)melamine:barbital, N,N'-bis(m-chlorophenyl)melamine:barbital tetrahydrofuran solvate, 5,5-diethylbarbituric acid:N,N'-bis(t-butyl)melamine, 5,5-diethylbarbituric acid:N,N'-di(t-butyl)melamine, 6,6'-diquinolyl ether:5,5-diethylbarbituric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, N,N'-bis(4-carboxymethylphenyl)melamine:barbital ethanol solvate, N,N'-bis(4-t-butylphenyl)melamine:barbital, tris(5,17-N,N'-bis(4-amino-6-(butylamino)-1,3,5-triazin-2-yl)diamino-11,23-dinitro-25,26,27,28-tetrapropoxycalix(4)arene):hexakis(diethylbarbituric acid) toluene solvate, N,N'-bis(m-fluorophenyl)melamine:barbital, N,N'-bis(m-bromophenyl)melamine:barbital acetone solvate, N,N'-bis(m-iodophenyl)melamine:barbital acetonitrile solvate, N,N'-bis(m-trifluoromethylphenyl)melamine:barbital acetonitrile solvate, aminopyrine:barbital, N,N'-bis(4-fluorophenyl)melamine:barbital, N,N'-bis(4-trifluoromethylphenyl)melamine:barbital, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine:barbital, hydroxybutyrate:hydroxyvalerate, 2-aminopyrimidine:succinic acid, 1,3-bis(((6-methylpyrid-2-yl)amino)carbonyl)benzene:glutaric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, bis(dithiobiuret-S,S')nickel(II):diuracil, platinum 3,3'-dihydroxymethyl-2,2'-bipyridine dichloride:AgF₃CSO₃, 4,4'-bipyridyl:isophthalic acid, 4,4'-bipyridyl:1,4-naphthalenedicarboxylic acid, 4,4'-bipyridyl:1,3,5-cyclohexanetricarboxylic acid, 4,4'-bipyridyl:tricarballic acid, urotropin:azelaic acid, insulin:C8-HI (octanoyl-N⁶-LysB29-human insulin), isonicotinamide:cinnamic acid, isonicotinamide:3-hydroxybenzoic acid, isonicotinamide:3-N,N-dimethylaminobenzoic acid, isonicotinamide:3,5-bis(trifluoromethyl)-benzoic acid, isonicotinamide:d,l-mandelic acid,

isonicotinamide:chloroacetic acid, isonicotinamide:fumaric acid monoethyl ester,
 isonicotinamide:12-bromododecanoic acid, isonicotinamide:fumaric acid,
 isonicotinamide:succinic acid, isonicotinamide:4-ketopimelic acid,
 isonicotinamide:thiodiglycolic acid, 1,3,5-cyclohexane-tricarboxylic
 acid:hexamethyltetramine, 1,3,5-cyclohexane-tricarboxylic acid:4,7-phenanthroline, 4,7-
 phenanthroline:oxalic acid, 4,7-phenanthroline:terephthalic acid, 4,7-phenanthroline: 1,3,5-
 cyclohexane-tricarboxylic acid, 4,7-phenanthroline:1,4-naphthalenedicarboxylic acid,
 pyrazine:methanoic acid, pyrazine:ethanoic acid, pyrazine:propanoic acid, pyrazine:butanoic
 acid, pyrazine:pentanoic acid, pyrazine:hexanoic acid, pyrazine:heptanoic acid,
 pyrazine:octanoic acid, pyrazine:nonanoic acid, pyrazine:decanoic acid, diammine-(deoxy-
 quanyl-quanyl-N⁷,N⁷)-platinum:tris(glycine) hydrate, 2-aminopyrimidine:p-
 phenylenediacetic acid, bis(2-aminopyrimidin-1-ium)fumarate:fumaric acid, 2-
 aminopyrimidine:indole-3-acetic acid, 2-aminopyrimidine:N-methylpyrrole-2-carboxylic
 acid, 2-aminopyrimidine:thiophen-2-carboxylic acid, 2-aminopyrimidine:(+)-camphoric acid,
 2,4,6-Trinitrobenzoic acid: 2-aminopyrimidine, 2-aminopyrimidine:4-aminobenzoic acid, 2-
 aminopyrimidine:bis(phenoxyacetic acid), 2-aminopyrimidine:(2,4-dichlorophenoxy)acetic
 acid, 2-aminopyrimidine:(3,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:indole-2-
 carboxylic acid, 2-aminopyrimidine:terephthalic acid, 2-aminopyrimidine:bis(2-nitrobenzoic
 acid), 2-aminopyrimidine:bis(2-aminobenzoic acid), 2-aminopyrimidine:3-aminobenzoic
 acid, 2-hexenoic acid:isonicotinamide, 4-nitrobenzoic acid:isonicotinamide, 3,5-
 dinitrobenzoic acid:isonicotinamide:4-methylbenzoic acid, 2-amino-5-nitropyrimidine:2-
 amino-3-nitropyridine, 3,5-dinitrobenzoic acid:4-chlorobenzamide, 3-dimethylaminobenzoic
 acid:4-chlorobenzamide, fumaric acid:4-chlorobenzamide, oxine:4-nitrobenzoic acid,
 oxine:3,5-dinitrobenzoic acid, oxine:3,5-dinitrosalicylic acid, 3-[2-(N',N'-
 dimethylhydrazino)-4-thiazolylmethylthio]-N²-sulfamoylpropionamide:maleic acid, 5-
 fluorouracil:9-ethylhypoxanthine, 5-fluorouracil:cytosine dihydrate, 5-
 fluorouracil:theophylline monohydrate, stearic acid:nicotinamide, cis-1-{{4-(1-
 imidazolylmethyl)cyclohexyl}methyl}imidazole:succinic acid, CGS18320B:succinic acid,
 sulfaproxyl:caffeine, 4-aminobenzoic acid:4-aminobenzonitrile, 3,5-dinitrobenzoic
 acid:isonicotinamide:3-methylbenzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-
 (dimethylamino)benzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-hydroxy-3-
 methoxycinnamic acid, isonicotinamide:oxalic acid, isonicotinamide:malonic acid,
 isonicotinamide:succinic acid, isonicotinamide:glutaric acid, isonicotinamide:adipic acid,
 benzoic acid:isonicotinamide, mazapertine:succinate, betaine:dichloronitrophenol,

betainepyridine:dichloronitrophenol, betainepyridine:pentachlorophenol, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:methyl 2,4-dihydroxybenzoate, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxypropiofenone, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxyacetophenone, squaric acid:4,4'-dipyridylacetylene, squaric acid:1,2-bis(4-pyridyl)ethylene, chloranilic acid:1,4-bis[(4-pyridyl)ethynyl]benzene, 4,4'-bipyridine:phthalic acid, 4,4'-dipyridylacetylene:phthalic acid, bis(pentamethylcyclopentadienyl)iron:bromanilic acid, bis(pentamethylcyclopentadienyl)iron:chloranilic acid, bis(pentamethylcyclopentadienyl)iron:cyananilic acid, pyrazinotetrathiafulvalene:chloranilic acid, phenol:pentafluorophenol, co-crystals of itraconazole, and co-crystals of topiramate.




Figure 1

Sample: carb_389_285E6
 Size: 0.1440 mg
 Method: Ramp

DSC

File: Y:\carb_389_285E6.d01
 Operator: MJS
 Run Date: 03-Dec-02 13:43
 Instrument: DSC Q1000 V6.19 Build 227




Figure 2




Figure 3

Sampler: carb_389_278_C4
 Size: 0.1340 mg
 Method: Ramp

DSC

File: Y:\Carb_389_278\carb_389_278_C4.001
 Operator: MBH
 Run Date: 19-Nov-02 19:40
 Instrument: DSC Q1000 V6.19 Build 227




Figure 4




Figure 5




Figure 6

Sample: topiramate_18crown6
Size: 0.8210 mg
Method: Ramp

DSC

File: Y:_DSC\Magali\topiramate_18crown6.001
Operator: MBH
Run Date: 19-May-03 05:35
Instrument: DSC Q1000 V6.10 Build 227




Figure 7




Figure 8

Sample: 1102_204_D2
Stat: 0.7890 mg
Method: Ramp

DSC

File: Y:\Aloenzapine\1102\1102_204_D2.002
Operator: MBH
Run Date: 14-May-03 08:58
Instrument: DSC Q1000 V8.19 Build 227




Figure 9




Figure 10

Sample: Celecoxib/18-crown-6
Size: 0.9600 mg
Method: Ramp

DSC

File: V:\MT_143_45_A\Celecoxib 18-C-8.001
Operator: MDT
Run Date: 17-Mar-03 13:42
Ink/Print: DSC Q1000 V6.19 Build 227




Figure 11

TransForm Pharmaceuticals, Inc.

[2020R4P10/Administrator]@cd:DATA: Monday, Jul 08, 2022 08:17a (AEDU/AD25)




Figure 12

Sample: MM_90_110_A
Size: 1.8060 mg
Method: Ramp

DSC

File: W:\Vibraconsole\MM_90_110_A.001
Operator: MM
Run Date: 08-Jul-02 08:11
Instrument: DSC Q1000 V5.1 Build 191




Figure 13




Figure 14

Sample: MM_90_48_B_DSC
Size: 2.3890 mg
Method: Ramp

DSC

File: \LVR_81_53_D_Mg_open_DSC.004
Operator: MM
Run Date: 11-Jun-02 10:48
Instrument: DSC Q1000 V5.1 Build 191




Figure 15




Figure 16

Sample: MM_109_15_Tar
Size: 1.0759 mg
Method: Ramp

DSC

File: U...Uraconozole\MM_109_15_Tar.001
Operator: MM
Run Date: 01-Aug-02 16:16
Instrument: DSC Q1000 V6.1 Build 161




Figure 17




Figure 18

Sample: MM_109_15_Tar
Size: 1.2140 mg
Method: Ramp

DSC

File: Y:\Ultraconazole\MM_109_15_Mal.001
Operator: MM
Run Date: 01-Aug-02 14:18
Instrument: DSC Q1000 V6.1 Build 101




Figure 19




Figure 20

Sample: MM_109_38_A
Size: 1.5086 mg
Method: Ramp

DSC

File: V:_Virasozole\MM_109_38_A.001
Operator: MM
Run Date: 11-Sep-02 10:57
Instrument: DSC Q1000 V8.19 Build 227





Figure 21






Figure 24




Figure 25




Figure 26





Figure 27



Dissolution profiles into 0.1 N HCl at 25 °C

Sporanoz Beads (amorphous freebase) (Rectangle)

l-Malate (Inverted triangle)

l-Tartrate (Oval)

Succinate (Triangle)

Crystalline Freebase (Diamond)

Figure 28




Figure 29




Figure 30




Figure 31

Molecular structure of the Olanzapine-nicotinamide-H₂O-IPOAc crystal:




Figure 32A





Figure 32B



The Olanzapine molecules occupy the spaces shown above and are hydrogen bonded to the water molecules.




Figure 32C

The arrangement of the Olanzapine molecules is similar to that observed from the methanol solvate and the published structures for the hydrates. The water molecules bridge the Olanzapine moieties resulting in hydrogen-bonded zigzag sheets.




Figure 32D




Figure 33

=

Sample : fluorinated_urea_
Size : 2.4500 mg
Method : Ramp
Comment : stabilitystudy initial sample

TGA




Figure 34




Figure 35





Figure 36







Figure 36



Materials Data, Inc.

Tuesday, Sep 07, 2010 11:11a (MOLVAD00)

Figure 39




Figure 40





Figure 41



FIND PEAKS:

Spectrum: MO-157-72C_Modafinil-Malonic
 Region: 3432 200
 Absolute threshold: 568.428
 Sensitivity: 50

Peak list:

Position	Intensity
1004	48630.113
222	41631.178
533	30431.455
255	27932.348
1032	25424.103
1163	23485.441
814	21886.129
1601	20374.211
490	18017.468
718	18779.322
757	10001.541
361	15080.872
917	12551.253
1104	11703.740
880	11172.533
412	11137.415
1225	6027.109
1251	6044.533
1368	6262.702
1442	5738.554
1731	5730.550
1288	5700.050
3085	1835.514
2048	1042.835

Exposure time: 2.00 sec

Number of exposures: 15

Number of background exposures: 15

Grating: 300 lines/mm

Spectrograph aperture: 100 μ m slit

Figure 42




Figure 43




Figure 44A




Figure 44B




Figure 45A




Figure 45B




Figure 46A



Figure 46C




Figure 46B




Figure 46D

Figure 47A




Figure 47C





Figure 47B




Figure 47D

Figure 48A





Figure 48C






Figure 48B




Figure 48D




Figure 49A




Figure 49B




Figure 50A




Figure 50B




Figure 51




Figure 52




Figure 53A




Figure 53B




Figure 53C




Figure 54A




Figure 54B




Figure 55A




Figure 55B




Figure 56A




Figure 56B




Figure 57A




Figure 57B




Figure 58A




Figure 58B




Figure 59

Sample: CAL-RLC
Date: 1/25/00
File: Job Nic

DSC




Figure 60




Figure 61





Figure 62

(Figure 63)


1. One-dimensional (linear) hydrogen-bonded chains:



2. Isolated rings:



3. Extended Networks:



4. Isolated triads:



INTERNATIONAL SEARCH REPORT

 International Application No.
 PCT/US 03/27772

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/14 C07C233/00 C07D233/00 A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category * Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

E

 WO 03/074474 A (ZAWOROTKO MICHAEL J ;
 MOULTON BRIAN (US); UNIV MICHIGAN (US);
 RODRIGUE) 12 September 2003 (2003-09-12)

 the whole document
 paragraphs [0006], [0008], [0023],
 [0038], [0043], [0052], [0055],
 [0056]; claims 1,5-11,21-24,28; examples
 1-9

-/--

 1-4,
 13-16,
 18,52,
 53,62-74

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

 "A" document defining the general state of the art which is not
 considered to be of particular relevance

 "E" earlier document but published on or after the international
 filing date

 "L" document which may throw doubt on priority claim(s) or
 which is cited to establish the publication date of another
 citation or other special reason (as specified)

 "O" document referring to an oral disclosure, use, exhibition or
 other means

 "P" document published prior to the international filing date but
 later than the priority date claimed

 "T" later document published after the international filing date
 or priority date and not in conflict with the application but
 cited to understand the principle or theory underlying the
 invention

 "X" document of particular relevance; the claimed invention
 cannot be considered novel or cannot be considered to
 involve an inventive step when the document is taken alone

 "Y" document of particular relevance; the claimed invention
 cannot be considered to involve an inventive step when the
 document is combined with one or more other such docu-
 ments, such combination being obvious to a person skilled
 in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

10 February 2004

Date of mailing of the international search report

21. 06. 2004

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Palenstein 2
 NL-2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 eponi,
 Fax: (+31-70) 340-3016

Authorized officer

Luangkhot, N

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/27772

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/033462 A (KIM KIBUM ; UNIV MICHIGAN (US); LANG MEIDONG (US); MATZGER ADAM J (US)) 24 April 2003 (2003-04-24) the whole document page 1, lines 18-23 page 14, line 27 - page 15, line 6 claims 1-5,19,37-45	1-4, 13-16, 18,22, 24,52, 53,62-74
X	WO 01/51919 A (TRANSFORM PHARMACEUTICALS INC ; CIMA MICHAEL J (US); LEMMO ANTHONY V (I) 19 July 2001 (2001-07-19) the whole document page 1, lines 10-19 page 63, lines 11-16 page 63, line 23 - page 64, line 25 page 65, lines 3-6 pages 66,68 page 16, lines 4-20 claims 1,6,11 page 35, line 15	1-4, 13-16, 18,52, 53,62-74
Y	WEISSBUCH I ET AL: "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries" 1995, ACTA CRYSTALLOGRAPHICA, SECTION B, STRUCTURAL SCIENCE, MUNKSGAARD, COPENHAGEN, DK, PAGE(5) 115-148 , XP002960386 ISSN: 0108-7661 the whole document	22,24
Y	abstract page 145, column 2, paragraph 2	22,24
X	WO 01/42222 A (MIYAKE PATRICIA J ; FERRO LEONARD J (IL); PHARMACIA CORP (US)) 14 June 2001 (2001-06-14) the whole document	22,24
Y	pages 60,61; examples 1,2 page 1, lines 19-27 page 4, lines 5-19 page 5, line 15 - page 6, line 8 page 10, line 30 - page 14, line 19 page 48, lines 9-18 page 50, line 9 - page 56, line 34 page 60, line 11 - page 64, line 4 claims 1,57-175	22,24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/27772

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-4, 13-16, 18, 52-53, 62-74 (all in part), 22 and 24 (whole)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-4,13-16,18, 52-53, 62-74 (all in part), 22 and 24 (whole)

A co-crystal comprising celecoxib, and nicotinamide or 18-crown-16; its use in a pharmaceutical composition and method of preparation

- 1.1. claims: 1-4,13-16,18, 52-53, 62-74 (all in part), 22 (whole)

A co-crystal comprising celecoxib and nicotinamide; its use in a pharmaceutical composition and method of preparation

- 1.2. claims: 1-4, 13-16,18, 52-53, 62-74 (all in part), 24 (whole)

A co-crystal comprising celecoxib and 18-crown-16; its use in a pharmaceutical composition and method of preparation

2. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 19 (whole)

A co-crystal comprising carbamazepine and saccharin, its use in a pharmaceutical composition and method of preparation

3. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 20 (whole)

A co-crystal comprising carbamazepine and nicotinamide, its use in a pharmaceutical composition and method of preparation

4. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 21 (whole)

A co-crystal comprising carbamazepine and trimesic acid, its use in a pharmaceutical composition and method of preparation

5. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 47 (whole)

A co-crystal comprising carbamazepine and p-phthaldehyde, its use in a pharmaceutical composition and method of preparation

6. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 48 (whole)

A co-crystal comprising carbamazepine and 2,6-pyridinecarboxylic acid, its use in a pharmaceutical composition and method of preparation

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 49 (whole)

A co-crystal comprising carbamazepine and 5-nitroisophthalic acid, its use in a pharmaceutical composition and method of preparation

8. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 50 (whole)

A co-crystal comprising carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid, its use in a pharmaceutical composition and method of preparation

9. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 51 (whole)

A co-crystal comprising carbamazepine and benzoquinone, its use in a pharmaceutical composition and method of preparation

10. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 25 (whole)

A co-crystal comprising itraconazole and succinic acid, its use in a pharmaceutical composition and method of preparation

11. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 26 (whole)

A co-crystal comprising itraconazole and fumaric acid, its use in a pharmaceutical composition and method of preparation

12. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 27 (whole)

A co-crystal comprising itraconazole and tartaric acid, its use in a pharmaceutical composition and method of preparation

13. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 28 (whole)

A co-crystal comprising itraconazole and malic acid, its use in a pharmaceutical composition and method of preparation

14. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 29 (whole)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A co-crystal comprising itraconazole and tartaric acid, its use in a pharmaceutical composition and method of preparation

15. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 23 (whole)

A co-crystal comprising olanzapine and nicotinamide, its use in a pharmaceutical composition and method of preparation

16. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 36 (whole)

A co-crystal comprising topiramate and 18-crown-16, its use in a pharmaceutical composition and method of preparation

17. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 30-35 (whole)

A co-crystal comprising modafinil, and malonic acid or benzamide or mandelic, glycolic, fumaric or maleic acid, its use in a pharmaceutical composition and method of preparation

18. claims: 1-4, 13-15,17,18, 52-53, 62-74 (all in part), 37 (whole)

A co-crystal comprising 5-fluorouracil and uread, its use in a pharmaceutical composition and method of preparation

19. claims: 1-4, 13-15,17,18, 52-53, 62-74 (all in part), 38-40 (whole)

A co-crystal comprising hydrochlorothiazide, and nicotinic acid or 18-crown-6 or piperazine, its use in a pharmaceutical composition and method of preparation

20. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 41 (whole)

A co-crystal comprising acetaminophen and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

21. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 43 (whole)

A co-crystal comprising aspirine and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

22. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 45-46 (whole)

A co-crystal comprising flurbiprofen, and 4,4'-bipyridine or trans-1,2-bis(4-pyridyl)ethylene, its use in a pharmaceutical composition and method of preparation

23. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 42 (whole)

A co-crystal comprising phenytoin and pyridone, its use in a pharmaceutical composition and method of preparation

24. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 44 (whole)

A co-crystal comprising ibuprofen and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

25. claims: 5,54-56 (whole), 62-74 (in part)

A pharmaceutical co-crystal composition comprising a/ a solid active pharmaceutical ingredient (API), b/ a solid co-crystal former, c/ a third molecule, wherein the API and the third molecule are bonded to each other, and the co-crystal former and the third molecule are hydrogen bonded to each other; and its method of preparation

26. claims: 6-7 (whole), 62-72 (in part)

A pharmaceutical co-crystal composition comprising a/ an active pharmaceutical ingredient (API), b/ a co-crystal former, wherein (a) is liquid and (b) is solid at room temperature, and (a) and (b) are hydrogen bonded to each other; and its method of preparation

27. claims: 8-9,57-58 (whole), 62-74 (in part)

A pharmaceutical co-crystal composition comprising a1/ a solid active pharmaceutical ingredient (API), a2/ a second solid API, wherein (a1) and (a2) are hydrogen bonded to each other; and its method of preparation

28. claims: 10-12, 59-61 (whole), 62-72 (in part)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical co-crystal composition comprising b1/ a solid co-crystal former, b2/ a second solid co-crystal former, wherein (b1) and (b2) are hydrogen bonded to each other; and its method of preparation

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 03/27772

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03074474	A	12-09-2003	WO 03074474 A2 2003224006 A1	12-09-2003 04-12-2003
WO 03033462	A	24-04-2003	US 2003113802 A1 WO 03033462 A2	19-06-2003 24-04-2003
WO 0151919	A	19-07-2001	AU 2930501 A BR 0107456 A CA 2396079 A1 CZ 20022332 A3 EP 1248869 A2 JP 2003519698 T NZ 519984 A SK 9742002 A3 WO 0151919 A2 US 2003162226 A1 US 2002048610 A1	24-07-2001 08-10-2002 19-07-2001 15-01-2003 16-10-2002 24-06-2003 26-03-2004 04-02-2003 19-07-2001 28-08-2003 25-04-2002
WO 0142222	A	14-06-2001	AU 1805901 A AU 1930301 A AU 1931001 A AU 1931101 A AU 2041201 A AU 750978 B2 AU 2057101 A BG 105808 A BG 105873 A BR 0008058 A BR 0008059 A BR 0008060 A BR 0008088 A CA 2362673 A1 CA 2362675 A1 CA 2362815 A1 CA 2362816 A1 CN 1376146 T CN 1379669 T CN 1411447 T CZ 20012875 A3 CZ 20013162 A3 CZ 20013163 A3 CZ 20013210 A3 EA 3639 B1 EA 3612 B1 EA 3464 B1 EE 200100414 A EE 200100419 A EP 1175214 A2 EP 1165072 A2 EP 1150959 A1 EP 1150960 A1 HR 20010582 A1 HR 20010589 A1 HU 0200409 A2 HU 0200580 A2 HU 0201450 A2 HU 0201463 A2 JP 2003523954 T	18-06-2001 18-06-2001 18-06-2001 18-06-2001 18-06-2001 01-08-2002 18-06-2001 30-09-2002 30-04-2002 26-03-2002 26-03-2002 05-02-2002 09-04-2002 14-06-2001 14-06-2001 14-06-2001 14-06-2001 23-10-2002 13-11-2002 16-04-2003 13-02-2002 12-06-2002 12-06-2002 13-03-2002 28-08-2003 26-06-2003 26-06-2003 16-12-2002 16-12-2002 30-01-2002 02-01-2002 07-11-2001 07-11-2001 31-08-2002 31-08-2002 29-06-2002 28-11-2002 28-12-2002 28-05-2004 12-08-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/27772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0142222 A		JP 2003516353 T	13-05-2003
		JP 2004500358 T	08-01-2004
		JP 2003516394 T	13-05-2003
		MA 25868 A1	01-10-2003
		NO 20013855 A	05-10-2001
		NO 20013858 A	08-10-2001